---
title: "Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Product information and disease description"
description: "Formulary evidence on Tovorafenib (DAY101, TAK-580) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Product information and disease description. Covers Product description and Place of product in therapy. 479 evidence topics quoted from 139 sources."
canonical: "https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/product-information-and-disease-description"
published: "2026-09-17T18:16:08-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: regulatory and development status as of September 2026

Tovorafenib is approved in the United States (accelerated approval, 23 April 2024), the European Union (conditional marketing authorisation, April 2026), and Japan (16 September 2026). The US and EU indications are limited to relapsed or refractory (EU: progressed after one or more prior systemic therapies) pediatric low-grade glioma with a BRAF fusion or rearrangement or BRAF V600 mutation, based on the single-arm phase 2 FIREFLY-1 trial. The FDA listed the accelerated approval as ongoing (clinical benefit not yet verified) as of 16 September 2026. No approved indication, supplemental new drug application, or EU variation for first-line use was identified. The first-line trial LOGGIC/FIREFLY-2 (tovorafenib vs standard-of-care chemotherapy) completed enrollment of approximately 400 participants in May 2026; the sponsor expects topline data by mid-2027. FIREFLY-2 is also the confirmatory trial for the US accelerated approval (interim report due April 2028, final report April 2032) and the specific obligation for the EU conditional authorisation (final report due 30 April 2032). The EMA overview page gives 20 April 2026 as the authorisation date, while the Ipsen announcement is dated 22 April 2026. Day One Biopharmaceuticals became a wholly owned subsidiary of Servier after the tender offer closed on 22 April 2026.

Source: [FDA accelerated approval announcement (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric); [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals); [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf); [EMA Ojemda medicine overview (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda); [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf); [Ipsen EU approval announcement (2026)](https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/); [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html); [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG); [Servier acquisition completion announcement (2026)](https://servier.com/en/newsroom/servier-completes-the-acquisition-of-day-one-biopharmaceuticals/)

<a id="topic-2.1.1-2"></a>

##### United States: accelerated approval for relapsed or refractory pLGG

> “On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.”
> “This represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions.”
> “This application was granted accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials.”

Source: [FDA accelerated approval announcement (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric)

<a id="topic-2.1.1-3"></a>

##### United States: approval pathway stated in the approval letter

> “It is approved under accelerated approval pursuant to section 506(c) of the Federal Food, Drug, and Cosmetic Act (FDCA) and 21 CFR 314.510, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”
> “Your application for Ojemda was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues that were unexpected for a drug in the intended population.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.1.1-4"></a>

##### United States: expedited programs and designations

> “This application was granted priority review, breakthrough designation and orphan drug designation.”

Source: [FDA accelerated approval announcement (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric)

> “Tovorafenib was granted Breakthrough Therapy and Rare Pediatric Disease designations by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration, and it was evaluated by the FDA under priority review. Tovorafenib has also received Orphan Drug designation from the FDA for the treatment of malignant glioma and from the European Commission for the treatment of glioma.”

Source: [Day One Biopharmaceuticals accelerated approval announcement (2024)](https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated)

<a id="topic-2.1.1-5"></a>

##### United States: breakthrough therapy and orphan designation dates

> “31 Aug 2020 IND 108340 Breakthrough Therapy Designation granted by FDA in the treatment of pediatric patients with low-grade glioma harboring an activating RAF alteration who have progressed after one or more therapies.”
> “24 Sep 2020 IND 108340 Orphan Drug Designation granted by FDA for tovorafenib for the treatment of malignant glioma.”

Source: [FDA multi-discipline review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000MultidisciplineR.pdf)

<a id="topic-2.1.1-6"></a>

##### United States: rare pediatric disease priority review voucher

> “We also inform you that you have been granted a rare pediatric disease priority review voucher, as provided under section 529 of the FDCA.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.1.1-7"></a>

##### United States: August 2025 labeling supplements

> “Prior Approval sNDA 002 provides for updates to the U.S. Prescribing Information (USPI) and Patient Information labeling, based on safety and efficacy data generated from Study DAY101-001/PNOC026 (FIREFLY-1); and references the availability of an FDA-approved companion diagnostic.”
> ““Changes Being Effected” sNDA 003 provides for a new 20 count carton configuration comprised of four blister cards each containing five 100 mg tablets to support the 500 mg once weekly dose packaging configuration.”

Source: [FDA supplement approval letter NDA 217700 (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217700Orig1s002,%20s003,%20s004ltr.pdf)

<a id="topic-2.1.1-8"></a>

##### United States: accelerated approval status in September 2026

> “Patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.”

Source: [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)

<a id="topic-2.1.1-9"></a>

##### First-line pLGG: FIREFLY-2 enrollment completion and expected data timing

> “today announced that it has completed enrollment in the FIREFLY-2 clinical trial, which is evaluating the efficacy, safety and tolerability of tovorafenib vs standard of care chemotherapy in the front-line setting of therapy for patients aged 6 months to 25 years with low-grade glioma.”
> “It is being conducted at approximately 140 sites across the U.S., Canada, Europe, Australia, South America, Middle East and Asia, and in just over three years has enrolled approximately 400 participants who are receiving either tovorafenib once weekly or one of four standard of care (SoC) chemotherapy regimens.”
> “The primary analysis is expected to occur approximately 12 months after the last patient is enrolled; preliminary insights are expected to be available in 2027.”

Source: [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.1.1-10"></a>

##### First-line pLGG: FIREFLY-2 status at the time of the EU assessment

> “Study DAY101-002 [LOGGIC/FIREFLY-2] is a Phase 3, randomized, global, multicenter trial of tovorafenib monotherapy versus standard of care chemotherapy in paediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy.”
> “As of 15 January 2025, there are currently 110 active sites and 169 randomized patients.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.1-11"></a>

##### Regulatory status: Submission planned; FIREFLY-2 topline data expected by mid-2027, with a potential first-line approval in 2028

> “Complete enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial in first-line pLGG in the first half of 2026, enabling a mid-2027 data readout and a potential approval in 2028”

Source: [Day One Biopharmaceuticals preliminary 2025 revenue announcement (2026)](https://www.globenewswire.com/news-release/2026/01/11/3216499/0/en/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance.html)

> “Trial aims to extend OJEMDA's indication beyond relapsed/refractory setting to address significant unmet need; topline data expected by mid-2027”

Source: [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.1.1-12"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-13"></a>

##### European Union: conditional marketing authorisation

> “Ojemda has been given conditional authorisation for use in the EU. This means that it has been authorised on the basis of less comprehensive data than are normally required, because it fulfils an unmet medical need.”
> “Ojemda received a conditional marketing authorisation valid throughout the EU on 20 April 2026.”

Source: [EMA Ojemda medicine overview (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda)

> “today announced that the European Commission (EC) has granted conditional marketing authorization for Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.”
> “This EC decision applies across all 27 EU Member States, as well as Iceland, Liechtenstein, and Norway.”

Source: [Ipsen EU approval announcement (2026)](https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/)

<a id="topic-2.1.1-14"></a>

##### European Union: assessment procedure and orphan designation

> “The CHMP did not grant this request, as it considered that, based on the submitted data package, the justification for an accelerated assessment was not sufficiently substantiated.”
> “Orphan Designation for the treatment of glioma granted on 20 May 2021 (EU/3/21/2434)”
> “The application was received by the EMA on 26 February 2025”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.1-15"></a>

##### Japan: marketing approval

> “IPSEN Co., Ltd. obtained a regulatory approval from the MHLW on September 16, 2026.”

Source: [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html)

> “A key Japanese health ministry panel on August 24 recommended approval of a batch of new medicines and indications including a subcutaneous version of MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Ipsen’s targeted glioma therapy tovorafenib, known as Ojemda.”

Source: [Pharma Japan (2026)](https://pj.jiho.jp/article/256174)

<a id="topic-2.1.1-16"></a>

##### Other countries: approvals and orphan designations reported by the ex-US licensee

> “Tovorafenib has also been approved in EAU and has been granted Orphan Drug Designation in Russia, Switzerland, Taiwan, Japan South Korea and Australia.”

Source: [Ipsen EU approval announcement (2026)](https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/)

<a id="topic-2.1.1-17"></a>

##### United Kingdom, Canada, and Australia: marketing authorisation

No evidence found.

Additional sources: [ClinicalTrials.gov NCT05566795](https://clinicaltrials.gov/study/NCT05566795)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Day One Biopharmaceuticals

> “Manufactured for: Day One Biopharmaceuticals, Inc., Brisbane CA 94005”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Day One Biopharmaceuticals, Inc., now part of Servier Group, today announced that it has completed enrollment in the FIREFLY-2 clinical trial”

Source: [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name, brand name, and US labeler

> “OJEMDA (tovorafenib) tablets, for oral use”
> “OJEMDA (tovorafenib) for oral suspension”
> “Initial U.S. Approval: 2024”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.1-3"></a>

###### Development codes

> “Tovorafenib, previously known as DAY101, TAK-580, MLN2480, BSK1369 and BIIB024 at various points during development (these names appear in this submission), is an oral, central nervous system (CNS)-penetrant, selective small-molecule, Type II rapidly accelerated fibrosarcoma (RAF) inhibitor.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class

> “OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “OJEMDA (tovorafenib) is a Type II RAF kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases.”

Source: [Day One Biopharmaceuticals accelerated approval announcement (2024)](https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated)

<a id="topic-2.1.2.1-5"></a>

###### Origin: acquisition of rights from Takeda

> “Day One also announced today that it acquired Takeda’s rights to develop and commercialize DAY101 (formerly TAK-580) worldwide, including certain rights previously licensed by Takeda from Sunesis Pharmaceuticals.”
> “Takeda retains license to develop and commercialize DAY101 in certain rare disease indications.”

Source: [Day One Biopharmaceuticals Series A announcement (2020)](https://ir.dayonebio.com/news-releases/news-release-details/day-one-biopharmaceuticals-shares-plans-rapidly-develop-new)

<a id="topic-2.1.2.1-6"></a>

###### Ex-US licensing agreement with Ipsen

> “Day One will maintain exclusive global development and U.S. commercial rights for tovorafenib.”
> “Under the terms of the agreement, Ipsen will be responsible for the regulatory and commercial activities for tovorafenib in all territories outside of the U.S. Day One will receive an upfront payment of approximately $111 million, which includes approximately $71 million in cash as well as a $40 million equity investment at a premium and up to approximately $350 million in additional launch and sales milestone payments.”

Source: [Ipsen and Day One Biopharmaceuticals licensing announcement (2024)](https://www.ipsen.com/press-release/ipsen-and-day-one-enter-into-exclusive-ex-u-s-licensing-agreement-to-commercialize-tovorafenib-for-the-most-common-childhood-brain-tumor-2918482/)

<a id="topic-2.1.2.1-7"></a>

###### Acquisition of Day One Biopharmaceuticals by Servier

> “Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share.”
> “As a result of the Merger, Day One will become a wholly owned subsidiary of Parent. With completion of the Merger, the transaction will represent a total equity value of approximately $2.5 billion.”

Source: [Servier acquisition completion announcement (2026)](https://servier.com/en/newsroom/servier-completes-the-acquisition-of-day-one-biopharmaceuticals/)

<a id="topic-2.1.2.1-8"></a>

###### EU marketing authorisation holder

> “Ipsen (the Applicant) has acquired the rights from Day One Biopharmaceuticals, Inc. to register and commercialize tovorafenib in countries other than the United States (US).”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### United States: tablets and powder for oral suspension

> “Each tablet contains 100 mg of tovorafenib.”
> “25 mg/mL: white to off white powder. After reconstitution, each mL of strawberry flavored tovorafenib suspension contains 25 mg of tovorafenib. Each bottle delivers 300 mg of tovorafenib in 12 mL.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.2-2"></a>

###### United States: tablet carton configurations by weekly dose

| Weekly dose | Each carton contains | Each blister card contains | NDC |
| --- | --- | --- | --- |
| 400 mg | “4 blister cards” | “four 100 mg tablets” | “NDC 82950-001-16” |
| 500 mg | “4 blister cards” | “five 100 mg tablets” | “NDC 82950-001-20” |
| 600 mg | “4 blister cards” | “six 100 mg tablets” | “NDC 82950-001-24” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.2-3"></a>

###### United States: oral suspension kit

> “25 mg/mL: white to off white powder in a clear glass bottle, co-packaged with a press-in bottle adaptor and a 20 mL oral dosing syringe (NDC# 82950-012-01).”
> “Suspension must be used immediately after reconstitution.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.2-4"></a>

###### European Union: film-coated tablets and powder for oral suspension

> “Each film-coated tablet contains 100 mg tovorafenib.”
> “Each carton contains 16, 20 or 24 film-coated tablets.”
> “One bottle of Ojemda contains 300 mg of tovorafenib. After reconstitution, one bottle of oral suspension delivers 12 ml of tovorafenib at a concentration of 25 mg/ml.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.2-5"></a>

###### Japan: tablets and dry syrup

> “Ojemda® Tablets 100 mg and Ojemda Dry Syrup 300 mg (generic name: tovorafenib)”

Source: [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Summary: estimated monthly and annual cost

- Price basis: U.S. wholesale acquisition cost (WAC) as of July 2026 published by Day One Biopharmaceuticals, $41,412.11 per tablet carton (16, 20, or 24 tablets of 100 mg; the same price for all three cartons) and $10,353.03 per single-use oral suspension bottle. Tovorafenib is FDA-approved and marketed for relapsed or refractory BRAF-altered pediatric low-grade glioma; no first-line indication is approved, so this estimate applies the price of the approved product to first-line use.
- Dosing basis: 380 mg/m2 orally once weekly (maximum 600 mg) per the US prescribing information; tablets at 400, 500, or 600 mg once weekly for BSA of 0.90 m2 or more, with each carton holding 4 weekly blister cards; oral suspension at 125 to 600 mg once weekly for BSA of 0.30 m2 or more, with each bottle delivering 300 mg and two bottles reconstituted for doses greater than 300 mg. Treatment continues until disease progression or intolerable toxicity, and the estimate assumes 52 weekly doses per year without interruption.
- Base case: tablets at any BSA of 0.90 m2 or more, $41,412.11 per carton of 4 weekly doses × 13 cartons per year = $538,357 per year; ÷ 12 = $44,863 per month. Oral suspension at 300 mg or less (one bottle per week, BSA 0.30 to 0.83 m2) gives the same cost: $10,353.03 × 52 weeks = $538,358 per year; ÷ 12 = $44,863 per month.
- Range: $538,357 to $1,076,715 per year ($44,863 to $89,726 per month). The upper bound is two oral suspension bottles per week: $20,706.06 × 52 weeks = $1,076,715 per year; ÷ 12 = $89,726 per month.
- Rationale for the range: the flat carton price makes tablet cost independent of the 400, 500, or 600 mg dose and of tablet dose reductions; an oral suspension dose greater than 300 mg requires two single-use bottles, which applies to the 350 mg dose for BSA 0.84 to 0.89 m2 (below the tablet range), to suspension use at BSA of 0.90 m2 or more (375 to 600 mg), and to the second tablet dose reduction for BSA 1.13 to 1.39 m2, which moves to suspension doses of 325 or 375 mg; the suspension dose reductions bring every BSA band of 0.89 m2 or less to 300 mg or less, one bottle per week. Drug holidays and treatment interruptions would lower annual cost and are not modeled.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.

Source: [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2026)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_01.07.26.pdf); [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.3-2"></a>

###### United States: wholesale acquisition cost by package, July 2026

| Package | NDC | WAC price |
| --- | --- | --- |
| Tablets, 16 count | “82950-0001-16” | “$41,412.11” |
| Tablets, 20 count | “82950-0001-20” | “$41,412.11” |
| Tablets, 24 count | “82950-0001-24” | “$41,412.11” |
| Oral suspension, 1 bottle | “82950-0012-01” | “$10,353.03” |

Source: [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2026)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_01.07.26.pdf)

<a id="topic-2.1.2.3-3"></a>

###### United States: wholesale acquisition cost disclosure terms, July 2026

> “OJEMDA 100 MG TABLET (24 tablets)”
> “Data as of: 07/01/2026”
> “WAC does not reflect discounts, rebates and other reductions in price.”

Source: [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2026)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_01.07.26.pdf)

<a id="topic-2.1.2.3-4"></a>

###### United States: wholesale acquisition cost by package, January 2025

| Package | NDC | WAC price |
| --- | --- | --- |
| Tablets, 16 count | “82950-0001-16” | “$35,272.64” |
| Oral suspension, 1 bottle | “82950-0012-01” | “$8,818.16” |

Source: [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2025)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_VF.pdf)

<a id="topic-2.1.2.3-5"></a>

###### United States: wholesale acquisition cost disclosure terms, January 2025

> “OJEMDA 100 MG TABLET (20 tablets)”
> “OJEMDA for oral suspension (1 single use bottle, 7-day supply, 4 bottles for 28-day supply)”
> “Data as of: 01/01/2025”
> “WAC does not reflect discounts, rebates and other reductions in price.”

Source: [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2025)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_VF.pdf)

<a id="topic-2.1.2.3-6"></a>

###### United States: annual launch list price and estimated net price

| Drug | Annual list price | Best annual net price estimate |
| --- | --- | --- |
| Ojemda (tovorafenib) | “$330,720.00” | “$297,648.00” |

Source: [ICER Launch Price and Access Report (2025)](https://icer.org/wp-content/uploads/2025/10/ICER_2025_Launch-Price-and-Access-Final-Report_For-Publication.pdf)

<a id="topic-2.1.2.3-7"></a>

###### United States: dose assumption for the annual price estimate

> “We used the 375 mg weekly dose in our calculations.”

Source: [ICER Launch Price and Access Report (2025)](https://icer.org/wp-content/uploads/2025/10/ICER_2025_Launch-Price-and-Access-Final-Report_For-Publication.pdf)

<a id="topic-2.1.2.3-8"></a>

###### United States: average sales price

Not applicable.

<a id="topic-2.1.2.3-9"></a>

###### Prices outside the United States

No evidence found.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS drug class

| Field | Quoted record |
| --- | --- |
| Brand name | “Ojemda” |
| Drug class | “Antineoplastic Agents” |

Source: [ASHP AHFS DI Essentials tovorafenib monograph (2025)](https://www.drugs.com/monograph/tovorafenib.html)

<a id="topic-2.1.2.4-2"></a>

###### ATC classification

> “Pharmacotherapeutic group: Antineoplastic agent, protein kinase inhibitor, B-Raf serine-threonine kinase (RAF) inhibitor, ATC code: L01EC04”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Summary: labeled indications and first-line use

The US and EU labels restrict tovorafenib to relapsed or refractory disease (US) or disease that progressed after one or more prior systemic therapies (EU). Neither label includes first-line (treatment-naive) systemic therapy of pLGG, so first-line use in the US and EU is outside the approved indication until FIREFLY-2 results are reviewed. The Japanese indication statement issued with the September 2026 approval (low-grade glioma with a BRAF gene mutation or fusion gene) does not name a line of therapy, although the supporting data came from FIREFLY-1 in relapsed or progressive disease.

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad); [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf); [IPSEN Japan approval announcement (2026)](https://bio.nikkeibp.co.jp/atcl/release/26/09/17/28792/); [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html); [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.1.2.5-2"></a>

###### United States: labeled indication, relapsed or refractory pLGG

> “OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.”
> “This indication is approved under accelerated approval based on response rate and duration of response”
> “Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.5-3"></a>

###### European Union: labeled indication, pLGG progressed after prior systemic therapy

> “Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2).”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.5-4"></a>

###### Japan: approved indication

> “オジェンダ®（一般名：トボラフェニブ）について、「BRAF遺伝子変異又は融合遺伝子を有する低悪性度神経膠腫」を効能又は効果として、厚生労働省より製造販売承認を取得したことをお知らせいたします。”

Source: [IPSEN Japan approval announcement (2026)](https://bio.nikkeibp.co.jp/atcl/release/26/09/17/28792/)

> “The efficacy and safety of tovorafenib for relapsed or progressive low-grade glioma with BRAF V600 alterations or BRAF fusion gene-positive were evaluated in an overseas Phase II clinical study (FIREFLY-1 study).”

Source: [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html)

<a id="topic-2.1.2.5-5"></a>

###### First-line pLGG: indication under evaluation

> “Tovorafenib is under evaluation as a therapy for patients aged less than 25 years with pLGG harboring BRAF fusion or rearrangement, or BRAF V600 mutation requiring front-line treatment (Phase III FIREFLY-2/LOGGIC).”

Source: [Ipsen EU approval announcement (2026)](https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Summary: type II RAF inhibition and relevance to BRAF fusion-driven pLGG

Tovorafenib is an oral, CNS-penetrant type II RAF kinase inhibitor of BRAF V600E, wild-type BRAF, and wild-type CRAF, with in vitro IC50 values of 7.1, 10.1, and 0.7 nM, respectively. Type I BRAF inhibitors such as dabrafenib act on monomeric BRAF V600E, do not block signaling from the dimer-dependent KIAA1549:BRAF fusion, and can cause paradoxical MAPK pathway activation in BRAF fusion-driven or BRAF wild-type tumors. Tovorafenib binds RAF monomers and dimers; preclinical studies in pediatric low-grade astrocytoma models showed equipotent activity against BRAF V600E and KIAA1549:BRAF with brain penetrance, and the EMA assessment found no paradoxical activation in BRAF fusion models. Tovorafenib is relatively sparing of ARAF, and in NF1 loss-of-function models without a BRAF alteration it increased ERK phosphorylation at low concentrations, which underlies the NF1-associated tumor warning. The mechanistic data apply to both the approved relapsed or refractory indication and the investigational first-line setting (FIREFLY-2).

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf); [Sun et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5464455/); [Tkacik et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10149214/); [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.1.2.6.1-2"></a>

###### Labeled mechanism of action

> “Tovorafenib is a Type II RAF kinase inhibitor of mutant BRAF V600E, wild-type BRAF, and wild-type CRAF kinases.”
> “Tovorafenib exhibited antitumor activity in cultured cells and xenograft tumor models harboring BRAF V600E and V600D mutations, and in a xenograft model harboring a BRAF fusion.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Tovorafenib is a central nervous system (CNS) penetrant, selective small molecule Type II RAF kinase inhibitor of mutant BRAF V600E, wild-type BRAF, and wild-type CRAF kinases, including RAF monomers and dimers and BRAF fusion, suppressing activation of the mitogen-activated protein kinase (MAPK) pathway”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.6.1-3"></a>

###### Binding mode and kinase potency

> “Tovorafenib is a type-II RAF kinase inhibitor that inhibits RAF monomers and dimers.”
> “This binding mode is similar to that of sorafenib and differs from that of the Type-I BRAF inhibitor vemurafenib. In vitro, tovorafenib inhibited the kinase activity of BRAF V600E, WT BRAF, and WT CRAF kinases, with IC50 values of 7.1, 10.1, and 0.7 nM, respectively.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Rationale for a type II inhibitor in KIAA1549:BRAF fusion tumors

> “These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA.”
> “We identify a type II RAF inhibitor that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers. This drug (MLN2480, also known as TAK-580) has good brain penetrance and is active on authentic human PLGA cells in brain organotypic cultures.”

Source: [Sun et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5464455/)

> “Type I RAF inhibitors such as dabrafenib are not indicated for the treatment of tumors harboring a BRAF fusion due to paradoxical activation which may increase the risk of tumor growth”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.1.2.6.1-5"></a>

###### Paradoxical MAPK activation: BRAF fusion models versus NF1 loss-of-function models

> “Data generated in preclinical BRAF fusion models suggest that tovorafenib is capable of inhibiting MAPK pathway signalling without inducing paradoxical activation in BRAF fusion–driven systems. However, the translational relevance of these models is limited, as they do not adequately reflect the genetic and biological characteristics of paediatric low-grade gliomas, particularly with regard to TP53 status.”
> “This effect is suggestive of paradoxical activation of the pathway in NF1-LOF tumour cell lines. Indeed, paradoxical activation by tovorafenib at subtherapeutic doses (0.01–0.1 µM) was also described in literature. This could be linked to tovorafenib being ARAF sparing.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.1-6"></a>

###### RAF isoform selectivity: relative ARAF sparing

> “We find that tovorafenib and naporafenib are most potent against CRAF but markedly less potent against ARAF.”
> “Type II RAF inhibitors are generally regarded as pan-RAF inhibitors, but our studies of these two agents, together with recent work with type II inhibitors belvarafenib and naporafenib, indicate that relative sparing of ARAF may be a property of multiple drugs of this class.”

Source: [Tkacik et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10149214/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Exposure-response relationships: US prescribing information

> “Tovorafenib exposure is associated with reduction in height-for-age z-scores in pediatric patients. Reduced height-for-age risk persists during treatment with tovorafenib.”
> “Higher tovorafenib exposure is associated with increased risk of skin rash, elevated liver enzymes (AST and ALT), and elevated creatine phosphokinase.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.6.2-2"></a>

###### Dose optimization from 420 to 380 mg/m2 based on exposure-response analyses

> “There were no clinically significant differences in exposure-response relationships for ORR observed over the actual dose range of 290 to 476 mg/m 2 (0.76-1.25 times the approved recommended dosage) evaluated in Arm 1”
> “Based on pharmacokinetic/pharmacodynamic modeling, this dose reduction was also anticipated to partially mitigate the reductions in growth velocity observed in children in FIREFLY-1”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.1.2.6.2-3"></a>

###### Exposure-safety analyses: EMA assessment

> “Logistic regression analysis identified statistically significant positive correlations between Cmin and reporting of the following AEs: Grade ≥2 elevated ALT, Grade ≥2 or Grade ≥3 elevated AST, Grade ≥2 fatigue, Grade ≥1 or ≥2 facial edema, Grade ≥2 or Grade ≥3 skin rash, and Grade ≥3 TEAE.”
> “Separate PK/PD models demonstrated a correlation between tovorafenib concentration and hemoglobin, AST, and CPK. Higher tovorafenib concentrations were associated with decreased hemoglobin and increased AST and CPK.”
> “The claimed dose has been investigated in the pivotal clinical study. No therapeutic window could be drawn from the available data.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Cardiac electrophysiology

> “At the recommended tovorafenib dose of 380 mg/m2 orally once weekly (not to exceed 600 mg), a mean increase in the QT interval > 20 milliseconds was not observed.”
> “In hERG-transfected HEK293 cells, hERG channel was inhibited indicating potential for QT prolongation. Half-maximal inhibitory concentration was 8.9 μM which is 32-fold higher than the clinical plasma unbound concentration in adults.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Tumor pharmacodynamic biomarkers: adult melanoma (pERK)

> “There were median decreases from baseline in the level of pERK staining on Day 21 of ≥70% in the BRAF mutation-positive treatment-naïve cohort (-94.5% [range: -100% to -89%])”
> “No PD biomarker investigation was performed in the phase II paediatric glioma study FIREFLY-1.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### Preclinical activity in pediatric low-grade astrocytoma models

> “In genetically engineered murine models of paediatric low-grade astrocytoma with either KIAA1549:BRAF fusion or the BRAFV600E expression (p53-/- mouse neuroprogenitor cells stably transduced with the indicated constructs) described by Sun et al. (2017), tovorafenib inhibited pERK in a concentration-dependent manner and reduced cell proliferation with an”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.2-7"></a>

###### Preclinical NF1 model without BRAF alteration

> “In vitro, tovorafenib increased phosphorylation of ERK at clinically relevant concentrations in cells with neurofibromatosis Type 1-loss of function (NF1-LOF) suggesting activation, rather than inhibition, of the MAP kinase pathway. In an NF1 genetically engineered mouse model of plexiform neurofibroma without BRAF alteration, tovorafenib did not have antitumor activity, and while not statistically significant, an increase in tumor volume was noted in 2/12 mice (approximately 17%).”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

Additional sources: [FDA multi-discipline review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000MultidisciplineR.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Summary: pharmacokinetic profile

Based on population PK modelling, tovorafenib at the labeled dose has a steady-state Cmax of 6.9 µg/mL and AUC of 508 µg·h/mL, reaches steady state in 12 days, and has a terminal half-life of approximately 56 hours with no clinically significant accumulation on once-weekly dosing. Median Tmax is 3 hours for tablets and oral suspension; a high-fat meal delays Tmax to 6.5 hours without clinically significant changes in Cmax or AUC. Plasma protein binding is 97.5%. Aldehyde oxidase and CYP2C8 are the primary metabolic enzymes (CYP2C8 fraction metabolized estimated at 49.23% in the PBPK model), and 65% to 66.1% of a radiolabeled dose is recovered in feces and 27% to 28.7% in urine, with less than 0.2% excreted unchanged in urine. In adults (phase 1, 600 mg once weekly), the mean terminal half-life was approximately 70 hours. No formal PK studies were conducted in the pediatric glioma population; exposure was estimated from sparse sampling, and the EMA considered predictions for participants younger than 2 years unreliable (three observations), requiring additional PK data by 30 April 2032. The popPK model estimated 21.5% higher apparent clearance in males than in females.

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad); [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf); [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf); [Rasco et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10261210/)

<a id="topic-2.1.2.6.3-2"></a>

###### Pharmacokinetic parameters: US prescribing information

| Parameter | Quoted value |
| --- | --- |
| Steady-state exposure | “Tovorafenib steady state maximum concentration (C max ) is 6.9 µg/mL (23%) and the area under the concentration-time curve (AUC) is 508 µg*h/mL (31%).” |
| Time to steady state and accumulation | “Time to reach steady state of tovorafenib is 12 days (33%). Tovorafenib exposure increases in a dose-proportional manner. No clinically significant tovorafenib accumulation occurs.” |
| Absorption | “is 3 hours (1.5, 4 hours), following a single dose with tablets or oral suspension.” |
| Effect of food | “No clinically significant differences in tovorafenib C max and AUC were observed following administration of tablets with a high-fat meal (approximately 859 total calories, 54% fat) compared to fasted conditions, but the T max was delayed to 6.5 hours.” |
| Distribution | “Tovorafenib apparent volume of distribution is 60 L/m 2 (23%). Tovorafenib is 97.5% bound to human plasma proteins in vitro.” |
| Elimination | “Tovorafenib terminal half-life is approximately 56 hours (33%) and the apparent clearance is 0.7 L/h/m 2 (31%).” |
| Metabolism | “Tovorafenib is primarily metabolized by aldehyde oxidase and CYP2C8 in vitro. CYP3A, CYP2C9, and CYP2C19 metabolize tovorafenib to a minor extent.” |
| Excretion | “Following a single oral dose of radiolabeled tovorafenib, 65% of the total radiolabeled dose was recovered in the feces (8.6% unchanged) and 27% of the dose was recovered in the urine (0.2% unchanged).” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.6.3-3"></a>

###### Plasma protein binding and mass balance: EU product information

> “Tovorafenib is highly protein-bound to albumin (≈ 95%) and moderately bound to alpha-1 acid glycoprotein (AAG) (≈42%).”
> “Based on clinical study in healthy volunteers, following a single oral dose of radiolabelled tovorafenib, 66.1% of the total radiolabelled dose was recovered in the faeces (8.6% unchanged) and 28.7% of the dose was recovered in the urine (0.2% unchanged).”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Population PK model structure and data sources

> “According to the applicant, tovorafenib concentration-time course was described by a one-compartment model with three-transit compartments absorption model (designated as Ka [Tablet]) for”
> “No formal studies were conducted in paediatric and young adult patients with glioma. In this target group of patients only sparse samples were collected and analysed according to a PPK approach.”
> “The PBPK model was refined by adjusting the CYP2C8 fractional metabolism value to 49.23%, based on available enzyme kinetic and clinical mass balance data.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.3-5"></a>

###### Covariates: sex, renal function, and hepatic function in the popPK analysis

> “Based on this analysis CL /F was associated with sex, where males were estimated to have a 21.5% higher CL/F than females.”
> “In this PPK analysis 21 patients with moderate and 107 patients with mild RI were part of the analysed dataset.”
> “Moderate and mild hepatic impairment was not identified as a significant covariate of clearance in population PK analysis by the applicant.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.3-6"></a>

###### Pediatric exposure and uncertainty below 2 years of age

> “Cmax and AUC in paediatric patients aged 11 months to 17 years were within the range of values observed in adults given the same dose per body surface area.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

> “No reliable estimation could be made in patients under two-years of age even with the model incorporating maturation functions.”
> “The reliability of the predictions of the systemic exposure in paediatric patients below 2 years could not be confirmed as very few data are available in this sub-group of patients (three observations).”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.3-7"></a>

###### Brain distribution: nonclinical

> “The brain:plasma AUC ratio of tovorafenib-derived radioactivity was 0.57 (cerebellum), 0.54 (cerebrum) and 0.67 (medulla) indicating the passage of the blood-brain barrier.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.6.3-8"></a>

###### Adults with advanced solid tumors: once-weekly pharmacokinetics

> “The mean plasma terminal half-life ( t 1/2 ) of tovorafenib was approximately 70 h (range 31–119 h) as defined in 20 evaluable patients receiving 600 mg QW.”
> “For QW dosing regimens, minimum drug accumulation was observed and the geometric mean R auc (accumulation ratio based on AUC 0-last ) was in the range of 1.03–1.09.”

Source: [Rasco et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10261210/)

<a id="topic-2.1.2.6.3-9"></a>

###### Children with relapsed or recurrent MAPK-altered tumors: PNOC014 phase 1

> “Administration of tovorafenib once every week to children resulted in dose-proportional increases in Cmax and AUC like that described in the adult study”
> “Much of the PK sampling for this phase was disrupted due to COVID-19 restrictions on travel.”

Source: [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)

Additional sources: [FDA multi-discipline review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000MultidisciplineR.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Summary: labeled warnings and safety profile

All labeled safety data derive from relapsed or refractory disease (FIREFLY-1, 137 participants with pLGG; pooled population of 172 participants including adults with solid tumors at a 600 mg flat dose); the first-line FIREFLY-2 trial is active, not recruiting, with primary completion estimated for June 2027, and no first-line safety results were identified. The US label has no contraindications and no boxed warning; the EU SmPC lists hypersensitivity as the only contraindication. Warnings and precautions cover hemorrhage (37% of the pooled population, including intratumoral hemorrhage in 9% and one fatal tumor hemorrhage), skin toxicity (rash 67%, grade 3 rash 12%; photosensitivity 12%), hepatotoxicity (increased AST 74% and ALT 42%), effect on growth (46% of 133 participants aged 18 years or younger, 35% grade 3 or higher), embryo-fetal toxicity, and possible tumor growth in NF1. In FIREFLY-1, serious adverse reactions occurred in 45% of participants; adverse reactions led to dose interruption in 57%, dose reduction in 24%, and permanent discontinuation in 7%. Growth velocity recovered after treatment stopped in 34 of 38 evaluable participants (89%) in a pooled analysis of three studies. The EU risk management plan lists growth retardation and intratumoral hemorrhage as important identified risks, decreased fertility as an important potential risk, and long-term safety as missing information.

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad); [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf); [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf); [Kline et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10029); [ClinicalTrials.gov NCT05566795](https://clinicaltrials.gov/study/NCT05566795)

<a id="topic-2.1.2.7.1-2"></a>

###### Contraindications

> “None .”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.7.1-3"></a>

###### Boxed warning and REMS

No evidence found.

<a id="topic-2.1.2.7.1-4"></a>

###### Hemorrhage

> “Hemorrhage, including major hemorrhage defined as symptomatic bleeding in a critical area or organ, can occur with OJEMDA. In the pooled safety population [see Adverse Reactions (6.1) ], hemorrhagic events occurred in 37% of patients, including epistaxis in 26% and intratumoral hemorrhage in 9%. Serious events of bleeding occurred in 5% of patients including Grade 5 tumor hemorrhage in 1 patient (0.6%). OJEMDA was permanently discontinued for hemorrhage in 2% of patients.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “In FIREFLY-1, intratumoural haemorrhage (Including terms tumour haemorrhage and intracranial tumour haemorrhage) were observed in 13.9% patients, 3.6% patients reported Grade ≥ 3 events, 0.7% patient reported a Grade 5 event. Tovorafenib was permanently discontinued due to ITH events in 2.9% of patients.”
> “The risk of tumour haemorrhage may be increased with concomitant use of anticoagulants and antiplatelet therapy.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

> “However, half (eight of 15) of the patients with intratumoral hemorrhage were asymptomatic, with areas of tumor hemorrhage identified on routine trial MRI only.”

Source: [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/)

<a id="topic-2.1.2.7.1-5"></a>

###### Skin toxicity including photosensitivity

> “OJEMDA can cause rash, including maculopapular rash and photosensitivity. In the pooled safety population [see Adverse Reactions (6.1) ], rash occurred in 67% of patients treated with OJEMDA, including Grade 3 rash in 12%. Rash resulted in dose interruption in 15% of patients and dose reduction in 7% of patients. OJEMDA was permanently discontinued due to rash in 1% of patients (n=2).”
> “In the pooled safety population [see Adverse Reactions (6.1) ], photosensitivity occurred in 12% of patients treated with OJEMDA, including Grade 3 events in 0.6% of patients (n=1).”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-6"></a>

###### Rash incidence, time course, and resolution: FIREFLY-1 post hoc analysis

> “93% (128/137) of pts had a treatment-emergent rash.”
> “First rash episode median time to onset (TTO) was 0.43 mos, with 47% (60) G1, 41% (52) G2, and 13% (16) G3. First rash episodes resolved for 74% (95/128) of pts within a median of 2.67 mos.”
> “Only 1 (1%) pt had a rash-related tovorafenib discontinuation. 18% (23) of pts had dose interruptions due to rash. 11% (14) of pts had a dose reduction due to rash; of those, 57% (8) required no additional dose reductions due to rash.”

Source: [Witt et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10037)

<a id="topic-2.1.2.7.1-7"></a>

###### Hepatotoxicity

> “OJEMDA can cause hepatotoxicity. In the pooled safety population [see Adverse Reactions (6.1) ] , increased alanine aminotransferase (ALT) occurred in 42% and increased aspartate aminotransferase (AST) occurred in 74%, including Grade 3 ALT in 4% and increased AST in 2% of patients treated with OJEMDA. The median time to onset of increased ALT or AST was 14 days (range: 3 to 280 days).”
> “Monitor liver function tests, including ALT, AST and bilirubin, before initiation of OJEMDA, one month after initiation and then every three months thereafter and as clinically indicated.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-8"></a>

###### Effect on growth: US prescribing information

> “OJEMDA can cause reductions in growth velocity. In FIREFLY-1 [see Adverse Reactions (6.1) ] , treatment-emergent adverse effects on growth were reported in 46% of 133 patients 18 years of age or younger; 35% were Grade 3 or higher. Reduction in growth velocity resulted in dose interruption in 5% of patients, dose reduction in 2.3% of patients, and permanent discontinuation in 3% of patients.”
> “Growth velocity improved after interruption of treatment with OJEMDA. Among 81 evaluable patients, the median annualized growth velocity ranged from 0.86 to 1.8 cm/year during the 2-year treatment period. Of those, 17 patients had height measurements recorded at least 90 days off-treatment and had a 4.2 cm/year median annualized growth velocity.”
> “Among 35 patients who experienced reductions in growth velocity who had hand radiographs taken to assess bone age, there was no evidence of premature closure of the epiphyseal growth plates or advancement of bone age.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-9"></a>

###### Effect on growth: proposed mechanism and off-treatment recovery across three studies

> “Based on preclinical data, CRAF plays an essential role in chondrocyte maturation, a required step in linear bone growth.”
> “Median on-treatment AGV was 1.7 cm/yr [n = 36, interquartile range (IQR) 0.4 - 2.2] at 12 mo and 2.3 cm/yr (n = 25, IQR 0 - 3.3) at 24 mo.”
> “Thirty-four (89%) patients had recovery of AGV, and 28 (74%) had an increase in Z-score towards baseline indicating catch-up growth.”
> “Preliminary findings indicate tumor-associated precocious puberty/Tanner stage 4 in females may be a risk factor for slow AGV recovery.”

Source: [Kline et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10029)

<a id="topic-2.1.2.7.1-10"></a>

###### Effect on growth: comorbidities in participants with decreased growth velocity

> “Overall, 29% had decreased GV from baseline (BL); 19% had ≥50% decrease. Of the 40 with this AESI, 75% had pre-existing neuromuscular or endocrine comorbidities potentially affecting normal growth, including 6 on GnRH-analogues for precocious puberty and 9 with BL heights 2 SDs above/below average for age and sex.”

Source: [Kline et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11183845/)

<a id="topic-2.1.2.7.1-11"></a>

###### Effect on growth: PNOC014 phase 1

> “Eleven of 12 patients (92%) on drug for more than 6 months and not postpubertal experienced grade 3 growth suppression.”
> “For patients who received treatment for more than 6 months (n = 19), the average growth velocity was 0.94 cm/year (range: 0-3.6).”

Source: [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)

<a id="topic-2.1.2.7.1-12"></a>

###### Embryo-fetal toxicity

> “Based on findings from animal studies and its mechanism of action, OJEMDA may cause fetal harm when administered to a pregnant woman. Tovorafenib was embryo lethal in rats at doses approximately 0.8-fold the human exposure at the recommended dose based on area under the curve (AUC).”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-13"></a>

###### NF1-associated tumors

> “Based on nonclinical data in NF1 models without BRAF alterations, tovorafenib may promote tumor growth in patients with NF1 tumors [see Nonclinical Toxicology (13.2) ]. Confirm evidence of a BRAF alteration prior to initiation of treatment with OJEMDA .”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Additionally, we observed significant growth in the tumor of one patient with neurofibromatosis type 1 (NF1), raising concern for possible inadvertent paradoxical activation of the MAPK pathway as had been seen with other BRAF inhibitors.”

Source: [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)

<a id="topic-2.1.2.7.1-14"></a>

###### Relapsed or refractory pLGG: serious adverse reactions, dose modifications, and discontinuations in FIREFLY-1

> “Serious adverse reactions occurred in 45% of patients who received OJEMDA. Serious adverse reactions in >2% of patients included viral infection (9%), pneumonia (4%), and sepsis (4%). A fatal adverse reaction of tumor hemorrhage occurred in 1 patient (1%).”
> “Permanent discontinuation of OJEMDA due to an adverse reaction occurred in 7% of patients. Adverse reactions which resulted in permanent discontinuation of OJEMDA in more than one patient were tumor hemorrhage and reduction in growth velocity.”
> “Dosage interruptions of OJEMDA due to an adverse reaction occurred in 57% of patients. Adverse reactions which required dose interruption in ≥5% of patients included rash, pyrexia, vomiting, and hemorrhage.”
> “Dosage reductions of OJEMDA due to an adverse reaction occurred in 24% of patients. Adverse reactions which required dose reduction in ≥2% of patients included rash, and fatigue.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-15"></a>

###### Relapsed or refractory pLGG: adverse reactions in 20% or more of participants in FIREFLY-1 (N=137)

| Adverse reaction | All grades (%) | Grade 3 or 4 (%) |
| --- | --- | --- |
| Rash | “77” | “12” |
| Hair color changes | “76” | “0” |
| Fatigue | “55” | “4” |
| Viral infection | “55” | “7” |
| Vomiting | “50” | “4” |
| Headache | “45” | “1” |
| Hemorrhage | “42” | “5” |
| Pyrexia | “39” | “4” |
| Dry skin | “36” | “0” |
| Constipation | “33” | “0” |
| Nausea | “33” | “0” |
| Dermatitis acneiform | “31” | “1” |
| Upper respiratory tract infection | “31” | “1.5” |
| Abdominal pain | “28” | “0” |
| Pruritus | “26” | “1” |
| Edema | “26” | “0” |
| Paronychia | “26” | “1.5” |
| Diarrhea | “22” | “1.5” |
| Stomatitis | “20” | “0” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-16"></a>

###### Relapsed or refractory pLGG: laboratory abnormalities worsening from baseline in 20% or more of participants in FIREFLY-1

| Laboratory abnormality | All grades (%) | Grade 3 or 4 (%) |
| --- | --- | --- |
| Decreased hemoglobin | “90” | “15” |
| Decreased phosphate | “87” | “25” |
| Increased AST | “83” | “2” |
| Increased creatine phosphokinase | “83” | “11” |
| Increased LDH | “73” | “0” |
| Decreased potassium | “51” | “2” |
| Decreased lymphocytes | “50” | “2” |
| Increased ALT | “50” | “5” |
| Decreased leukocytes | “31” | “2” |
| Decreased albumin | “24” | “5” |
| Increased lymphocytes | “23” | “0” |
| Increased bilirubin | “22” | “1” |
| Decreased sodium | “20” | “2” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-17"></a>

###### Creatine phosphokinase elevation and anemia: EU product information

> “In FIREFLY-1, 62% of patients reported events of blood creatine phosphokinase (CPK) increased. 12.4% of patients reported Grade ≥ 3 events. All events were non-serious.”
> “In FIREFLY-1, anaemia was reported in 61.3% of patients. 13.1% of patients reported anemia events Grade ≥ 3.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.7.1-18"></a>

###### Adverse events not observed in FIREFLY-1

> “No signs of ocular toxicity, adverse impact on cardiac function or abnormal weight gain were observed in children treated with tovorafenib, unlike those observed with MEK inhibitors”
> “Although skin rashes were common in children treated with tovorafenib, no patients experienced life-threatening skin reactions, and development of squamous cell carcinomas and keratoacanthomas were not observed.”

Source: [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/)

<a id="topic-2.1.2.7.1-19"></a>

###### Fertility: nonclinical findings

> “Based on findings in animals, OJEMDA may impact fertility in males and females of reproductive potential. The effects on male animal fertility were reversible. The effects on female animal fertility were not reversible”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.7.1-20"></a>

###### EU risk management plan safety concerns

| Category | Quoted safety concern |
| --- | --- |
| Important identified risks | “Growth retardation” |
| Important identified risks | “Intratumoral haemorrhage” |
| Important potential risks | “Decreased fertility risk” |
| Missing information | “Long-term safety” |

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.7.1-21"></a>

###### FDA postmarketing requirements related to safety

> “PMRs have been issued to obtain additional data to characterize tovorafenib’s long-term safety, impact on growth and development, potential for gonadal toxicity, and drug-drug interactions.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.1.2.7.1-22"></a>

###### First-line pLGG: safety results from FIREFLY-2

No evidence found.

<a id="topic-2.1.2.7.1-23"></a>

###### Hemorrhage incidence and MAPK inhibitor exposure in a retrospective pediatric low-grade glioma cohort

> “Twelve patients (5.1%) experienced hemorrhage over 2,234 person-years (incidence: 0.54/100 person-years). Hemorrhage typically occurred years after initial tumor diagnosis (median 6.4 years).”
> “MAPK inhibitor exposure was associated with increased hemorrhage risk (HR 4.70, 95% CI 1.36–16.28, p = 0.015)”
> “tovorafenib showed a high hemorrhage rate (3/4 patients, 75.0%; p = 0.0004, OR 74.33)”
> “The observation is hypothesis-generating and supports prospective monitoring in clinical trials but does not establish causality.”

Source: [Grin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42414678/)

<a id="topic-2.1.2.7.1-24"></a>

###### Bone age, skeletal, and growth hormone findings in participants with decreased growth velocity

> “Nineteen of the 40 patients with this AESI had on-treatment bone age assessments; none showed advancement of bone age from BL or premature closure of growth plates. No osteopenia or abnormal fractures were reported.”
> “Of the 35 patients with growth hormone (GH) testing, only 2 had signs of GH deficiency (both had optic pathway tumors; 1 had GH deficiency at BL, the other, a new tumor-associated GH deficiency).”

Source: [Kline et al. (2024a)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10036)

Additional sources: [FDA multi-discipline review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000MultidisciplineR.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pediatric use and age limits

> “The safety and effectiveness of OJEMDA in patients younger than 6 months of age have not been established.”
> “Of these 137 patients, 2% (n=3) were 6 month to < 2 years of age, 67% (n=92) were 2 years to < 12 years of age, and 31% (n=42) were >12 years of age”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Tovorafenib paediatric clinical experience is limited, particularly in the specific age range 6 months to 2 years.”
> “The MAH shall generate additional PK data in paediatrics patients below 2 years of age and submit an updated population PK model incorporating these data, including an assessment of systemic exposure and, if necessary, revised dosing recommendations for this subgroup of patients.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Small body surface area

> “A recommended dosage for patients with BSA less than 0.3 m 2 has not been established.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.8-3"></a>

###### First-line pLGG: age range in FIREFLY-2

> “Less than 25 years of age with LGG with known activating RAF alteration.”

Source: [ClinicalTrials.gov NCT05566795](https://clinicaltrials.gov/study/NCT05566795)

<a id="topic-2.1.2.8-4"></a>

###### Hepatic impairment

> “No dose adjustment is recommended for patients with mild (bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN or bilirubin > 1× to 1.5× ULN and any AST) hepatic impairment. OJEMDA has not been studied in patients with moderate (bilirubin > 1.5× to 3× ULN and any AST) to severe (bilirubin > 3× ULN and any AST) hepatic impairment”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Patients with moderately or severely abnormal liver function tests should be monitored carefully when treated with tovorafenib.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

> “Despite liver being the primary route of elimination of tovorafenib, no dedicated study in patients with hepatic impairment (HI) was conducted.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Renal impairment

> “No dose adjustment is recommended for patients with mild-to-moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m 2 calculated by Schwartz equation or MDRD equation). OJEMDA has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m 2 )”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.8-6"></a>

###### Age, sex, and race

> “No clinically significant differences of tovorafenib were observed based on age (range: 1 to 94 years), sex, race (White, Black, Asian), mild hepatic impairment”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.8-7"></a>

###### Pregnancy

> “There are no available data on the use of OJEMDA in pregnant women. Oral administration of tovorafenib to pregnant rats during the period of organogenesis resulted in embryo lethality at exposures 0.8 times the human exposure at the recommended dose based on AUC”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Tovorafenib should not be administered to pregnant women unless the potential benefit to the mother outweighs the possible risk to the foetus.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.8-8"></a>

###### Lactation

> “There are no data on the presence of tovorafenib or its metabolites in human milk, their effects on the breastfed child, or on milk production. Due to the potential for serious adverse reactions in breastfed children from OJEMDA, advise lactating women not to breastfeed during treatment with OJEMDA and for 2 weeks following the last dose.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.8-9"></a>

###### Females and males of reproductive potential: pregnancy testing and contraception

> “Verify pregnancy status in females of reproductive potential prior to initiating OJEMDA”
> “Advise females of reproductive potential to use effective nonhormonal contraception during treatment with OJEMDA and for 28 days after the last dose. OJEMDA can render hormonal contraceptives ineffective”
> “Advise male patients with female partners of reproductive potential to use effective contraception during treatment with OJEMDA and for 2 weeks after the last dose.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Male patients with female partners of reproductive potential must use condoms and effective methods of contraception during treatment with tovorafenib and for 2 weeks after the last dose.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.8-10"></a>

###### Fertility

> “There are no data on the effects of tovorafenib on fertility in humans. Based on findings in animals, tovorafenib may impact fertility in males and females of reproductive potential and may not be reversible (see section 5.3).”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.8-11"></a>

###### Neurofibromatosis type 1

> “Patients with tumors harboring additional activating molecular alteration(s) (e.g., IDH1/2 mutations, FGFR mutations, etc.) or patients with known or suspected diagnosis of neurofibromatosis type 1 (NF1) were excluded.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Known or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2).”

Source: [ClinicalTrials.gov NCT05566795](https://clinicaltrials.gov/study/NCT05566795)

<a id="topic-2.1.2.8-12"></a>

###### Geriatric use

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Tovorafenib

<a id="topic-2.1.2.9.1-1"></a>

###### Strong or moderate CYP2C8 inhibitors and inducers: US prescribing information

> “Avoid coadministration of OJEMDA with a strong or moderate CYP2C8 inhibitor.”
> “Tovorafenib is a CYP2C8 substrate. Strong or moderate CYP2C8 inhibitors are predicted to increase tovorafenib exposure based on a mechanistic understanding of its elimination [see Clinical Pharmacology (12.3) ], which may increase the risk of adverse reactions with OJEMDA.”
> “Avoid coadministration of OJEMDA with a strong or moderate CYP2C8 inducer.”
> “Tovorafenib is a CYP2C8 substrate. Strong or moderate CYP2C8 inducers are predicted to decrease tovorafenib exposure based on a mechanistic understanding of its elimination [see Clinical Pharmacology (12.3) ], which may reduce the effectiveness of OJEMDA.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.9.1-2"></a>

###### Examples of CYP2C8 modulators: EU product information

> “Coadministration of tovorafenib with a strong or moderate CYP2C8 inhibitor (e.g. gemfibrozil) should be avoided.”
> “Coadministration of tovorafenib with a strong or moderate CYP2C8 inducer (e.g. carbamazepine) should be avoided.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.9.1-3"></a>

###### Evidentiary basis: no clinical DDI studies and ongoing gemfibrozil and carbamazepine study

> “No clinical DDI studies were conducted.”
> “In response, the Applicant stated that a Phase 1 drug-drug interaction study of tovorafenib as a victim is ongoing. This study will assess the effects of gemfibrozil (a strong CYP2C8 inhibitor) and carbamazepine (a moderate CYP2C8 inducer) on the pharmacokinetics of tovorafenib in healthy participants (REC).”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.9.1-4"></a>

###### Transporters

> “Tovorafenib is not a substrate of BCRP, P-glycoprotein (P-gp), OATP1B1 and OATP1B3. Tovorafenib has not been evaluated as a substrate of OAT1, OAT3, MATE1, MATE2-K and OCT2.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.9.1-5"></a>

###### Anticoagulants and antiplatelet agents: hemorrhage risk

> “The risk of haemorrhage may be increased with concomitant use of anticoagulants and antiplatelet therapy.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.9.1-6"></a>

###### Clinical trial restriction: PNOC014

> “Patients also could not receive treatment with strong CYP2C inducers or CYP2C8 inhibitors within 14 days of the first dose.”

Source: [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)

<a id="topic-2.1.2.9.1-7"></a>

###### Drug-disease interaction: NF1 loss of function

> “Based on these non-clinical data and discussions, and literature articles Rastogi et al. (2025)/ Bessler et al. (2024)2, in the NF1-LOF setting, there is a potential risk of increased tumour growth in response to tovorafenib, and this is reflected in the sections 4.4 and 5.3 of the SmPC.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.9.1-8"></a>

###### Gastric acid-reducing agents

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Tovorafenib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### CYP3A substrates and hormonal contraceptives: US prescribing information

> “Hormonal Contraceptives : Avoid coadministration of hormonal contraceptives with OJEMDA. If coadministration is unavoidable, use an additional effective nonhormonal contraceptive method during coadministration and for 28 days after discontinuation of OJEMDA.”
> “Other CYP3A Substrates: Avoid coadministration of OJEMDA with certain CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures. If coadministration is unavoidable, monitor patients for loss of efficacy unless otherwise recommended in the Prescribing Information for CYP3A substrates.”
> “Coadministration with hormonal contraceptives (CYP3A substrate) may decrease progestin-x and ethinyl estradiol exposure, which may lead to contraceptive failure and/or an increase in breakthrough bleeding”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.9.2-2"></a>

###### Model-predicted effect on midazolam and in vitro enzyme and transporter effects

> “CYP3A Substrates: Midazolam (CYP3A4 substrate) steady-state C max and AUC are predicted to decrease by at least 20% following coadministration with tovorafenib.”
> “CYP450 Enzymes : Tovorafenib inhibits CYP2C8, CYP2C9, CYP2C19 and CYP3A, but does not inhibit CYP1A2, CYP2B6, and CYP2D6 at clinically relevant concentrations.”
> “Tovorafenib induces CYP3A, CYP2C8, CYP1A2, CYP2B6, CYP2C9 and CYP2C19 at clinically relevant concentrations.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.9.2-3"></a>

###### Narrow therapeutic index CYP3A substrates, other CYP substrates, and transporter substrates: EU product information

> “Coadministration of tovorafenib with certain CYP3A substrates (e.g. tacrolimus) where minimal concentration changes may lead to serious therapeutic failures should be avoided.”
> “In vitro data indicated that tovorafenib may have the potential to induce CYP1A2 and CYP2B6 and to inhibit CYP2C8, CYP2C9. The clinical relevance of these findings is unknown.”
> “In vitro data indicated that tovorafenib may have the potential to inhibit BCRP, OATP1B1, OATP1B3 and MATE1, the clinical relevance of these findings is unknown.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.9.2-4"></a>

###### Ongoing clinical probe-substrate study

> “The MAH commits to submit the results of the study DAY101-104 to assess the effects of tovorafenib on the pharmacokinetics of probe substrates caffeine (CYP1A2), repaglinide (CYP2C8), flurbiprofen (CYP2C9), omeprazole (CYP2C19), midazolam (CYP3A4), bupropion (CYP2B6), and rosuvastatin (BCRP) in healthy participants.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.1.2.9.2-5"></a>

###### QT-prolonging agents

> “Tovorafenib presents a potential risk for QT prolongation, especially in case of association with other QT-prolonging agents.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Summary: dosing regimen and population context

The approved US and EU dose is 380 mg/m2 orally once weekly (maximum 600 mg), with the 100 mg tablet used for BSA of 0.90 m2 or more and the 25 mg/mL oral suspension for BSA of 0.30 to 0.89 m2; no dose is established for BSA below 0.3 m2. Treatment continues until disease progression or intolerable toxicity (EU: also loss of clinical benefit). The approved dose is lower than the 420 mg/m2 dose studied in PNOC014, FIREFLY-1 (actual range 290 to 476 mg/m2), and the first-line FIREFLY-2 trial; FDA selected 380 mg/m2 because exposure-response analyses showed no clinically significant relationship with response across the studied range, while higher exposure was associated with rash, liver enzyme elevation, and creatine phosphokinase elevation. The approved indications concern relapsed or refractory disease; no first-line dosing recommendation exists outside FIREFLY-2.

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad); [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf); [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)

<a id="topic-2.1.2.10.1-2"></a>

###### Recommended dosage: US prescribing information

> “The recommended dosage of OJEMDA based on body surface area (BSA) is 380 mg/m2 orally once weekly (the maximum recommended dosage is 600 mg orally once weekly) with or without food”
> “Continue once weekly dosing until disease progression or intolerable toxicity.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-3"></a>

###### Tablet dosing by body surface area

| BSA (m2) | Recommended dosage |
| --- | --- |
| 0.30-0.89 | “Administer OJEMDA oral suspension once weekly” |
| 0.90-1.12 | “400 mg once weekly” |
| 1.13-1.39 | “500 mg once weekly” |
| 1.40 or more | “600 mg once weekly” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-4"></a>

###### Oral suspension (25 mg/mL) dosing by body surface area

| BSA (m2) | Dose volume (mL) | Dosage |
| --- | --- | --- |
| 0.30-0.35 | “5” | “125 mg once weekly” |
| 0.36-0.42 | “6” | “150 mg once weekly” |
| 0.43-0.48 | “7” | “175 mg once weekly” |
| 0.49-0.54 | “8” | “200 mg once weekly” |
| 0.55-0.63 | “9” | “225 mg once weekly” |
| 0.64-0.77 | “11” | “275 mg once weekly” |
| 0.78-0.83 | “12” | “300 mg once weekly” |
| 0.84-0.89 | “14” | “350 mg once weekly” |
| 0.90-1.05 | “15” | “375 mg once weekly” |
| 1.06-1.25 | “18” | “450 mg once weekly” |
| 1.26-1.39 | “21” | “525 mg once weekly” |
| 1.40 or more | “24” | “600 mg once weekly” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose reductions for adverse reactions: tablets

| BSA (m2) | First dosage reduction | Second dosage reduction |
| --- | --- | --- |
| 1.13-1.39 | “400 mg once weekly” | “Administer OJEMDA oral suspension once weekly” |
| 1.40 or more | “500 mg once weekly” | “400 mg once weekly” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-6"></a>

###### Dose reductions for adverse reactions: oral suspension

| BSA (m2) | First reduction volume (mL) | First reduction dose | Second reduction volume (mL) | Second reduction dose |
| --- | --- | --- | --- | --- |
| 0.30-0.35 | “4” | “100 mg once weekly” | “3” | “75 mg once weekly” |
| 0.36-0.42 | “5” | “125 mg once weekly” | “4” | “100 mg once weekly” |
| 0.43-0.48 | “6” | “150 mg once weekly” | “5” | “125 mg once weekly” |
| 0.49-0.54 | “7” | “175 mg once weekly” | “6” | “150 mg once weekly” |
| 0.55-0.63 | “8” | “200 mg once weekly” | “6” | “150 mg once weekly” |
| 0.64-0.77 | “9” | “225 mg once weekly” | “8” | “200 mg once weekly” |
| 0.78-0.83 | “10” | “250 mg once weekly” | “8” | “200 mg once weekly” |
| 0.84-0.89 | “12” | “300 mg once weekly” | “10” | “250 mg once weekly” |
| 0.90-1.05 | “13” | “325 mg once weekly” | “11” | “275 mg once weekly” |
| 1.06-1.25 | “15” | “375 mg once weekly” | “13” | “325 mg once weekly” |
| 1.26-1.39 | “18” | “450 mg once weekly” | “15” | “375 mg once weekly” |
| 1.40 or more | “20” | “500 mg once weekly” | “16” | “400 mg once weekly” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-7"></a>

###### Dosage modifications by adverse reaction

| Adverse reaction and severity | Quoted modification |
| --- | --- |
| Hemorrhage, intolerable grade 2 or any grade 3 | “If improved to Grade 0-1, resume at lower dosage.” |
| Hemorrhage, recurrent grade 4 | “Permanently discontinue OJEMDA.” |
| Hepatotoxicity, grade 3 AST, ALT, or bilirubin | “If laboratory abnormality resolves within 8 days, resume OJEMDA at the same dose.” |
| Hepatotoxicity, grade 3 AST, ALT, or bilirubin | “If laboratory abnormality does not resolve within 8 days, resume OJEMDA at lower dosage.” |

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-8"></a>

###### Testing before initiation

> “Select patients for treatment with OJEMDA based on the presence of BRAF fusion or rearrangement, or BRAF V600 mutation in tumor specimens”
> “Before initiating OJEMDA, evaluate liver function tests, including ALT, AST and bilirubin”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.1-9"></a>

###### Recommended dose and duration: EU product information

> “The recommended dose of tovorafenib based on body surface area (BSA) is 380 mg/m2 once weekly. The maximum recommended dose is 600 mg once weekly (see Table 1).”
> “Treatment with tovorafenib should be continued once weekly until disease progression, loss of clinical benefit, or unacceptable toxicity.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.10.1-10"></a>

###### Relapsed or refractory pLGG: dose studied in FIREFLY-1 and optional drug holiday

> “Patients received tovorafenib approximately 420 mg/m2 orally once weekly (range: 290 to 476 mg/m2, 0.76-1.25 times the recommended dose) according to body surface area with a maximum dose of 600 mg until disease progression, loss of clinical benefit, or unacceptable toxicity.”
> “Per protocol, patients could also enter an optional drug holiday after completing 26 cycles of therapy/24 months of treatment and at the investigator discretion: 43% (33/76) patients were on a drug holiday, 14% (11/76) patients remained on treatment.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.10.1-11"></a>

###### Rationale for the approved dose lower than the phase 2 dose

> “As greater tovorafenib exposure is associated with increased risk of Grade ≥2 adverse events including skin rash, elevated liver enzymes, and elevated creatine phosphokinase, a modest reduction from 420 to 380 mg/m 2 was recommended to optimize the dose and improve the benefit-to-risk ratio in pediatric patients”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.1.2.10.1-12"></a>

###### Recommended phase 2 dose: PNOC014

> “The recommended phase II dose was 420 mg/m2 administered orally, once every week.”

Source: [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)

<a id="topic-2.1.2.10.1-13"></a>

###### First-line pLGG: dosing in FIREFLY-2

> “Dosage is adjusted for body surface area (BSA) calculated per the Mösteller Formula [√((height × weight)/3600)].”
> “Upon resolution and/or reversion, dosing may be restarted at the same dose or a lower dose, at the discretion of the local investigator.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Schedule, food, missed doses, and vomiting

> “Take OJEMDA at a regularly scheduled time once weekly.”
> “OJEMDA may be taken with or without food”
> “3 days or less, take the missed dose as soon as possible, and take the next dose on its regularly scheduled day.”
> “more than 3 days, skip the missed dose and take the next dose on its regularly scheduled day.”
> “If vomiting occurs immediately after taking a dose, repeat that dose.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.2-2"></a>

###### Minimum interval between doses: EU product information

> “A minimum of 4 days should occur between doses.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Tablets

> “Swallow tablets whole with water.”
> “Do not chew, cut, or crush.”
> “Dispense product in the original package. Tablets should not be removed from blister cards until immediately before use.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.2-4"></a>

###### Oral suspension: reconstitution, feeding tube use, and time limit

> “Reconstitute the powder in each supplied bottle with exactly 14 mL of room temperature water to form the OJEMDA for oral suspension. After reconstitution each mL contains 25 mg of tovorafenib. Product foaming after reconstitution reduces the deliverable volume.”
> “Each bottle delivers 300 mg of tovorafenib in 12 mL. For doses greater than 300 mg, reconstitute two bottles to achieve the dose.”
> “Administer OJEMDA for oral suspension using the supplied oral dosing syringe or feeding tube (minimum 12 French) immediately after preparation.”
> “If the OJEMDA for oral suspension is not administered within 15 minutes after preparation, instruct the patient to discard it.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.10.2-5"></a>

###### Formulation interchangeability and supervision: EU product information

> “The film-coated tablets and powder for oral suspension may be used interchangeably (see tovorafenib powder for oral suspension SmPC). For patients who are not able to swallow or with BSA less than 0.9 m2 the oral suspension should be provided”
> “Ojemda should be administered to paediatric patients under adult supervision.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.10.2-6"></a>

###### First-line pLGG: formulation use in FIREFLY-2

> “in the form of a tablet or liquid suspension, QW, continuously on days 1, 8, 15, and 22 of 28-day (four week) cycles.”
> “patients randomized to tovorafenib will receive an oral drug that is taken at home once weekly, that is available in both tablet and a pediatric friendly oral suspension that can be also given via a nasogastric or gastric tube, allowing continuation of daily activities such as attending school.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### United States: specialty pharmacy distribution

> “OJEMDA will be available in the U.S. through specialty pharmacy partners Biologics and Onco360.”

Source: [Day One Biopharmaceuticals accelerated approval announcement (2024)](https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated)

> “Tovorafenib is available only from a designated specialty pharmacy.”

Source: [ASHP AHFS DI Essentials tovorafenib monograph (2025)](https://www.drugs.com/monograph/tovorafenib.html)

> “Biologics and Onco360, will ship your patient’s medication to their home. They have pharmacists and nurses on staff who can help your patients with dosing and administration support.”

Source: [Day One Biopharmaceuticals EveryDay Support HCP support team page](https://www.everydaysupport.com/hcp/your-support-team/)

<a id="topic-2.1.2.11-2"></a>

###### United States: manufacturer patient support program

> “As part of this commitment, we are pleased to announce EveryDay Support From Day One™, a comprehensive program that offers personalized services for eligible patients and their care teams, including insurance coverage support, financial assistance options, shipping medication to patients' homes, and educational resources.”

Source: [Day One Biopharmaceuticals accelerated approval announcement (2024)](https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated)

<a id="topic-2.1.2.11-3"></a>

###### United States: copay assistance and free drug program

> “as little as $0 per month,”
> “and a program that may provide free medicine if you don’t have health insurance or are underinsured for OJEMDA.”
> “Restrictions and eligibility requirements apply. Not available for those with government insurance. Maximum benefit applies.”

Source: [Day One Biopharmaceuticals OJEMDA support page](https://www.ojemda.com/support-from-day-one)

<a id="topic-2.1.2.11-4"></a>

###### United States: manufacturer-reported coverage approval rate and time to receipt

> “Health insurers approve OJEMDA for over 90% of prescribed patients with BRAF-altered pLGG, and on average, children prescribed OJEMDA receive it in as little as 2 weeks.”
> “Data as of June 2025, sourced from specialty pharmacy distribution partners who report all OJEMDA prescription approvals.”

Source: [Day One Biopharmaceuticals OJEMDA support page](https://www.ojemda.com/support-from-day-one)

<a id="topic-2.1.2.11-5"></a>

###### United States: payer prior authorization criteria limited to relapsed or refractory disease

> “Ojemda may be considered medically necessary if the conditions indicated below are met.”
> “Ojemda may be considered investigational for all other indications.”
> “1. Relapsed or refractory pediatric low-grade glioma (LGG)”

Source: [Blue Cross Blue Shield Association FEP medical policy 5.21.222 (2025)](https://www.fepblue.org/-/media/PDFs/Medical-Policies/2025/October/Pharmacy-Policies/Remove-and-Replace/521222-Ojemda-tovorafenib.pdf)

<a id="topic-2.1.2.11-6"></a>

###### United States: biomarker testing requirement

> “Information on FDA-approved tests for the detection of BRAF fusions, BRAF rearrangements, and BRAF V600 mutations is available at”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.11-7"></a>

###### United States: Risk Evaluation and Mitigation Strategy

> “DRM and Division of Oncology 2 (D02) agree that a REMS is not necessary to ensure the benefits of tovorafenib outweigh its risks.”

Source: [FDA risk assessment and risk mitigation review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000RiskR.pdf)

<a id="topic-2.1.2.11-8"></a>

###### European Union: prescription status, Joint Clinical Assessment, and launch

> “Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

> “The JCA report highlights the absence of a clearly established clinical comparator for much of the pLGG patient population, underscoring the significant unmet need in a setting with very limited approved treatments, as well as the challenges of generating comparative evidence in small, heterogeneous patient cohorts.”
> “We look forward to engaging with Member States and the pLGG community to facilitate timely reimbursement and access to this innovation for eligible patients.”

Source: [Ipsen Joint Clinical Assessment publication update (2026)](https://www.ipsen.com/update/ipsen-welcomes-the-european-unions-publication-of-the-joint-clinical-assessment-for-ojemda-tovorafenib-3309159/)

> “Ojemda: first sales, mainly related to specialized access schemes in Rest of World and launch in Germany.”

Source: [Ipsen H1 2026 results (2026)](https://www.ipsen.com/wp-content/uploads/2026/07/Ipsen-PR_HY-2026_30072026.pdf)

<a id="topic-2.1.2.11-9"></a>

###### Japan: companion diagnostic approval

> “announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) on June 17, 2026 for FoundationOne®CDx Cancer Genomic Profile to be used as a companion diagnostic for Ojemda® Tablets 100 mg and Ojemda Dry Syrup 300 mg (generic name: tovorafenib)”

Source: [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html)

<a id="topic-2.1.2.11-10"></a>

###### First-line pLGG: access outside clinical trials

No evidence found.

<a id="topic-2.1.2.11-11"></a>

###### NCCN Guidelines listing

No evidence found.

Additional sources: [Gajjar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40073837/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Summary: supportive care during tovorafenib treatment

Labeled supportive measures comprise ultraviolet protection (sunscreen, sunglasses, protective clothing; the EU SmPC specifies SPF 50 or higher), dermatologic consultation and supportive care for skin reactions, liver function monitoring before treatment, at 1 month, and every 3 months, routine growth monitoring, and effective nonhormonal contraception. In FIREFLY-1 (relapsed or refractory pLGG), the protocol recommended a gentle skin care routine with thick unscented moisturizers and SPF 30 or higher sunscreen for all participants, and 102 of 128 participants with rash (80%) received standard rash treatments, primarily topical steroids or antibiotics, oral antihistamines, and emollients. In a pooled growth analysis of 38 participants, 4 (11%) received a gonadotropin-releasing hormone analogue and 2 (5%) received growth hormone concurrently with tovorafenib. No published supportive care guideline specific to first-line tovorafenib use was identified.

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad); [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf); [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/); [Witt et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10037); [Kline et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10029)

<a id="topic-2.1.2.12-2"></a>

###### Sun protection: US prescribing information

> “Advise patients to use precautionary measures against ultraviolet exposure such as use of sunscreen, sunglasses, and/or protective clothing during treatment with OJEMDA.”
> “Monitor for new or worsening skin reactions. Consider dermatologic consultation and initiate supportive care as clinically indicated.”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

<a id="topic-2.1.2.12-3"></a>

###### Sun protection: EU product information

> “The use of precautionary measures against ultraviolet exposure such as use of sunscreen (SPF ≥ 50), sunglasses, and/or protective clothing during treatment with tovorafenib is recommended.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Relapsed or refractory pLGG: protocol skin care and rash management in FIREFLY-1

> “It was recommended that all trial patients followed a gentle skin care routine comprising short lukewarm showers/baths, the use of unscented, gentle cleansers and the application of unscented thick moisturizers (creams over lotions) immediately after showers. In addition, the prophylactic use of SPF 30+ sunscreen whenever going outside, with this reapplied every 2 h, and the wearing of sun-protective clothing were recommended for all patients.”
> “Patients were to be referred to a dermatology department if cutaneous symptoms were impairing function (for example, if the patient could not sleep or sit still) or were psychosocially bothersome and/or when management techniques failed to resolve the condition.”

Source: [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/)

<a id="topic-2.1.2.12-5"></a>

###### Relapsed or refractory pLGG: rash treatments used in FIREFLY-1

> “80% (102) of pts received standard of care (SOC) treatments for rash, primarily topical steroids/antibiotics, oral antihistamines, and emollients.”

Source: [Witt et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10037)

<a id="topic-2.1.2.12-6"></a>

###### Growth and endocrine monitoring

> “Routinely monitor patient growth during treatment with OJEMDA”

Source: [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)

> “Monitoring for growth and development should be done prior to initiation, routinely during and following discontinuation of treatment with tovorafenib.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

> “Normative data for growth in this patient population are lacking, and future studies of targeted therapies in pLGG should include baseline and longitudinal assessments of endocrine function and monitoring of growth velocity during therapy.”

Source: [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/)

<a id="topic-2.1.2.12-7"></a>

###### Concomitant endocrine therapies in treated participants

> “Four (11%) were receiving a gonadotropin-releasing hormone analogue for precocious puberty and 2 (5%) were receiving growth hormone replacement concurrent with tovorafenib.”

Source: [Kline et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10029)

<a id="topic-2.1.2.12-8"></a>

###### First-line pLGG: safety monitoring in FIREFLY-2

> “In addition to standard ophthalmology examination, monitoring for safety will include physical examination, neurologic examination, dermatology examination, cardiac evaluation, bone assessment (for patients with Tanner stage < 4–5), Karnofsky/Lansky performance score, clinical AEs, laboratory variables and vital signs, including height and weight.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.1.2.12-9"></a>

###### Nonhormonal contraception

> “Women of childbearing potential must use effective non-hormonal contraception such as a barrier method during therapy and for 28 days after the last dose of tovorafenib (see section 4.5 and section 4.6).”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.1.2.12-10"></a>

###### Antiemetic prophylaxis and premedication

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Tovorafenib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

###### Quality measures for pediatric low-grade glioma or pediatric CNS tumor care that reference targeted therapy

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Summary: comparative evidence for tovorafenib versus other systemic options

No randomized comparison of tovorafenib with any other therapy has been reported as of September 2026. The phase 3 LOGGIC/FIREFLY-2 trial, which compares tovorafenib with investigator's choice of standard chemotherapy in first-line RAF-altered pLGG, completed enrollment of approximately 400 participants in May 2026, with preliminary results expected in 2027. The only formal indirect comparison identified is the EU Joint Clinical Assessment (JCA) of tovorafenib in relapsed or refractory pLGG, endorsed on 30 April 2026. Of 8 PICO questions, the developer submitted comparative data for 2 (PICO 5 and PICO 7), and the assessors included 1: an unanchored matching-adjusted indirect comparison (MAIC) of FIREFLY-1 against a phase I/II dabrafenib plus trametinib study in the BRAF V600E subpopulation. The effective sample size was 5.81 to 14.26. For independent review committee (IRC)-assessed progression-free survival (PFS) by RANO-LGG, the hazard ratio was 4.88 (95% CI 2.14 to 11.14; nominal p = 0.011), a direction unfavorable to tovorafenib; objective response comparisons were inconclusive; and the odds ratio for grade 3 or higher adverse events was 12.65 (95% CI 2.30 to 69.58). The assessors stated that these estimates "should not necessarily be interpreted as causal effects of treatment." The comparison with trametinib (TRAM-01) was excluded because the comparator was reported only in conference abstracts.

Independent reviews published in 2025 and 2026 compare agents on mechanism and indication rather than head-to-head efficacy. Type I BRAF inhibitors (dabrafenib, vemurafenib) are restricted to BRAF V600-mutant tumors because of paradoxical MAPK activation in BRAF fusion-driven tumors, whereas tovorafenib is active in both fusion and V600 tumors. Reviewers describe once-weekly dosing without food restrictions and an available oral suspension for tovorafenib, compared with once- or twice-daily dosing for MEK and BRAF inhibitors. Reviewers also describe differences in adverse event profiles: reduced growth velocity has been reported only with tovorafenib, and intratumoral hemorrhage was reported in 9% of the pooled pediatric tovorafenib safety population, while pyrexia is more frequent with dabrafenib plus trametinib and cardiac and ocular monitoring is emphasized for MEK inhibitors. A 2026 systematic review found rebound regrowth after MAPK inhibitor discontinuation in at least 23 of 131 evaluable participants (17.6%) and 1 rebound event among 24 evaluable FIREFLY-1 participants who entered a drug holiday, while noting short post-discontinuation follow-up.

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf); [Ramagopalan and Pannelay (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13329894/); [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG); [Bazer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449833/); [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/); [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/); [Damodharan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13372930/); [Alshammari et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13123665/); [Styczewska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13168116/)

<a id="topic-2.1.2.14-2"></a>

###### Direct randomized comparisons: status of LOGGIC/FIREFLY-2

> “The primary analysis is expected to occur approximately 12 months after the last patient is enrolled; preliminary insights are expected to be available in 2027.”
> “It is being conducted at approximately 140 sites across the U.S., Canada, Europe, Australia, South America, Middle East and Asia, and in just over three years has enrolled approximately 400 participants who are receiving either tovorafenib once weekly or one of four standard of care (SoC) chemotherapy regimens.”

Source: [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.1.2.14-3"></a>

###### EU joint clinical assessment: comparators and data submitted per PICO

| Population and PICO | Comparator | Results submitted | Data included in the JCA report |
| --- | --- | --- | --- |
| Population 1 (full claimed indication), PICO 3 | “Combination of carboplatin and vincristine” | “no” | “no” |
| Population 1 (full claimed indication), PICO 4 | “Vinblastine” | “no” | “no” |
| Population 2 (BRAF V600E mutation in patients > 1 year), PICO 5 | “Combination of dabrafenib and trametinib” | “yes” | “yes” |
| Population 3 (BRAF fusion, rearrangement, or V600 [non-E] mutation), PICO 7 | “Trametinib” | “yes” | “no” |

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

> “The HTD does not include comparative evidence addressing patients in the full claimed indication, corresponding to PICOs 1-4 in the assessment scope.”
> “For PICO 5, all included relative effectiveness and safety results are based on unanchored MAIC methods. The results presented for these outcomes are associated with a number of major uncertainties and the effect estimates should not necessarily be interpreted as causal”

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Relapsed or refractory BRAF V600E pLGG: unanchored MAIC versus dabrafenib plus trametinib, efficacy

| Outcome | Tovorafenib (FIREFLY-1) | Dabrafenib plus trametinib (Bouffet 2023) | ESS | Relative effect |
| --- | --- | --- | --- | --- |
| 6-month PFS, RANO-LGG, IRC | “94 [85, 100]” | “86 [75, 98]” | “5.81” | “RR: 1.09 [0.92; 1.30]” |
| 12-month PFS, RANO-LGG, IRC | “76 [52, 100]” | “83 [71, 96]” | “5.81” | “RR: 0.92 [0.61, 1.38]” |
| CR+PR by RANO-HGG, investigator | “40.0 [12.2, 73.8]” | “52.8 [NR, NR]” | “6.64” | “OR: 0.56 [0.08, 3.84]” |
| CR+PR by RANO-HGG, IRC | “50.0 [18.7, 81.3]” | “19.4 [8.2, 36.0]” | “6.64” | “OR: 7.26 [0.98, 53.68]” |
| PFS by RANO-LGG, IRC, median months | “13.67 [4.60, 24.87]” | “36.9 [36.0, NE]” | “5.81” | “4.88 [2.14, 11.14]” |

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

> “Hazard ratios less than 1 indicate longer PFS with tovorafenib”
> “Values reported in these cells correspond to the unadjusted FIREFLY-1 data, i.e., prior to MAIC-weighting. The corresponding weighted values were not reported by the HTD.”

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Relapsed or refractory BRAF V600E pLGG: unanchored MAIC versus dabrafenib plus trametinib, safety

| Outcome | Tovorafenib (FIREFLY-1) | Dabrafenib plus trametinib (Bouffet 2023) | ESS | Odds ratio [95% CI] |
| --- | --- | --- | --- | --- |
| Severe AE (CTCAE grade 3 or higher) | “20 (22)” | “22 (36)” | “14.26” | “12.65 [2.30, 69.58]” |
| Serious AE | “13 (22)” | “15 (36)” | “14.26” | “3.04 [0.77, 12.10]” |
| Treatment interruption due to AE | “15 (22)” | “26 (36)” | “14.26” | “1.15 [0.28, 4.76]” |
| Treatment discontinuation due to AE | “3 (22)” | “8 (36)” | “14.26” | “0.58 [0.11, 3.03]” |
| Death related to AE | “2 (22)” | “0 (36)” | Not reported | “NA: Indirect comparison not provided due to zero event rate in dabrafenib + trametinib group” |

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

<a id="topic-2.1.2.14-6"></a>

###### EU joint clinical assessment: uncertainties of the indirect comparison

> “The Bouffet 2023 study included small proportions of patients with a diagnosis of high-grade glioma (HGG) (rather than paediatric LGG) or who had not received prior systemic therapy.”
> “All treatment effect estimates are associated with a risk of bias of unknown magnitude and direction due to residual confounding. This is likely to arise from identified prognostic variables and/or effect modifiers (PVs/EMs) that were not adjusted for in the MAIC, including histological type, primary tumour location and prior chemotherapy”
> “The effective sample size (ESS) for the analyses of all outcomes is small (ranging from 5.81 to 14.26), leading to statistical imprecision (i.e., wide confidence intervals) for the resulting effect estimates.”
> “The analysis of IRC-assessed ORR by RANO-LGG, presented by the HTD, is not included due to the use of methodologically flawed and inappropriate analysis methods.”
> “There is a substantial difference between INV- and IRC-assessed ORR by RANO-HGG in Bouffet 2023. The reason for this difference is unclear.”

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

<a id="topic-2.1.2.14-7"></a>

###### EU joint clinical assessment: comparison with trametinib not assessed

> “The HTD provides an unanchored MAIC of tovorafenib with trametinib for PICO 7. However, this comparison based on the studies FIREFLY-1 and TRAM-01 is not included in the JCA report due to insufficient information available for the assessment of TRAM-01.”

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

> “Its comparator was trametinib, and the only evidence available for that arm came from a trial (TRAM-01) reported solely in conference abstracts rather than in a full publication.”

Source: [Ramagopalan and Pannelay (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13329894/)

<a id="topic-2.1.2.14-8"></a>

###### Independent commentary on the joint clinical assessment findings

> “Overall survival could not be estimated at all. The only outcome reaching nominal statistical significance was progression-free survival, and it favored the comparator. Objective response was inconclusive.”
> “On the descriptive safety data, tovorafenib showed numerically more serious and severe adverse events than the comparator.”
> “Yet the limitations are so pervasive – small numbers, an unanchored comparison – that the report cannot conclude the drug is inferior.”

Source: [Ramagopalan and Pannelay (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13329894/)

<a id="topic-2.1.2.14-9"></a>

###### Mechanism-based selection: type II RAF inhibitor versus type I BRAF inhibitors

> “BRAF targeted therapy should be selected in a mutation-specific fashion. Type 1 BRAFi (i.e., dabrafenib) are not effective against BRAF fusions and can result in paradoxical activation and tumor progression. Tovorafenib is effective in recurrent pLGG with BRAFV600 or BRAF fusions, while dabrafenib is ineffective in tumors with BRAF fusions.”

Source: [Bazer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449833/)

> “Type I RAF inhibitors such as dabrafenib are not indicated for the treatment of tumors harboring a BRAF fusion due to paradoxical activation which may increase the risk of tumor growth (10). Prior to the approval of tovorafenib, there were no approved targeted therapies for patients with pLGG harboring BRAF fusions.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.1.2.14-10"></a>

###### Review table: regulatory status and key considerations by agent

| Molecular target | Drug | Regulatory status | Key considerations |
| --- | --- | --- | --- |
| BRAF V600E | Dabrafenib plus trametinib | “Approved (FDA/EMA/Canada)” | “First-line pLGG; superior to chemotherapy (ORR 47% vs 11%);AEs: Pyrexia (68%), headache, rash, weight gain; optimal duration unknown” |
| BRAF fusion | Trametinib | “Not pLGG-specific (FDA/EMA/Canada)” | “Second-line option when treatment required; avoids paradoxical MAPK activation; not yet approved as a first lineAEs: Acneiform rash, GI symptoms, elevated CPK; rebound risk on discontinuation” |
| BRAF fusion or V600E | Tovorafenib | “FDA: Accelerated approval (April 2024); EMA/Canada: Under review” | “Active in fusion and V600E tumors; CNS-penetrant; ORR 51%AEs: Rash (93%), hair color changes, fatigue, hemorrhage, reduced growth velocity; frontline trials ongoing” |
| NF1-associated pLGG | Selumetinib | “FDA/EMA/Canada: Approved for NF1 PN only (off-label for pLGG)” | “Could be used off-label for NF1-associated pLGG but access remains difficult off study.AEs: GI symptoms, elevated CPK, acneiform rash, paronychia; cardiac and ocular monitoring required” |

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.1.2.14-11"></a>

###### Review table: evidence in pLGG by agent

| Drug | Target | Evidence in pLGG |
| --- | --- | --- |
| Dabrafenib | “B-raf enzyme” | “Phase II evidence:- 47% ORR when combined with dabrafenib in BRAFv600E-mutant pLGG (26)” |
| Selumetinib | “MEK1/2” | “Phase I evidence:- 20% sustained PR (20)Phase II evidence:-36% sustained PR (19)” |
| Trametinib | “MEK1/2” | “Phase II evidence:- 47% ORR when combined with dabrafenib in BRAF v600E-mutant pLGG (26)- Retrospective evidence for monotherapy (34–36)” |
| Tovorafenib | “RAF kinase” | “Phase II evidence:- 67% ORR by RANO-HGG and 51% ORR by RAPNO criteria (37)” |

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.1.2.14-12"></a>

###### Adverse event profiles across MAPK inhibitor classes

> “The common acute adverse effects of the type II RAF inhibitor tovorafenib included hair color change (Figure 2E), anemia, elevated creatine kinase, and cutaneous reactions. Importantly, a reversible decrease in growth velocity (Figure 2F), and an increased incidence of intra-tumoral hemorrhage were reported. Pyrexia, diarrhea, and weight gain were reported to be less common than MEK/BRAF inhibitors, and no signs of ocular and cardiac toxicity were reported.”

Source: [Alshammari et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13123665/)

> “While most toxicities of MAPKi therapies are thought to be a direct effect of MAPKi inhibition, type I BRAFi are selective mutant inhibitors, which can proceed to paradoxical activation of the MAPK pathway resulting in secondary skin malignancy;27,28 this is not seen with type II RAFi and MEKi.”
> “Similarly, reductions in growth velocity have only been observed in patients with pLGG treated with tovorafenib.”

Source: [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/)

> “Interestingly, tovorafenib can lead to growth arrest – a side effect that hasn’t been reported with any of the MEK inhibitors, and it is unknown whether this particular toxicity is considered a class effect.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.1.2.14-13"></a>

###### Intracranial hemorrhage across MAPK inhibitors

> “In the phase 2 FIREFLY-1 trial of tovorafenib in BRAF-altered pLGG (n = 137), any-site hemorrhage of any grade occurred in 42% of patients with grade 3-4 hemorrhage in 7 patients (5%) and, separately, one fatal grade 5 intratumoral hemorrhage; in the overlapping pooled FDA-label safety population (N = 140), intratumoral hemorrhage specifically was reported in 9%.”
> “Reported incidence varies by agent, population, and hemorrhage ascertainment method (active imaging-based surveillance versus clinical reporting), from < 1% symptomatic ICH with dabrafenib in adult melanoma to 9% intratumoral hemorrhage in the pooled pediatric tovorafenib safety population.”

Source: [Damodharan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13372930/)

> “The presence of a KIAA1549::BRAF fusion in the tumor had the strongest association with hemorrhage, persisting across multivariable models (approximately sixfold increased risk), although estimates were limited by low event number. MAPK inhibitor exposure (specifically binimetinib and tovorafenib) was associated with hemorrhage in univariate analysis but partially confounded by fusion status.”

Source: [Grin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42414678/)

<a id="topic-2.1.2.14-14"></a>

###### Dosing schedule, formulation, and route compared with other agents

> “The availability of a liquid formulation, a weekly dosing regimen (in contrast to daily doses for other available BRAF/MEK inhibitors) and lack of food effect, may make drug compliance easier for young patients.”

Source: [Alshammari et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13123665/)

> “Based on pharmacokinetic studies, MEK and BRAF inhibitors are given daily (once to twice per day), with some MEK inhibitors requiring an empty stomach for optimal absorbtion (45, 55). Tovorafenib can be taken with or without food and is administered once weekly.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.1.2.14-15"></a>

###### Rebound regrowth after discontinuation: pan-RAF inhibitor versus earlier agents

> “it seems that the incidence of RR following pan-RAF inhibitors may be lower compared to earlier generation drugs, although these findings should be interpreted with caution given the relatively short post-discontinuation follow-up (range: 0.6–10.9 months), limiting detection of delayed events (30).”

Source: [Styczewska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13168116/)

<a id="topic-2.1.2.14-16"></a>

###### Targeted therapy versus chemotherapy in BRAF V600-mutant pLGG: meta-analysis

> “Ten studies (16 treatment arms; 4 RCTs, 6 RS were included). Pooled ORR was 42.35% (95% CI, 29.41-55.29), and the median PFS was 23.03 months (95% CI, 17.18-28.88). Grade 3/4 AEs occurred in 30.56% (95% CI, 22.60-38.53), most commonly rash, fatigue, and fever. Subgroup analyses suggested higher efficacy and lower toxicity with BRAF inhibitors or combination therapy.”
> “Emerging evidence suggests potential benefit in selected molecularly defined patients; however, further prospective studies are required to define their role in first-line treatment.”

Source: [Figueira and Pigott (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13499688/)

<a id="topic-2.1.2.14-17"></a>

###### Cost-effectiveness of first-line dabrafenib plus trametinib versus chemotherapy

> “Dab-Tram was associated with a 2.21 quality-adjusted life-year (QALY) gain at an incremental cost of $554,769 Canadian dollars (CAD) compared with standard chemotherapy. The base case incremental cost-effectiveness ratio (ICER) was $251,027 CAD/QALY. Two-year Dab-Tram resulted in an ICER of $44,740 CAD/QALY”

Source: [Gascon et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41740060/)

<a id="topic-2.1.2.14-18"></a>

###### Weight gain with dabrafenib plus trametinib in first-line pediatric low-grade glioma

> “However, weight gain as an adverse event or an increase of at least 2 BMI-for-age percentiles was reported in 32 of 73 patients who received dabrafenib plus trametinib.”
> “Our analysis suggests that tumor location does not appear to be associated with the weight gain observed with dabrafenib plus trametinib, findings that support other reports that suggest weight gain as a safety signal with MAPK-targeted therapy in this patient population.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.1.2.14-19"></a>

###### Any-grade adverse events and reasons for dose modification with dabrafenib plus trametinib compared with carboplatin and vincristine

> “Overall, 106 patients were included in the safety analysis (73 for dabrafenib plus trametinib and 33 for chemotherapy).”
> “The most common adverse events of any grade with dabrafenib plus trametinib as compared with chemotherapy were pyrexia (in 68% vs. 18%), headache (in 47% vs. 27%), and vomiting (in 34% vs. 48%).”
> “Among the patients who received dabrafenib plus trametinib, dose adjustments or interruptions were more frequent because of pyrexia (in 53% vs. 0 with chemotherapy) and were less frequent because of a decreased neutrophil count (in 3% vs. 27% with chemotherapy).”
> “Although skin toxic effects (including dry skin and rash) occurred more frequently with dabrafenib plus trametinib, only 8% of patients had resultant dose interruption or adjustment.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.1.2.14-20"></a>

###### Progression events by independent versus investigator assessment in the comparator trial

> “A discrepancy in progression events was noted between independent and investigator assessments in the two trial groups (30 vs. 9 events with dabrafenib plus trametinib and 22 vs. 9 with chemotherapy).”
> “Strict interpretation of the RANO criteria by the independent reviewer may have contributed to the higher number of progression events reported as compared with investigator review, because the criteria for progressive disease are sensitive to increases relative to nadir, regardless of changes from baseline.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.1.2.14-21"></a>

###### Hemorrhage rates by individual MAPK pathway inhibitor

> “Binimetinib showed a particularly strong association (3/17 patients, 17.6%; HR 6.24, 95% CI 1.55–25.11, p = 0.010, OR 5.00)”
> “Selumetinib (0/11), trametinib (1/9, 11.1%), and dabrafenib (0/6) showed no significant associations.”
> “Cytotoxic chemotherapy, radiation, and other systemic therapies (including anti-angiogenic agents) were not associated with increased hemorrhage risk.”

Source: [Grin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42414678/)

<a id="topic-2.1.2.14-22"></a>

###### EU joint clinical assessment: failed attempt to construct external control arms for the comparisons without trial data

> “For the PICOs with a lack of published data on the comparator (PICOs 1 to 4, 6 and 8), the HTD described an attempt to construct external control arms using patient data acquired outside of clinical studies to allow comparative effectiveness analyses. The HTD performed a feasibility study to identify suitable data sources to construct the external control arms. According to the HTD, one US database initially demonstrated feasibility for use but was deemed unsuitable due to an insufficient number of patients with BRAF alterations and adequate follow-up in the R/R setting. The HTD concluded that finding a fit-for-purpose and reliable comparator data source was not possible.”
> “The HTD's approach to include studies with an individualised treatment comparator, only if the comparator included all treatment options, is not adequate.”

Source: [HTACG tovorafenib JCA report (2026)](https://health.ec.europa.eu/document/download/395c2ba0-849a-4f3b-9251-aa2495b3efd7_en?filename=HTA_20260507_TEST_JCA_report_Ojemda_en.pdf)

<a id="topic-2.1.2.14-23"></a>

###### Germany: orphan drug rule restricting the benefit assessment to patient numbers and costs

> “In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier. After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit.”

Source: [IQWiG G26-11 project page (2026)](https://www.iqwig.de/en/projects/g26-11.html)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Summary: definition and molecular etiology

Pediatric low-grade glioma (pLGG) is a heterogeneous group of WHO CNS grade 1 and 2 glial, glioneuronal, and neuronal tumors that account for 30% to 40% of pediatric CNS tumors. The 2021 fifth edition of the WHO classification (WHO CNS5) distributes these tumors across three families: pediatric-type diffuse low-grade gliomas (4 types, including diffuse low-grade glioma, MAPK pathway-altered), circumscribed astrocytic gliomas (including pilocytic astrocytoma, the most common type), and glioneuronal and neuronal tumors. Diagnosis is integrated and layered, combining histology with molecular findings.

The disease is driven predominantly by alterations that activate the RAS/MAPK pathway. In a population-based cohort from Toronto with molecular profiling of 477 tumors, a driver alteration was identified in 84%; KIAA1549-BRAF fusion was the most frequent alteration (35%), followed by BRAF p.V600E (17%), with germline NF1, FGFR1/2 (6.1%), and rare RAF1, NTRK2, ALK, and ROS1 alterations accounting for most of the remainder. Whole-genome sequencing of 96 pilocytic astrocytomas found MAPK pathway alterations in 100%. Germline NF1 is the main hereditary predisposition, with 15% to 20% of children with NF1 developing an optic pathway glioma.

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/); [Louis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/); [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/); [Jones et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3951336/)

<a id="topic-2.2.1.1-2"></a>

###### Definition: pLGG as WHO grade 1 and 2 tumors, the most common childhood CNS tumor

> “pLGG comprises 30%–40% of all pediatric CNS tumors, including a heterogeneous group of World Health Organization (WHO) grades 1 and 2 glioma, glioneuronal and neuronal neoplasms.”
> “Tumors that have historically been classified as pLGG now fall under several subcategories within the 2021 WHO glioma, glioneuronal, and neuronal tumor sections, including pediatric-type diffuse low-grade glioma, circumscribed astrocytic tumors, and glioneuronal and neuronal tumors (Table 1).”
> “For example, the most common type of pLGG, the pilocytic astrocytoma, remains a distinct entity, but it is now characterized as a type of circumscribed astrocytic tumor.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

<a id="topic-2.2.1.1-3"></a>

###### WHO CNS5 (2021): pediatric-type diffuse low-grade gliomas and circumscribed astrocytic gliomas

> “WHO CNS5 has taken a new approach to classify the Gliomas, Glioneuronal Tumors, and Neuronal Tumors, and dividing them into 6 different families: (1) Adult-type diffuse gliomas (the majority of primary brain tumors in neuro-oncology practice of adults, eg, glioblastoma, IDH-wildtype); (2) Pediatric-type diffuse low-grade gliomas (expected to have good prognoses)”
> “For CNS5, the 4 types are Diffuse astrocytoma, MYB- or MYBL1-altered; Angiocentric glioma; Polymorphous low-grade neuroepithelial tumor of the young (often abbreviated as PLNTY; Figure 1); and Diffuse low-grade glioma, MAPK pathway-altered.”
> “For these tumors (as for most other glioma types), precise classification requires molecular characterization and the integration of histopathological and molecular information in a tiered diagnostic format. Clear delineation of the specific molecular features, in turn, sets the stage for targeted therapies of such tumors.”
> “Two specific aspects of CNS tumor grading have changed for WHO CNS5: Arabic numerals are employed (rather than Roman numerals) and neoplasms are graded within types (rather than across different tumor types).”

Source: [Louis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/)

<a id="topic-2.2.1.1-4"></a>

###### WHO CNS5 (2021): key diagnostic genes for tumor types within the pLGG spectrum

| Tumor type | Key diagnostic genes, molecules, pathways, or combinations |
| --- | --- |
| Pilocytic astrocytoma | “KIAA1549-BRAF, BRAF, NF1” |
| Diffuse low-grade glioma, MAPK pathway-altered | “FGFR1, BRAF” |
| Polymorphous low-grade neuroepithelial tumor of the young | “BRAF, FGFR family” |
| Pleomorphic xanthoastrocytoma | “BRAF, CDKN2A/B” |
| Diffuse astrocytoma, MYB- or MYBL1-altered | “MYB, MYBL1” |
| Angiocentric glioma | “MYB” |

Source: [Louis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology: RAS/MAPK pathway alterations in a cohort of more than 1,000 pLGG

> “84% of cases harbored a driver alteration, while those without an identified alteration also often exhibited up-regulation of the RAS/MAPK pathway.”
> “KIAA1549-BRAF was the most frequent alteration in pLGG (35%) and was almost exclusively a single-event driver (n=175/180, 97%)”
> “BRAF p.V600E was the second most common alteration in pLGG (17%) and was frequently associated with additional alterations, most commonly deletion of CDKN2A (n=13, 9.6%) (Figure 2A).”
> “A further 1.3% (n=6) of cases contained alterations in other direct members of the RAS/MAPK pathway, including 3 RAF1 fusions, 2 KRAS mutations and one patient with a short deletion in MAP2K1”
> “Alterations in FGFR most frequently involved FGFR1/2 (n=29, 6.1%)”
> “as well as fusions involving ALK (n=2, 0.4%), ROS1 (n=2, 0.4%), and NTRK2 (n=2, 0.4%)”
> “In our study, NF1-driven pLGG accounted for 14% of cases (n=133).”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

<a id="topic-2.2.1.1-6"></a>

###### Etiology: KIAA1549::BRAF fusion from tandem duplication at 7q34

> “This rearrangement, which was not observed in a series of 244 higher-grade astrocytomas, results in an in-frame fusion gene incorporating the kinase domain of the BRAF oncogene. We further show that the resulting fusion protein has constitutive BRAF kinase activity, and is able to transform NIH3T3 cells.”

Source: [Jones et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2577184/)

> “KIAA1549-BRAF accounts for 30-40% of pLGG at the population level”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

> “Second, structural variants in the BRAF gene are the most common somatic driver event, found in approximately 70% of all sporadic pLGG.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “BRAF fusions, most commonly KIAA1549::BRAF, arise through tandem duplication at chromosome 7q34 and account for 60–80% of pilocytic astrocytomas (PAs) and approximately 15% of other pLGGs”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.2.1.1-7"></a>

###### Etiology: BRAF V600E frequency across histologies and locations

> “BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice.”
> “As expected, the highest incidence of the mutation was observed in pleomorphic xanthoastrocytoma (78%) followed by gangliogliomas (49%); however, the mutation was also commonly observed in diffuse astrocytomas (43%) and WHO grade I astrocytomas (20%; Table 1).”
> “Overall, 33% of BRAF V600E PLGGs originated in the midline (diencephalon and brainstem).”

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

<a id="topic-2.2.1.1-8"></a>

###### Etiology: pilocytic astrocytoma as a single-pathway disease; FGFR1 and NTRK2 alterations

> “We identified recurrent activating mutations in FGFR1 and PTPN11 and novel NTRK2 fusion genes in non-cerebellar tumors. New BRAF activating changes were also observed. MAPK pathway alterations affected 100% of tumors analyzed, with no other significant mutations, indicating pilocytic astrocytoma as predominantly a single-pathway disease.”

Source: [Jones et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3951336/)

> “NTRK fusions, are identified in approximately 2% of pediatric gliomas overall”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.2.1.1-9"></a>

###### Etiology: neurofibromatosis type 1 as the principal predisposition syndrome

> “10-15% of children with NF1 will develop a low-grade glioma within the optic pathway, with an additional 3-5% arising outside of the optic pathway”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

> “Individuals with NF1 account for over 70% of the optic pathway/hypothalamic gliomas in children, and it is estimated that 15%–20% of all children with NF1 will develop an optic pathway glioma (OPG) during early childhood.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

<a id="topic-2.2.1.1-10"></a>

###### Company description of RAF alteration frequency

> “Over the last decade, it has been found that between 50% and 60% of pLGGs are driven by abnormal signaling due to alterations in RAF, approximately 85% to 90% of which are a gene fusion known as KIAA1549-BRAF.”
> “In addition, between 5% and 17% of children with pLGGs have tumors with a BRAF V600E activating mutation.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

<a id="topic-2.2.1.2.1-1"></a>

###### Summary: incidence estimates and the population requiring first-line systemic therapy

No identified publication reports the incidence of RAF-altered pLGG requiring first-line systemic therapy directly. The available components are as follows.

- Overall incidence, United States: the CBTRUS childhood and adolescent report (2017 to 2021 diagnoses) reports an annual incidence of 0.98 per 100,000 for pilocytic astrocytoma in ages 0 to 19 years and projects 730 new pilocytic astrocytoma cases in 2025. The LOGGIC/FIREFLY-2 design publication cites 1,200 to 1,500 new pLGG cases per year in the United States. Day One Biopharmaceuticals cites an annual incidence of 1.3 to 2.1 per 100,000.
- Overall incidence, Europe: in Great Britain, the incidence of pilocytic astrocytoma at ages 0 to 14 years was 8.6 per million in 2006 to 2010.
- RAF-altered fraction: KIAA1549-BRAF fusion was found in 35% and BRAF p.V600E in 17% of profiled tumors in a population-based Toronto cohort. Day One Biopharmaceuticals estimates that approximately 1,100 patients under 25 years of age are newly diagnosed with BRAF-altered pLGG in the United States each year.
- Fraction requiring nonsurgical therapy: in the UK CCLG CNS9702 population-based cohort, 165 of 639 children (25.8%) started nonsurgical treatment at diagnosis (113 chemotherapy, 52 radiotherapy). In the German HIT-LGG-1996 cohort of 1,031 children, 184 proceeded to nonsurgical treatment at diagnosis and 35.2% ultimately received nonsurgical treatment. In SIOP-LGG 2004, 1,057 of 3,417 registered, previously untreated patients (30.9%) received chemotherapy. Reviews state that up to half of patients require adjuvant therapy.

Source: [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm); [Stiller et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6371471/); [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/); [Stokland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3018938/); [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/); [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/); [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States: CBTRUS incidence of pilocytic astrocytoma and glioma in ages 0 to 19 years

> “Among CBTRUS specific histopathology groupings, incidence rates were highest for pilocytic astrocytoma (0.98 per 100,000) and tumors of the pituitary (0.98 per 100,000).”
> “The most frequently reported histopathology in all ages (0-19 years) was pilocytic astrocytoma (16.3%). Overall, gliomas accounted for 45% of all brain tumors diagnosed in ages 0-19 years.”
> “Pilocytic astrocytoma and tumors of the pituitary had the highest number of estimated new cases, with 730 new cases per histopathology expected to be diagnosed in 2025.”
> “The median age of glioma diagnosis was 9 years with subtypes ranging from 7 years for pilocytic astrocytoma to 11 years for other low-grade glioma.”
> “In children ages 0-3 years, pilocytic astrocytoma tumors had a significant increase in incidence during the entire period (APC: 3.0%; 2.1%, 3.9%).”

Source: [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/)

<a id="topic-2.2.1.2.1-3"></a>

###### United States: registry coding change for pilocytic astrocytoma from 2023

> “It should be noted that cases of pilocytic astrocytoma or juvenile pilocytic astrocytoma diagnosed in, or after, 2023 (and therefore not available for analysis until 2026) will no longer be considered malignant (/3), but uncertain (/1); ICD-O-3 code 9421/3 will be reserved for high grade astrocytoma with piloid features.”

Source: [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/)

<a id="topic-2.2.1.2.1-4"></a>

###### United States: annual number of new pLGG cases

> “Pediatric low-grade glioma (pLGG) is a heterogeneous group of World Health Organization (WHO) grade 1 and 2 tumors comprising several subgroups and is the most frequent pediatric central nervous system (CNS) tumor diagnosis, with 1200 to 1500 new cases per year in the United States (US)”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.1.2.1-5"></a>

###### United States: company estimates of pLGG and BRAF-altered pLGG incidence

> “While pLGG is the most common brain tumor diagnosed, representing approximately 30% of all childhood brain tumors, the annual estimated incidence of pLGG is 1.3 to 2.1 per 100,000 in the United States.”
> “Based on incidence results published in academic journals, we estimate that approximately 1,100 patients under the age of 25 are newly diagnosed with BRAF-altered pLGG every year.”
> “Potential for tovorafenib, a type-II RAF inhibitor, to be a high-impact targeted therapeutic in pLGG where approximately 70% of tumors are BRAF-altered pLGG in the United States.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.2.1-6"></a>

###### Europe: population-based incidence of pilocytic astrocytoma in Great Britain

> “Age-standardised incidence in 2001–10 was 40.1 per million.”
> “Between the same two periods, the proportional increase was greater for pilocytic astrocytoma (202%, from 2.9 per million to 8.6 per million) than for astrocytomas of other or unspecified subtype (40%, from 5.8 per million to 8.2 per million)”
> “The most frequent single histological type of tumour was pilocytic astrocytoma, which accounted for one half of all astrocytomas and 21% of all tumours.”
> “The highest incidence of pilocytic astrocytoma and unspecified optic nerve astrocytoma was at age 1–4 years.”

Source: [Stiller et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6371471/)

<a id="topic-2.2.1.2.1-7"></a>

###### Europe: proportion of children starting nonsurgical therapy in the UK population-based CNS9702 cohort

> “This network registered 80%–86% of the UK cases of childhood LGG registered by the national childhood cancer registry during this time period.”
> “Four hundred and seventy-four (74.2%) were initially observed (median age: 7.43 years; Fig. 1). One hundred and sixty-five (25.8%) started nonsurgical treatment (median age: 4.95 years), 113 had chemotherapy (median age: 3.65 years), and 52 had radiotherapy (median age: 9.36 years).”

Source: [Stokland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3018938/)

<a id="topic-2.2.1.2.1-8"></a>

###### Europe: proportion of children receiving nonsurgical therapy in the German HIT-LGG-1996 cohort

> “Following first surgical intervention in 916 children and radiologic diagnosis in 115 children, 847 patients were observed and 184 proceeded to nonsurgical treatment at diagnosis (1 without exact date).”
> “After initial observation, progression occurred in 40.9% of cases within 10 years and indicated nonsurgical therapy in 51.7%.”
> “Ultimately, 35.2% of patients in our study received nonsurgical treatment.”

Source: [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)

<a id="topic-2.2.1.2.1-9"></a>

###### Europe: registrations and chemotherapy use in the SIOP-LGG 2004 study

> “3417 previously untreated patients from 118 institutions in 11 countries were registered at the SIOP-LGG 2004 database following the SIOP-LGG treatment strategy.”
> “During the trial period, 1057 patients received chemotherapy.”

Source: [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

<a id="topic-2.2.1.2.1-10"></a>

###### Proportion requiring therapy beyond surgery by tumor location

> “However, with progression-free survival (PFS) at approximately 50%, up to half of patients will require adjuvant therapy.”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

> “However, many pLGGs arise within structures of the brain that cannot be safely resected without causing substantial morbidity, for example, the optic pathway; midline locations involving the hypothalamus, thalamus, or brainstem; or those intricately associated with motor pathways. Tumors in these locations, in addition to those pLGGs with multiply recurrent or metastatic disease, often require therapy beyond surgery with a few exceptions.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “hypothalamic-chiasmatic tumours in particular are generally considered unresectable, they present when the children are very young and can threaten vision, endocrine function and require non-surgical therapy”

Source: [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

<a id="topic-2.2.1.2.1-11"></a>

###### Directly measured incidence of RAF-altered pLGG requiring first-line systemic therapy

No evidence found.

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

<a id="topic-2.2.1.2.2-1"></a>

###### Summary: prevalence estimates

No identified publication reports the prevalence of RAF-altered pLGG requiring first-line systemic therapy. CBTRUS projects that 42,864 children and adolescents aged 0 to 19 years in the United States were living with a primary brain or other CNS tumor in 2025, including 21,591 with glioma and 9,193 with pilocytic astrocytoma; these figures exclude survivors who have reached adulthood. Day One Biopharmaceuticals reports a registry-based estimate (SEER and CBTRUS) of 26,000 patients under 25 years of age with BRAF-altered pLGG in the United States as of January 1, 2017, and an addressable pool of 2,000 to 3,000 patients per year with recurrent, progressive, or refractory pLGG at steady state.

Source: [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.2.2-2"></a>

###### United States: CBTRUS prevalence of pilocytic astrocytoma and glioma in ages 0 to 19 years

> “An estimated 42,864 children and adolescents ages 0-19 years will be living with a primary brain or other CNS tumor diagnosis in 2025, making it the most prevalent tumor type in the age range.”
> “The histopathologic group with the highest prevalence was gliomas, with 21,591 cases.”
> “In 2025, the most prevalent histopathologic group is expected to be pilocytic astrocytoma (an estimated 9,193 cases).”
> “As these estimates include only children and adolescents 0-19 years of age at time of prevalence estimate, the total population of childhood and adolescent brain tumor survivors including those that are now in adulthood is significantly larger.”

Source: [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States: company estimates of BRAF-altered pLGG prevalence and addressable population

> “We partnered with an epidemiology firm to perform SEER and CBTRUS registry analysis that estimates the prevalence, as of January 1, 2017, in the United States for BRAF-altered patients with pLGG under the age of 25 to be 26,000. The estimated addressable pool of recurrent, progressive, or refractory patients with pLGG for tovorafenib is approximately between 2,000 to 3,000 per year at steady state.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.2.2-4"></a>

###### Prevalence of RAF-altered pLGG requiring first-line systemic therapy

No evidence found.

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Summary: survival, progression, and mortality

Long-term overall survival in pLGG is high, and tumor-related mortality is uncommon. In 4,040 children in SEER (1973 to 2008), 20-year overall cancer-specific survival was 87% and the 20-year cumulative incidence of death due to glioma was 12%, falling to 7% after age 22 years. In a population-based Ontario cohort of 1,202 children, 93 deaths (7.7%) occurred over a median of 12.73 years, with 20-year overall survival of 90.1%. Upfront radiotherapy was associated with higher late mortality in both cohorts (hazard ratios 3.9 and 3.3).

Progression is frequent among children who need systemic therapy. In COG A9952 (274 randomized children younger than 10 years), 5-year event-free survival was 39% with carboplatin and vincristine and 52% with TPCV, and was 19% in children younger than 1 year. In SIOP-LGG 2004 (497 randomized non-NF1 patients), 5-year progression-free survival was 46% with vincristine and carboplatin and 45% with added etoposide. In HIT-LGG-1996, 10-year progression-free survival after chemotherapy was 44%. Approximately 40% to 50% of children require subsequent chemotherapy lines.

Molecular subtype modifies prognosis. In the Toronto cohort, 5-year progression-free survival was 69% for KIAA1549-BRAF and 52% for BRAF p.V600E tumors. BRAF V600E tumors had 10-year progression-free survival of 27% versus 60.2% for wild-type tumors, and 5-year progression-free survival after first-line chemotherapy of 30.4%. BRAF p.V600E with CDKN2A deletion was associated with 10-year progression-free survival of 0% and 10-year overall survival of 41%. Low-risk tumors (fusions or germline NF1) often stop growing, with few progressions after 10 years. Malignant transformation was observed in fewer than 1% of the HIT-LGG-1996 cohort.

Source: [Bandopadhayay et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657506/); [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/); [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/); [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/); [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/); [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/); [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/); [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

<a id="topic-2.2.1.3-2"></a>

###### Long-term overall survival and tumor-related death: SEER cohort of 4,040 children

> “The 20-year OS was 87% ± 0.8% and the 20-year cumulative incidence of death due to glioma was 12% ± 0.8%. The incidence of death after transition to adulthood (age greater than 22 years) was slightly lower, with 20-year cumulative incidence of disease death of 7% ± 1.8%.”
> “The 30-year OS of the 4,040 patients was 74.8% ± 2%, including all causes of death.”
> “Of the 4,040 patients, 347 patients died as a result of PLGG and 78 patients died of other causes.”
> “We performed a multivariate Cox model analysis (Table II) and identified an increased risk of cancer-specific death in children who were treated with radiation therapy (HR = 3.9, P < 0.0001).”

Source: [Bandopadhayay et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657506/)

<a id="topic-2.2.1.3-3"></a>

###### Long-term survival and late mortality: Ontario population-based cohort

> “At a median follow-up of 12.73 years (range, 0.02-33 years), only 93 deaths (7.7%) were recorded, and the 20-year OS rate was 90.1% ± 1.1%.”
> “Children with neurofibromatosis type 1 had excellent survival and no tumor-related deaths during adulthood.”
> “For patients with unresectable tumors surviving more than 5 years after the diagnosis, upfront radiotherapy was associated with an approximately 3-fold increased risk of overall late deaths (hazard ratio [HR], 3.3; 95% confidence interval [CI], 1.6-6.6; P = .001)”
> “In contrast to early deaths, late mortality was associated not with PLGG progression but rather with tumor transformation and non-oncological causes.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-4"></a>

###### Survival by extent of resection and progression rates in a molecularly profiled cohort

> “If complete surgical resection is possible, 10-year progression-free survival (PFS) exceeds 85%, but drops below 50% if there is radiologically visible residual tumor”
> “Importantly, only 7.5% of patients succumbed to their disease (median time to death=3.9 years, median OS follow-up=15.9 years) despite 33% experiencing tumor progression (median time to progression=2.3 years, median PFS follow-up=5.9 years) (Figure 1F).”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

<a id="topic-2.2.1.3-5"></a>

###### Outcome after first-line chemotherapy: COG A9952 carboplatin and vincristine versus TPCV

> “Of 274 randomly assigned patients who met eligibility requirements, 137 received CV and 137 received TPCV. The 5-year event-free survival (EFS) and overall survival (OS) rates for all eligible patients were 45% ± 3.2% and 86% ± 2.2%, respectively. The 5-year EFS rates were 39% ± 4% for CV and 52% ± 5% for TPCV (stratified log-rank test P = .10; cure model analysis P = .007).”
> “Five-year EFS was 19% ± 7% for patients younger than age 1 year, 51% ± 4% for those age 1 to 5 years, and 64% ± 4% for those older than 5 years.”

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

<a id="topic-2.2.1.3-6"></a>

###### Outcome after first-line chemotherapy: SIOP-LGG 2004 vincristine and carboplatin with or without etoposide

> “Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively. Age and diencephalic syndrome are adverse clinical risk factors for PFS and OS.”

Source: [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

<a id="topic-2.2.1.3-7"></a>

###### Outcome after first-line chemotherapy: HIT-LGG-1996 long-term follow-up

> “Following a median observation of 9.3 years, 10-year overall survival (OS) was 0.94 and 10-year event-free survival (EFS) was 0.47. Ten-year progression-free survival was 0.62 following radiotherapy and 0.44 following chemotherapy.”
> “Supporting other reports, satisfactory PFS in the first years steadily declined without plateau (Fig. 4A), in contrast to an OS of 0.88 at 10 years (Table 3).”
> “Following first or further progressions, 61 (28.2%) of 216 patients eventually received radiotherapy.”

Source: [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)

<a id="topic-2.2.1.3-8"></a>

###### Chronic course with multiple recurrences and subsequent lines of therapy

> “In previously untreated patients with sporadic pLGG, most chemotherapies have 5-year progression-free survival (PFS) rates ranging from 45% to 55%. However, approximately 50% of children will require alternative second-line chemotherapy.”
> “Since many children will have multiple recurrences throughout childhood with numerous chemotherapy interventions, alternative therapies are needed.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “Around 40-50% of PLGG patients require subsequent chemotherapy lines.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

> “Although pLGG is a low-grade tumor with an excellent 10-year overall survival (OS) rate of 94%, the 10-year progression-free survival (PFS) rate in case of an indication for systemic treatment with standard of care (SoC) chemotherapy is only 44%”
> “Therefore, pLGG may be considered a chronic disease in patients whose tumors are unresectable or cannot be completely resected, who will often require several treatment lines throughout life”
> “In addition, these chemotherapy regimens appear even less effective in infants with pLGG”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.1.3-9"></a>

###### Risk factors for progression in a UK population-based cohort

> “The 5-year overall survival and progression-free survival in the whole cohort were 94.6% and 69.4%, respectively.”
> “Multivariate analysis identified young age, fibrillary astrocytoma, and extent of surgical resection as significant independent risk factors for progression. Hypothalamic/chiasmatic tumors demonstrated the most sustained tendency to progress.”
> “This discrepancy underlines the chronic nature of the clinical course for patients with these tumors, which threaten life infrequently, yet continue to be at a sustained risk for progression when unresectable.”

Source: [Stokland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3018938/)

<a id="topic-2.2.1.3-10"></a>

###### Prognosis by molecular alteration: rearrangement-driven versus SNV-driven tumors

> “Rearrangement-driven tumors were diagnosed at a younger age, enriched for WHO grade I histology, infrequently progressed, and rarely resulted in death as compared to SNV-driven tumors.”
> “This pattern is evident in BRAF, where tumors with KIAA1549-BRAF have superior outcome to BRAF p.V600E (5-year PFS of 69% for KIAA1549-BRAF versus 52% for BRAF p.V600E, p=0.0058, log-rank test).”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

<a id="topic-2.2.1.3-11"></a>

###### Prognosis by molecular alteration: low-, intermediate-, and high-risk groups

> “pLGG harboring gene fusions or germline NF1 mutations comprise the low risk group. These tumors progress less frequently and often eventually stop growing with very few progressions seen after 10 years and almost no deaths at 20 years follow-up (10-year PFS of 67% and OS of 98%, 20-year PFS and OS of 58% and 96%, respectively) (Figure 7B–C).”
> “Intermediate risk tumors had a 10-year PFS and OS of 35% and 90%, respectively (Figure 7B–C). However, in contrast to the low risk tumors, these tumors continue to progress with a 20-year PFS of 27% and 20-year OS of 81%.”
> “High risk pLGG include those with H3.3 p.K27M, or BRAF p.V600E with CDKN2A deletion. These tumors almost invariably progress (10-year PFS of 0%) and these patients often succumb to their disease (10-year OS of 41%) (Figure 7B,C).”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

<a id="topic-2.2.1.3-12"></a>

###### Prognosis by molecular alteration: BRAF V600E and CDKN2A deletion

> “Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively (P < .001).”
> “Thirty-two percent of patients with BRAF V600E-mutant received chemotherapy. Five-year PFS after first-line chemotherapy was 30.4% (95% CI, 13.3% to 47.5%; Appendix Fig A1B).”
> “PFS in children with BRAF V600E PLGG was 24.0% (95% CI, 1.9% to 46.1%) and 68.7% (95% CI, 52.8% to 70.2%) for the CDKN2A deleted and balanced tumors, respectively, at 5 years and 0% and 45.9% (95% CI, 21.6% to 70.2%), respectively, at 10 years (P = .005; Fig 2C).”
> “Of importance, late deaths related to tumor progression were observed in BRAF V600E PLGG even at 25 years of follow-up.”

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

<a id="topic-2.2.1.3-13"></a>

###### Spontaneous stabilization, growth arrest, and regression

> “PLGGs have been reported to spontaneously stabilize or regress”

Source: [Bandopadhayay et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657506/)

> “Incompletely resected or unresected tumors may progress, remain stable, or even spontaneously involute.”

Source: [Stokland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3018938/)

> “The tumors are characterized by a slow growth rate and may show periods of growth arrest.”

Source: [Gnekow et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31108561/)

> “Numerous individual reports describe NF1-OPG in young children undergoing periods of rapid growth, prolonged quiescence, and rare spontaneous regression”

Source: [de Blank et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7410089/)

<a id="topic-2.2.1.3-14"></a>

###### Quiescence in adulthood

> “These populations of senescent cells may provide clues to the mechanisms underlying pLGG quiescence upon transition to adulthood”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “Because many pLGGs undergo senescence when patient ages reach their 20s, the goal of therapy is to maximize tumor control while minimizing treatment-associated toxicities from surgery, chemotherapy, and radiation.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.3-15"></a>

###### Malignant transformation

> “Importantly this highlights that PLGGs are very unlikely to undergo malignant transformation resulting in tumor-related death, which contrasts with the natural history of ALGGs”

Source: [Bandopadhayay et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657506/)

> “Malignant transformation is highlighted postradiotherapy, has been observed even without prior treatment, and is not restricted to the older age group or initial astrocytoma grade II. The frequency of <1% in our cohort is lower than incidence rates in smaller series.”

Source: [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)

> “Tumors harboring both BRAF p.V600E and CDKN2A deletion comprise a distinct clinical subtype of pLGG prone to transformation into secondary HGG”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.3-16"></a>

###### Mortality: late mortality among 5-year survivors of childhood CNS tumors in the Childhood Cancer Survivor Study

> “Among all eligible 5-year survivors (n = 2821), cumulative late mortality at 30 years was 25.8% (95% confidence interval [CI] = 23.4% to 28.3%), due primarily to recurrence and/or progression of primary disease.”
> “All-cause mortality at 30 years was higher in 5-year survivors of ependymoma (29.5%) and medulloblastoma (29.0%) than in 5-year survivors of astrocytoma and glial tumors (23.9%; P < .001 for both comparisons) (Figure 1, B).”

Source: [Armstrong et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2704230/)

<a id="topic-2.2.1.3-17"></a>

###### Mortality: brain and CNS tumor deaths in United States children and adolescents

> “Overall, 2,589 deaths were attributed to primary malignant brain and other CNS tumors. This represents an annual average age-specific mortality rate of 0.62 per 100,000 population and an average of 518 deaths per year caused by primary malignant brain and other CNS tumors.”

Source: [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/)

<a id="topic-2.2.1.3-18"></a>

###### Causes of early and late death and standardized mortality ratio in a population-based cohort

> “Despite the excellent overall outcomes, late deaths occurred up to 23 years after the initial diagnosis, and overall SMR was 16.1 (95% CI, 13.0-19.6).”
> “Overall, 55 of 803 patients died during the study period (Table 3).”
> “Importantly, although 37% of early deaths (<5 years after the diagnosis) were due to tumor progression, none of the late deaths was attributed to PLGG, and most could be attributed to late effects of therapy.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-19"></a>

###### Subgroups with inferior long-term survival in the Ontario cohort

> “In contrast, patients with brainstem and thalamic tumors had significantly lower survival than patients with tumors in the rest of the locations (P < .001; Fig. 1D).”
> “Importantly, most of these children who died had received upfront radiotherapy.”
> “In contrast, less than half of patients with pleomorphic xanthoastrocytoma in our study were long-term survivors.”
> “Children younger than 3 years with OPG also emerge as a distinct subgroup with poorer outcomes.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-20"></a>

###### Multivariable analysis of late mortality and the factors adjusted for

> “In a multivariate analysis adjusted for the age of diagnosis, upfront radiation treatment was the most significant factor associated with late overall deaths and tumor-related deaths (P = .012 and P = .014, respectively; Table 2).”
> “Finally, to assess the association of all factors simultaneously, Cox proportional regression was used to estimate hazard ratios (HRs) after adjustments for the age of diagnosis, tumor location, pathology, and radiation.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-21"></a>

###### Leading cause of death and when deaths occurred

> “Transformation to malignant glioma (n = 26) was the most common cause of death, and almost half of all deaths occurred in the first 5 years after the diagnosis (29 of 55 or 52.7%).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-22"></a>

###### Overall survival at 10, 20, and 30 years in the Ontario population-based cohort

> “There were a total of 93 deaths (7.7%) with 10-, 20-, and 30-year OS rates of 93.1% ± 0.8%, 90.1% ± 1.1%, and 88% ± 1.5%, respectively (Fig. 1A).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-23"></a>

###### Overall survival by tumor location

> “Patients with posterior fossa tumors had an excellent 20-year OS rate of 96.8% ± 1.1%, which was similar to the rates for patients with cerebral hemispheric tumors (89.1% ± 2.7%), OPG (90.6% ± 2.2%), and spinal tumors (89.7% ± 2.7%).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-24"></a>

###### Overall survival by histological subtype

> “Pilocytic astrocytoma was the most common histological subtype, and these patients exhibited excellent 20-year OS of 95.5% ± 1.7% (Fig. 1C); no significant differences were observed for most histological subgroups (astrocytoma ganglioglioma, mixed glioma, and low-grade astrocytoma not otherwise specified).”
> “whereas pleomorphic xanthoastrocytoma patients (n = 10) had significantly lower survival (10-year OS, 42.9% ± 20.8%; P < .001; Fig. 1C)”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.3-25"></a>

###### Optic pathway glioma: survival by age at diagnosis and by neurofibromatosis type 1 status

> “Young children with OPG diagnosed when they were 3 years old or younger had inferior outcomes in comparison with older children (20-year OS, 80.4% ± 6.1% vs 97.9% ± 1%; P = .007; Supporting Fig. 2 [see online supporting information]).”
> “Children with NF1 and tumors affecting the optic pathway had excellent survival outcomes (20-year OS, 95.1% ± 2.4%; SMR, 8.9; 95% CI, 2.3-19.7; Supporting Fig. 3A [see online supporting information]), but they were not significantly better than those of OPG patients without NF1 (20-year OS, 88.7% ± 3.6%; SMR, 17.5; 95% CI, 7.9-30.7; P = .06; Supporting Fig. 3B [see online supporting information]).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Summary: MAPK pathway activation and oncogene-induced senescence

pLGG is described as predominantly a single-pathway disease in which somatic or germline alterations converge on constitutive activation of the RAS/RAF/MEK/ERK (MAPK) pathway. KIAA1549::BRAF fusions arise from a tandem duplication at 7q34 that removes the N-terminal regulatory domain of BRAF, producing RAS-independent, dimeric RAF signaling. BRAF p.V600E acts as a phosphomimetic that produces constitutive monomeric kinase activity. Germline NF1 loss removes a negative regulator of RAS. Tumors without an identified driver show similar levels of MAPK pathway up-regulation. Sustained MAPK activation also induces oncogene-induced senescence mediated by p16(INK4a) and the senescence-associated secretory phenotype, which was found in 46 of 52 pilocytic astrocytomas (88.5%) and is proposed to explain slow growth and rare progression. CDKN2A deletion, which co-occurs with BRAF p.V600E, is associated with escape from senescence. Type I BRAF inhibitors are limited to BRAF V600E tumors because they can paradoxically activate MAPK signaling in RAF fusion-driven tumors.

Source: [Jones et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3951336/); [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/); [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/); [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/); [Jacob et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21610151/); [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/); [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.1.4-2"></a>

###### BRAF fusion: loss of the BRAF regulatory domain and RAS-independent dimeric signaling

> “This rearrangement resulted in the N-terminal regulatory domain of BRAF being lost, leading to downstream up-regulation of the RAS/MAPK signaling pathway”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

> “BRAF fusion-positive tumors demonstrate constitutive, RAS-independent, dimeric RAF signaling, resulting in sustained MAPK pathway activation.”
> “In contrast, activating BRAF point mutations, most commonly BRAF p.V600E (15–20% of pLGG), result in constitutive monomeric kinase activation and define a biologically and clinically distinct subgroup”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

> “This gene alteration results in the expression of a wild-type BRAF catalytic domain without its normal regulatory domain, thereby rendering constitutively active BRAF activity.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.4-3"></a>

###### BRAF V600E: constitutive kinase activation

> “Mutations in BRAF, primarily in which a valine is replaced with a glutamic acid at position 600 (p.V600E), act as a phosphomimetic within the RAS/MAPK pathway, rendering it constitutively active”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.4-4"></a>

###### Single-pathway disease: MAPK up-regulation including tumors without an identified driver

> “Pediatric low-grade glioma is predominantly a single pathway disease driven by alterations in the mitogen-activated protein kinase (MAPK) signaling pathway (also known as the RAS-RAF-MEK-ERK pathway).”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

> “Interestingly, all tumors had significantly increased ppERK as compared to normal brain controls (p<0.0001, ANOVA) (Figure 3A).”
> “indicating similar levels of RAS/MAPK up-regulation in pLGG lacking a clear molecular driver”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

<a id="topic-2.2.1.4-5"></a>

###### NF1: loss of neurofibromin as a negative regulator of RAS

> “NF1 is caused by a germline mutation in the NF1 tumor suppressor gene, which encodes neurofibromin, a GTPase-activating protein that functions as a negative regulator RAS”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.4-6"></a>

###### Oncogene-induced senescence in pilocytic astrocytoma

> “Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic β-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%).”
> “OIS may account for the slow growth pattern in PA, the lack of progression to higher-grade astrocytomas, and the high overall survival of affected patients.”

Source: [Jacob et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21610151/)

> “BRAF activation in human neural stem and progenitor cells initially promotes clonogenic growth in soft agarose, suggesting partial cellular transformation, but oncogene-induced senescence subsequently limits proliferation.”
> “Immunohistochemical examination of 66 pilocytic astrocytomas revealed p16 INK4a immunoreactivity in the majority of cases, but patients with tumors negative for p16 INK4a had significantly shorter overall survival.”

Source: [Raabe et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086658/)

<a id="topic-2.2.1.4-7"></a>

###### Senescence-associated secretory phenotype

> “MAPK signaling induces oncogene-induced senescence (OIS), which may cause unpredictable growth behavior of pilocytic astrocytomas.”
> “We provide evidence for the SASP regulating OIS in pediatric pilocytic astrocytoma, with IL1B as a relevant mediator.”
> “High IL1B and SASP expression in pilocytic astrocytoma tumors was associated with favorable progression-free survival.”

Source: [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)

> “While pLGG harbors fewer somatic driver alterations relative to other cancers, they also harbor significant transcriptional heterogeneity, with cells expressing MAPK programs, cell-cycle programs, and senescence programs.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

<a id="topic-2.2.1.4-8"></a>

###### CDKN2A loss and escape from senescence

> “In PLGGs, CDKN2A loss has been reported to be associated with escape from oncogene-induced senescence, especially when combined with BRAF mutations.”

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

> “This is in line with reports showing that co-occurrence of CDKN2A deletion with BRAF p.V600E is associated with escape from oncogene-induced senescence”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.4-9"></a>

###### Paradoxical MAPK activation by type I BRAF inhibitors in RAF fusion-driven tumors

> “The use of type I BRAF inhibitors is limited to patients with tumors harboring a BRAF V600E mutation due to the risk of paradoxical activation of the MAPK pathway and accelerated tumor growth if used in patients with tumors harboring a RAF fusion, such as those involving BRAF or CRAF/RAF1”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.1.4-10"></a>

###### Effect of prolonged MAPK inhibition on senescence

> “The impact of prolonged MAPK pathway inhibition on oncogene-induced senescence (OIS) in pLGG remains unknown and it represents an important gap in understanding what could be the long-term biological consequences of targeted therapies.”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.2.1.4-11"></a>

###### Absence of late progression-related death as clinical evidence for oncogene-induced senescence

> “Indeed, none of the NF1 patients died in adulthood, and none of the other PLGG adult survivors in this study died of tumor progression.”
> “These intriguing observations support the current biological hypothesis that in RAS/MAPK-driven tumors, oncogene-induced senescence causes spontaneous growth arrest and tumor burnout in adolescent and young adults with PLGG.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.1.4-12"></a>

###### Natural history of pilocytic astrocytoma as cycles of growth and dormancy

> “The natural history of PA is unique, as these tumors are self-containing, almost never progress to higher-grade astrocytomas, and their initial growth is usually followed by a decrease in tumor activity, after which they enter a dormant phase and either remain quiescent or restart cycle (s) of growth followed by dormancy, similar to what is observed in OIS in vitro.”
> “Moreover, artificial acceleration of this OIS program could present an interesting therapeutic possibility in patients with progressive disease.”

Source: [Jacob et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21610151/)

<a id="topic-2.2.1.4-13"></a>

###### Senescence-associated secretory phenotype expression and progression-free survival by resection status

> “We here show that a high SASP sum score is associated with favorable progression-free survival (PFS) independent of tumor resection status. We identify two distinct patient cohorts, one with high or intermediate SASP and complete resection (100% 3-year PFS), and one with low SASP and incomplete resection (0% 3-year PFS).”

Source: [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)

<a id="topic-2.2.1.4-14"></a>

###### Non-response of senescent tumor cells to chemotherapy and MEK inhibition

> “No significant response to carboplatin, vincristine, or trametinib was detected in senescent DKFZ-BT66 cells”
> “In conclusion, addition of a BCL2 family inhibitor to the standard-of-care treatment regimen for patients with pilocytic astrocytoma could help eradicate senescent pilocytic astrocytoma cells, which do not respond to chemotherapy and might be the source of tumor recurrence or progression at a later time point.”

Source: [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)

<a id="topic-2.2.1.4-15"></a>

###### Reversal of growth arrest by anti-inflammatory treatment

> “Treatment with the broad anti-inflammatory drug dexamethasone, however, induced proliferation, exemplary inhibition of the IL1 pathway, and suppression of the SASP in DKFZ-BT66 cells in OIS.”
> “As dexamethasone is a drug commonly used in pediatric clinical practice, this result is potentially of high clinical relevance.”
> “The SASP can induce growth arrest in proliferating pilocytic astrocytoma cells, while suppression of the SASP by anti-inflammatory treatment leads to bypass of growth arrest.”

Source: [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)

<a id="topic-2.2.1.4-16"></a>

###### Determinants of the induction and level of oncogene-induced senescence

> “Limiting signals affecting induction and levels of OIS may be dictated not only by the initiating genetic alteration but also by the threshold (intensity and duration) of the signaling and/or the tissue type (cell of origin, microenvironment including the stroma and immune response).”
> “This can explain the dichotomy between activation of an oncogenic pathway, which was recently found to be constitutively activated in 75% to 100% of PAs, and their tendency toward growth arrest.”

Source: [Jacob et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21610151/)

<a id="topic-2.2.1.4-17"></a>

###### MEK inhibition in the senescence model and the limits of a single cell line

> “An increase in metabolic activity in both proliferating and senescent DKFZ-BT66 cells was observed under trametinib treatment, as we have described previously”
> “The current lack of appropriate models beyond DKFZ-BT66 prevents reproduction in a second cell line, and as such represents a limitation of this study, highlighting the urgent need for new additional models at the same time.”
> “Follow-up studies are warranted to assess the clinical impact of the use of anti-inflammatory (and immunosuppressive) drugs such as, for example, dexamethasone in pediatric patients with pilocytic astrocytoma.”

Source: [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Summary: imaging, histology, and molecular testing

Diagnosis combines MRI with histopathology and molecular testing in an integrated, layered report, as endorsed by WHO CNS5. Molecular assays used for pLGG include immunohistochemistry for BRAF p.V600E, fluorescence in situ hybridization, RNA-based multiplex fusion panels (NanoString), next-generation sequencing panels, and DNA methylation profiling. Consensus reviews state that testing must detect structural variants and fusions, copy-number alterations, and single nucleotide variants. In a German population-based cohort of more than 1,200 children, multi-omic integration refined the diagnosis through a DNA methylation class in 50% and detected diagnostic or therapeutically relevant alterations in 47%. In the United States, FoundationOne CDx was approved as a companion diagnostic for OJEMDA in January 2025. Biopsy may be omitted for visual pathway gliomas with characteristic MRI findings, particularly in children with NF1; 115 of 1,031 children (11.2%) in HIT-LGG-1996 and 68 of 497 patients (13.7%) in the SIOP-LGG 2004 randomized trial had no histological verification.

Source: [Louis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/); [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/); [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/); [Sturm et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10115638/); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm); [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/); [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

<a id="topic-2.2.1.5-2"></a>

###### Integrated and layered diagnosis under WHO CNS5

> “Such reports feature an integrated diagnosis at the top, followed by layers that display histological, molecular, and other key types of information (Table 4).”

Source: [Louis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/)

> “Another key concept in the 2021 WHO CNS tumor classification is the recommendation to utilize integrated and layered diagnoses including tumor site, a combination of a tissue-based histologic diagnosis and molecular diagnosis, histopathological classification, CNS tumor grade, and molecular information.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “Given this, a layered diagnostic approach is recommended where both the histologic classification and molecular findings are reported in an integrated diagnosis”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.5-3"></a>

###### Molecular testing methods: immunohistochemistry, FISH, RNA fusion panels, sequencing, and methylation profiling

> “With respect to pLGG, IHC has been faithfully utilized in the detection of BRAF p.V600E”
> “FISH is widely available and can be used on FFPE material but is relatively labor-intensive, and can only test for a single alteration at a time.”
> “NanoString panels can be used to screen for the common fusions such as those involving BRAF (including both the canonical KIAA1549-BRAF and the non-canonical fusions described above) and FGFR1-TACC1”
> “Sequencing based approaches have the benefit of simultaneous detection of most clinically relevant alterations in a single test from which diagnostic, prognostic and therapy decisions can be made.”
> “However, the utility of the methylation classifier may be less robust in pLGG, possibly due to frequent inclusion of normal tissue in these tumors”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.5-4"></a>

###### Consensus recommendations on the scope of molecular testing

> “At a minimum, assays need to be designed to detect genetic alterations that are relevant to pLGG. An integrated approach that is sufficient to detect structural variants/copy-number alterations, single nucleotide variants, and expressed fusion proteins to help inform histopathological interpretation is essential.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “Therefore, comprehensive molecular profiling using platforms capable of detecting SNVs, copy-number changes, and structural variants (including gene fusions and internal tandem duplications [ITDs]) is integral to contemporary practice”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.2.1.5-5"></a>

###### Multi-omic neuropathology in a population-based pediatric cohort

> “We show that the multi-omic integration increased diagnostic accuracy in a substantial proportion of patients through annotation to a refining DNA methylation class (50%), detection of diagnostic or therapeutically relevant genetic alterations (47%) or identification of cancer predisposition syndromes (10%).”
> “For the most commonly affected gene BRAF (272/1,034), fusion events were observed in 158 of 237 DNA methylation-defined infratentorial (124/160), midline (28/51) or cortical LGG (6/26), whereas V600E mutations were further observed in GG (7/13) and PXA (17/23).”

Source: [Sturm et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10115638/)

<a id="topic-2.2.1.5-6"></a>

###### United States practice: routine genomic profiling and companion diagnostic

> “Comprehensive genomic profiling of newly diagnosed or recurrent/progressive pLGG is standard practice within pediatric neuro-oncology programs across the United States, either utilizing CLIA/College of American Pathologists, or CAP, accredited hospital laboratories or third-party commercial vendors.”
> “In January 2025, the FDA approved FoundationOne CDx to be used as a companion diagnostic for OJEMDA.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.5-7"></a>

###### Diagnosis without biopsy: visual pathway gliomas and NF1

> “Initial surgical intervention achieved complete resection in 34.8% of patients, 204 tumors underwent biopsy only (19.8%), and 115 children received a diagnosis of tumor on the basis of neuroradiologic findings (11.2%), with 65 being NF-1.”
> “For VP gliomas, MRI criteria combined with clinical information, such as NF-1 status, allowed diagnosis of the presence of an LGG and justified dispensing with a biopsy.”
> “although outside the VPs, LGG histology should be confirmed”

Source: [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)

> “Children with chiasmatic-hypothalamic tumours may be eligible without histological diagnosis, if neuroradiologic findings meet unequivocal criteria for the presence of a low grade glioma.”
> “Sixty-eight patients (13.7%) did not have verification biopsy of the LGG, due to unequivocal neuroradiological appearances.”

Source: [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

> “In addition, chiasmatic-hypothalamic tumors intrinsic to the optic pathway were eligible without pathologic confirmation.”

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

> “Historically, NF1-pLGG are not biopsied due to their precarious location and the lack of clinical utility of the additional information obtained.”
> “Therefore, obtaining a biopsy from, at minimum, patients deemed higher risk, may prove valuable in identifying patients that require refined and/or novel treatments and distinguishing them from NF1-HGG, particularly in adults.”

Source: [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)

<a id="topic-2.2.1.5-8"></a>

###### Molecular testing of midline tumors that are not routinely biopsied

> “Of importance, the mutation was common in midline tumors, including optic pathway, brainstem, and spinal cord tumors.”
> “For deeply located tumors, such as hypothalamic/chiasmatic LGGs, the need for biopsy before treatment decisions are made for these children is still debated.”

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

<a id="topic-2.2.1.5-9"></a>

###### Imaging: MRI standards and response assessment

> “RAPNO recommends that baseline brain MRI (or baseline spine MRI depending upon the primary lesion location), be performed pre-operatively and 24–72 h post-operatively, and that the post-operative scan should be utilized as the new baseline for response to systemic (and RT) therapy assessments.”
> “RAPNO specifically recommends utilizing T2/FLAIR images to measure a tumor and in assessing radiographic response, as contrast enhancement in pLGG is an unreliable measure of tumor response or progression.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “When a symptomatic NF1-OPG is suspected, MRI of the brain with dedicated high-resolution sequences of the optic nerves and chiasm is the imaging technique of choice to evaluate the extent of OPG involvement and to monitor for radiographic progression or response.”

Source: [de Blank et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7410089/)

<a id="topic-2.2.1.5-10"></a>

###### European guideline: observation versus treatment after diagnosis

> “Following incomplete resection observation is recommended, as long as there is no radiologic tumor growth and the patient does not suffer from significant, tumor-related symptoms. This also applies to patients with a diagnosis of LGG on the basis of radiological criteria. By contrast, clinical worsening and / or radiologic progression are an indication to treatment with either chemo- or radiotherapy.”

Source: [Gnekow et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31108561/)

<a id="topic-2.2.1.5-11"></a>

###### Tiered molecular testing pipeline and turnaround time per tier

> “Our tiered testing pipeline included three sequential stages, each increasing in cost and TAT as they progress. Tier 1 consisted of IHC. Tier 2 included FISH or an RNA-based targeted gene fusion panel (NanoString nCounter).”
> “LGG samples underwent Tier 1 IHC testing to assess BRAF p.V600E and IDH1 p.R132H (the latter if over age 10 years).”
> “TAT was defined as the time it takes from the acquisition of the tumor sample until a clinical report is generated in business days. The TAT per test is 2 days, 7 days, and 14 days for Tier 1, Tier 2, and Tier 3, respectively.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="topic-2.2.1.5-12"></a>

###### Testing yield in pediatric low-grade glioma and the proportion receiving a targeted agent

> “Using our tiered approach, 95% (78 of 82) of LGGs were successfully molecularly characterized.”
> “Within the LGG cohort, 95.1% (78 of 82) of patients had a targetable alteration detected using the tiered approach. Interestingly, only 23% (18 of 78) of those received a targeted agent at some point during therapy.”
> “Of the remaining 60 patients with a targetable alteration, 30 underwent a curative total resection and were subsequently monitored.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="topic-2.2.1.5-13"></a>

###### Yield of a tiered molecular characterization pipeline in pediatric glioma

> “Overall, the tiered approach successfully identified a molecular alteration in 96% (95 of 99) of gliomas diagnosed over a 2-year period.”
> “Within the LGG cohort, 95.1% (78 of 82) of patients had a targetable alteration detected using the tiered approach.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Tumor location as the determinant of presentation: anatomical distribution

> “At the population-level, tumors were distributed equally between the diencephalon (n=313, 32%; n=124, 13% were from Neurofibromatosis Type 1 [NF1] patients), cerebral hemispheres (n=265, 27%) and the cerebellum (n=252, 26%), whereas pure brainstem (n=92, 9.4%), spinal cord (n=41, 4.2%) and extensively disseminated tumors (n=13, 1.3%) were less frequent (Figure 1A).”
> “The median age of diagnosis was 7.6 years (range 0–18.7 years)”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

> “Anatomically implicated were 31.6% cerebellum, 24.6% chiasma/hypothalamus, 16.0% cerebral hemispheres, 9.9% brain stem, 6.1% other supratentorial midline structures, 5.9% optic nerve only, 4.5% spinal cord, and 1.4% others.”

Source: [Stokland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3018938/)

<a id="topic-2.2.1.6-2"></a>

###### Raised intracranial pressure and posterior fossa symptoms: headache, vomiting, ataxia, and papilloedema

> “nausea and vomiting (75%), headache (67%), abnormal gait and coordination (60%), and papilloedema (34%) for posterior fossa tumours”
> “Symptoms of raised intracranial pressure were absent in more than half of children with brain tumours.”
> “macrocephaly (41%), nausea and vomiting (30%), irritability (24%), and lethargy (21%) for children aged under 4 years with intracranial tumours”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

> “These symptoms can include headaches, nausea, vomiting, lethargy, sixth cranial nerve palsies, seizures and behavioral changes, depending on tumor location.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.6-3"></a>

###### Visual symptoms: optic pathway glioma

> “reduced visual acuity (41%), exophthalmia (16%), and optic atrophy (15%) for children with an intracranial tumour and neurofibromatosis”
> “headache (49%), abnormal eye movements (21%), squint (21%), and nausea and vomiting (19%) for central brain tumours”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

> “Optic pathway gliomas (OPGs) occur in 15%-20% of children with neurofibromatosis type 1 (NF1); up to half become symptomatic.”

Source: [Fisher et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3367846/)

> “In a study of 57 children with NF1-OPG, only 32 (59%) had signs or symptoms attributable to their tumor at diagnosis”
> “Because vision deficits due to NF1-OPG may go unnoticed and even precede a diagnosis of OPG, ophthalmologic abnormalities found at tumor presentation and thought to be chronic may not require therapy.”

Source: [de Blank et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7410089/)

<a id="topic-2.2.1.6-4"></a>

###### Endocrine symptoms: precocious puberty, growth failure, and hypothalamic dysfunction

> “Other features noted were weight loss, growth failure, and precocious puberty.”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

> “Precocious puberty or changes in growth hormone related to NF1-OPG are not indications for treatment with chemotherapy.”

Source: [de Blank et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7410089/)

<a id="topic-2.2.1.6-5"></a>

###### Nutritional symptoms: diencephalic syndrome in infants with hypothalamic-chiasmatic glioma

> “DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic–chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology.”
> “Diagnostic delays averaging 11 months contribute to irreversible complications.”

Source: [Ruggiero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12939502/)

> “By clinical definition, 28 children had DS, with hypothalamic-chiasmatic glioma (26/28) and a high frequency of primary dissemination (6/28). Their median age at diagnosis was 6.5 months (range, 2.4–27.1 mo; 23/28 <1 y).”

Source: [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)

<a id="topic-2.2.1.6-6"></a>

###### Seizures: supratentorial and hemispheric tumors

> “unspecified symptoms and signs of raised intracranial pressure (47%), seizures (38%), and papilloedema (21%) for supratentorial tumours”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-7"></a>

###### Brainstem and spinal cord symptoms: cranial nerve palsies, gait disturbance, and back pain

> “abnormal gait and coordination (78%), cranial nerve palsies (52%), pyramidal signs (33%), headache (23%), and squint (19%) for brainstem tumours”
> “back pain (67%), abnormalities of gait and coordination (42%), spinal deformity (39%), focal weakness (21%), and sphincter disturbance (20%) for spinal-cord tumours”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-8"></a>

###### Symptoms prompting nonsurgical treatment at diagnosis

> “Indications for immediate therapy were severe neurologic symptoms (67), visual impairment (74), and risk for tumor progression at a critical site (10)”

Source: [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)

> “Of 115 subjects, visual acuity (VA) decline and tumor progression were the primary reasons to initiate treatment, although there were significant differences in the pattern of indications cited among the institutions.”

Source: [Fisher et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3367846/)

<a id="topic-2.2.1.6-9"></a>

###### Ranked symptoms and signs in children with neurofibromatosis type 1 and an intracranial tumour

> “The ranked symptoms and signs were reduced visual acuity (41%), exophthalmia (16%), optic atrophy (15%), squint (13%), headache (9%), unspecified symptoms of raised intracranial pressure (8%), precocious puberty (8%), abnormal gait or coordination difficulties (7%), voice abnormalities (6%), developmental delay (5%), papilloedema (5%), and reduced visual fields (5%; figure 2).”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-10"></a>

###### Ranked symptoms and signs at diagnosis in children younger than 4 years

> “Ranked symptoms and signs at diagnosis were: macrocephaly (41%), nausea and vomiting (30%), irritability (24%), lethargy (21%), abnormal gait and coordination difficulties (19%), weight loss (14%), clinically apparent hydrocephalus (bulging fontanelle, splayed sutures; 13%), seizures (10%), papilloedema (10%), headache (10%), unspecified focal neurological signs (10%), unspecified symptoms of raised intracranial pressure (9%), focal motor weakness (7%), head tilt (7%), altered level of consciousness (7%), squint (6%), abnormal eye movements (6%), developmental delay (5%), and hemiplegia (5%; figure 2)”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-11"></a>

###### Interval between symptom onset and diagnosis

> “The reported median symptom interval ranges from 1 to 27 months.”
> “Increasing awareness of the varied and complex symptomatology that often occurs with CNS tumours could help tumour diagnosis and reduce the extended symptom interval experienced by many children.”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-12"></a>

###### Representation of low-grade astrocytoma in the pooled presentation data

> “Apart from optic pathway gliomas, these astrocytomas were under-represented in the studies identified.”
> “Despite this result, the distribution of tumour location in the studies identified here was similar to that seen in clinical practice (56% infratentorial, 23% hemispheric, 21% central), lending support to the analysis results.”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-13"></a>

###### Under-recording of behavioural change and school difficulties at presentation

> “In the meta-analysis, the frequency of change in behaviour or school performance (7% in all brain tumours, and 9% for central tumours) was lower than that reported by many individual studies. Several large cohorts reported a frequency of school difficulties and behavioural changes of 22-72%.”
> “Adults with brain tumours are often not asked about behavioural change, and similar reporting errors probably occur in children.”
> “The assumption was made that if a symptom or sign was not described in a study, it did not occur in that population.”

Source: [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)

<a id="topic-2.2.1.6-14"></a>

###### Presenting features in a sporadic optic pathway glioma cohort

> “Exactly half of patients presented with vision loss, and most (66%) presented with optic pallor. Nystagmus (45%), strabismus (32%), and hydrocephalus (29%) were also common.”

Source: [Hanania et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33739455/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Summary: tumor- and treatment-related late morbidity

Among 240 five-year survivors in a St. Jude cohort of 361 children, the 15-year cumulative incidence was 18% for monocular blindness, 22% for hearing loss, 29% for growth hormone deficiency, 33% for thyroid hormone deficiency, 26% for ACTH deficiency, 53% for overweight or obesity, and 38% for at least one seizure; 34% of 182 survivors tested had an IQ below 85, compared with 16% in the normative sample. Among children with progressive hypothalamic/chiasmatic tumors, the cumulative incidence of monocular blindness was 57% at 15 years. In a Dutch nationwide cohort of 117 children treated for optic pathway glioma, 18.8% had binocular severe visual impairment or blindness after a median of 8.3 years. In the Childhood Cancer Survivor Study, survivors of astrocytoma and glial tumors showed radiotherapy dose-dependent impairment in attention, processing speed, and memory, and cranial radiotherapy of 50 Gy or more was associated with a 25-year cumulative incidence of CNS subsequent neoplasms of 7.1%, compared with 1.0% without radiotherapy. Chemotherapy is associated with myelosuppression, peripheral neuropathy, allergic reactions, and other toxicities; grade 3 to 4 peripheral nervous system toxicity occurred in 19% of children receiving carboplatin and vincristine in COG A9952.

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/); [Bennebroek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12340183/); [Armstrong et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2704230/); [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/); [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

<a id="topic-2.2.1.7-2"></a>

###### Cumulative late effects among 5-year survivors: St. Jude cohort

> “OS at 15 years was 86% (95% confidence interval [CI] 82%–90%), and PFS was 55% (95% CI 51%–58%). Among the 240 5-year survivors, the 5-, 10-, and 15-year cumulative incidence of adverse outcomes included blindness: 10%, 13%, and 18%, respectively; hearing loss: 8%, 14%, and 22%; obesity/overweight: 18%, 35%, and 53%; hyperinsulinism: 1%, 5%, and 24%; growth hormone deficiency: 13%, 27%, and 29%;thyroid hormone deficiency: 16%, 28%, and 33%; and adrenocorticotropic hormone (ACTH) deficiency: 12%, 22%, and 26%.”
> “Survivors of childhood LGG experience substantial long-term adverse effects that continue to increase well beyond the 5-year survival time point.”

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)

<a id="topic-2.2.1.7-3"></a>

###### Visual impairment

> “Lesions in the hypothalamic/chiasmatic region were responsible for most cases of vision loss (27 of 31, 87%), and among patients with progressive gliomas in this location the cumulative incidence of monocular legal blindness was 57% at 15 years from diagnosis.”
> “Additionally, the cumulative incidence of a measured visual field deficit was 31.5% (95% CI 22.7%–40.3%) at 15 years, with a cumulative incidence of over 47% in hypothalamic/chiasmatic lesions, regardless of the progression status.”

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)

> “After a median follow‐up of 8.3 years (range: 0.1–23.8 years) after the start of treatment, severe VI or blindness (>1.0 LogMAR) was observed in both eyes in 18.8% of 117 patients and in 34.6% of 234 included eyes.”
> “Independent prognostic factors for severe VI or blindness included starting therapy under the age of 2 years and hypothalamic involvement of the OPG.”

Source: [Bennebroek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12340183/)

> “At completion of chemotherapy, VA improved (32% of subjects), remained stable (40%), or declined (28%). Tumor location was the most consistent prognostic factor for poor VA outcome. There was poor correlation between radiographic and VA outcomes.”

Source: [Fisher et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3367846/)

> “Visual impairment affects up to 80% of patients with optic pathway or hypothalamic tumors”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.2.1.7-4"></a>

###### Endocrine dysfunction and hypothalamic obesity

> “In Cox's multiple regression analysis, both location in the diencephalon and use of RT were statistically significant independent predictors of development of each of these outcomes (Table 4), while GTR was protective for development of GH deficiency (HR = 0.2, 95% CI 0.1–0.6).”
> “Consistent with a known risk for hypothalamic injury-mediated obesity, 75% of these patients are overweight or obese.”

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)

> “While overall survival exceeds 90% at five years, most patients experience significant long-term morbidity including visual impairment, multiple endocrine deficiencies, and hypothalamic obesity.”

Source: [Ruggiero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12939502/)

<a id="topic-2.2.1.7-5"></a>

###### Hearing loss

> “The cumulative incidence of hearing loss was 8%, 14%, and 22% (95% CI at 15 years 13.2–30.3) at 5, 10, and 15 years, respectively, but a deficit severe enough to recommend a hearing aid was uncommon (6%) at 15 years.”

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)

<a id="topic-2.2.1.7-6"></a>

###### Neurocognitive deficits

> “Sixty-one patients (34%) had an IQ score <85, compared with 16% in the normative sample (z = 0.18, P < .001, z-test for testing 1 sample proportion).”
> “In the multiple regression model, younger age at diagnosis (P = .016), epilepsy (P = .048), and shunt placement (P = .029) were significantly predictive of lower IQ.”

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)

> “Survivors diagnosed with astrocytoma and glial tumors were impaired in attention and/or processing speed and memory by a statistically significant extent, with a clear cranial RT dose–response pattern.”

Source: [Armstrong et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2704230/)

> “Neurocognitive impairment, most commonly attention deficits reported in 34–55% of survivors”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

<a id="topic-2.2.1.7-7"></a>

###### Seizures and epilepsy

> “The cumulative incidence of at least 1 seizure was 38.0% (95% CI 29.5%–46.5%) (Table 2). Both seizure and epilepsy were associated only with tumor location above the tentorium cerebri, but not with extent of resection.”

Source: [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)

<a id="topic-2.2.1.7-8"></a>

###### Late effects of radiotherapy: subsequent neoplasms, vasculopathy, and chronic conditions

> “Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT. Survivors had higher risk than siblings of developing new endocrine, neurological, or sensory complications 5 or more years after diagnosis.”
> “There was a dose-dependent association between RT to the frontal and/or temporal lobes and lower rates of employment, and marriage.”

Source: [Armstrong et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2704230/)

> “Although radiation therapy (RT) is an effective treatment modality for pLGG, it is associated with substantial risk of late effects, including neurocognitive deficits, endocrine abnormalities, secondary malignancy, and vascular complication; therefore, it is not recommended for the majority of children diagnosed with pLGG.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “Young children are more at risk for late effects of radiotherapy, including decrease in intellectual function, endocrine deficits, second neoplasms, hearing loss, and vasculopathy.”

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

> “however the hazard ratio of death due to non-glioma related causes of 2.4 (P-value = 0.0006) in patients treated with radiation suggests that radiation-induced mortality may have accounted for some of the deaths that were not directly due to glioma”

Source: [Bandopadhayay et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657506/)

<a id="topic-2.2.1.7-9"></a>

###### Toxicity of first-line chemotherapy

> “Chemotherapies have many associated toxicities, including risks for myelosuppression, peripheral neuropathy, allergic/anaphylactic reaction, constipation, sodium dysregulation, secondary malignancy, and renal and hepatic dysfunction.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “The incidence of peripheral nervous system grade 3 to 4 toxicity was 19% for CV and 19% for TPCV because of the vincristine in both regimens.”

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

<a id="topic-2.2.1.7-10"></a>

###### Chronic disease burden across functional domains

> “Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “The late adverse effects of the disease and treatment of it in combination with the damage to important functional structures puts a heavy burden on patients and can lead to loss of visual function and impairment of neurologic, endocrine, and cognitive functioning”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

> “The diverse domains that can potentially be affected are described as follows: motor function, speech, eating and swallowing, sensory functions, seizures, neuropathy, organ function after systemic treatment, late effects due to cranial radiation (vascular changes and secondary tumors, endocrine and hypothalamic function, sleep and energy, neuro-cognition and education, psychosocial effects, and quality of life.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.7-11"></a>

###### Visual acuity at long-term follow-up after first-line chemotherapy for optic pathway glioma

> “With an average follow-up of 6.5 years, VA improved or remained stable in 59% and 61% of children with NF1 and sporadic OPGs, respectively.”
> “These findings raise the question as to whether chemotherapy is effective in preserving vision; it may well be that treatment after a certain point of visual deterioration cannot prevent further decline.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.1.7-12"></a>

###### Residual morbidity and disability grade in survivors and their relation to quality of life

> “Despite the improved management and survival of pediatric low-grade glioma, roughly 80% of all survivors experience some morbidity.”
> “Greater disability was weakly but significantly correlated with lower scores on the proxy-evaluated total quality of life (r=-0.32, p<0.05). Disability also correlated with lower scores on the friends subscale (r>-0.3, p<0.05) in both the self- and proxy reports.”

Source: [Musial-Bright et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21538130/)

<a id="topic-2.2.1.7-13"></a>

###### Academic achievement and delayed emergence of cognitive impairment

> “Since the majority of pediatric LGG patients are survivors with the lasting effects of brain injury, they frequently are in long-term need for healthcare resources”
> “Problems with academic achievement play a role in 60% of LGG survivors, and over years, developmental problems can continue, and even worsen. Cognitive impairments may appear years after diagnosis, even in children without initial severe deficits.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.7-14"></a>

###### Neuropathy and renal toxicity attributable to first-line vincristine and carboplatin

> “The first-line chemotherapeutic treatment for low-grade glioma patients is the combination of vincristine and carboplatin. Peripheral neuropathy due to vincristine occurs during 57% of LGG treatment”
> “Carboplatin can cause kidney damage resulting in hypomagnesemia, rarely indicating supplement and sometimes hypocalcemia and distal renal tubular acidosis”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.7-15"></a>

###### Frequency of neurologic impairment by domain in children with low-grade glioma

> “Children with LGG may experience a diversity of neurologic impairments, including ataxia 40%, motor weakness 44%, seizures 16%, cranial nerve deficits 14%, eye movement disorders and/or visual impairment 46%, and hearing loss 16% and also cognitive dysfunction 36%”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.7-16"></a>

###### Endocrine and hypothalamic dysfunction at 30-year follow-up and what it requires of monitoring

> “After a 30-year follow-up, patients encounter GH deficiency in 40%, central precocious puberty in 26%, gonadotropin deficiency in 20%, thyroid dysfunction in 13%, and ACTH deficiency in 13%.”
> “Additionally to endocrine dysfunction also hypothalamic damage can be present especially in LGG of the supratentorial midline. These patients have twofold increased risk of endocrine deficiencies”
> “A proper attention for diverse features of hypothalamic dysfunction is needed: hyperphagia, hypophagia, body mass index, behavioral problems, sleep-wake problems, and temperature instability due to autonomic dysregulation.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.7-17"></a>

###### Seizures after resection and hearing loss after surgery or platinum chemotherapy

> “Also after the resection of hemispheric pLGG, seizures can occur, not only directly after surgery (ranging from 15 to 70%), but also on the long term in approximately 30% of patients”
> “About 10% of children experiences hearing loss after surgery on an LGG in the cerebellum”
> “For this reason, carboplatin has been used most often in the treatment of pediatric LGG with lesser risk of hearing loss”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.7-18"></a>

###### Occupation, income, and education in adulthood after radiotherapy

> “On the long term, younger age at diagnosis and treatment with radiotherapy in LGG patients resulted in sevenfold lower occupation scores, more sheltered work, lower income, and less education in adulthood”
> “This lower occupation score was also related to vision, hearing, and motor impairments.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Summary: health-related quality of life in pLGG

No study was identified that reports health-related quality of life (HRQoL) specifically in RAF-altered pLGG at the start of first-line systemic therapy, and no published patient-reported outcome (PRO) comparison of first-line chemotherapy versus a MAPK pathway inhibitor was located. Available evidence comes from survivorship cohorts, optic pathway glioma (OPG) cohorts, single-arm chemotherapy trials, and HTA testimony.

In a Mayo Clinic cohort of 121 survivors (median follow-up 21.9 years), mean EORTC QLQ-C30 global QoL was 78, compared with 76.4 in a healthy adult reference population; post-operative radiation, deep tumor location, and recurrence were associated with poorer HRQoL, and participants with recurrence reported more financial problems. In a German survey of 49 survivors, survivors rated their QoL higher than peers, but their parents did not. Among 36 children aged 10 years or younger with OPG, parent-proxy vision-specific QoL was lower with greater vision loss. In a Canadian phase 2 trial of weekly vinblastine in 54 chemotherapy-naive children, QoL was reported as not affected during 70 weeks of intravenous treatment. The ongoing phase 3 LOGGIC/FIREFLY-2 trial is collecting PedsQL-Core, PedsQL-Cancer, and PROMIS measures in both arms. In the NICE appraisal of dabrafenib plus trametinib (TA977), patient experts described regular hospital travel, costs, and time commitments with current treatments, and no child-specific utility values were identified; the committee judged that adult utility decrements likely underestimate the HRQoL loss in children.

Caregiver burden is documented for pediatric brain tumors generally: 85% of 40 caregivers of children newly hospitalized with a brain tumor rated distress 5 or greater on a 0 to 10 scale, and in a five-site matched study of 301 caregivers of brain tumor survivors 1 to 5 years after treatment, mothers reported higher caregiver burden, including financial impact, than mothers of comparison youth.

Source: [Nwachukwu et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4323958/); [Musial-Bright et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21538130/); [Avery and Hardy (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3947291/); [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [NICE TA977 (2024)](https://www.nice.org.uk/guidance/ta977/resources/dabrafenib-with-trametinib-for-treating-braf-v600e-mutationpositive-glioma-in-children-and-young-people-aged-1-year-and-over-pdf-82615854973381); [Rocque et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6944277/); [Bates et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8860870/)

<a id="topic-2.2.1.8.1-2"></a>

###### Long-term survivors: EORTC QLQ-C30 and QLQ-BN20 at a median of 21.9 years

> “QOL of 121 patients with a diagnosis of LGG from the Mayo Clinic were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 for cancer in general) and (EORTC QLQ-BN20 specific for brain tumors).”
> “Median follow-up was 21.9 years for the participants. Median age at diagnosis was 11.8 years and at assessment was 33 years. Mean (standard deviation) global QOL score for the study was 78 (18) and 76.4 (22.8) in a reference population of healthy adults.”
> “Patients with tumor recurrence reported lower role functioning (p=0.016), social functioning (p=0.040), and more financial problems (p=0.029) compared to their counterparts.”
> “In the multivariable analysis, radiation therapy remained an independent predictor of physical and role functioning as well as symptoms related to brain tumors like visual disorders and motor dysfunction.”
> “The following tumor and treatment related factors were most consistently associated with poorer QOL: CNS tumor location, post-operative radiation, and tumor recurrence.”

Source: [Nwachukwu et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4323958/)

<a id="topic-2.2.1.8.1-3"></a>

###### Long-term survivors: self-report versus parent report (KINDL)

> “We surveyed 49 survivors and their parents (KINDL questionnaire).”
> “Despite tumor and treatment-associated morbidity, survivors (25 boys and 24 girls, median age at diagnosis 7.8 years), but not their parents, rated their total quality of life higher than their peers. Although all survivors had some late morbidity, half of them were able to conduct their daily lives without restriction.”
> “These results reflect survivors' effective coping mechanisms and underscore the difficulties of assessing quality of life in pediatric populations.”

Source: [Musial-Bright et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21538130/)

<a id="topic-2.2.1.8.1-4"></a>

###### Optic pathway glioma: vision-specific quality of life by degree of vision loss

> “Vision specific QOL was assessed by parent proxy using the Children’s Visual Function Questionnaire (CVFQ), and scores were analyzed according to magnitude of visual acuity (VA) loss and presence of visual field (VF) loss. Thirty-six subjects completed the study (53% female) with median age of 4.6 years.”
> “Lower Competence scores were noted in participants with more profound vision loss (P < .05), reflecting a decreased ability to complete activities of daily living (e.g. feeding, grooming).”
> “Children with two visually impaired eyes were rated as having greater difficulty with social interactions and pleasurable activities (Personality subscale, p=.039) compared to those with only one impaired eye.”

Source: [Avery and Hardy (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3947291/)

<a id="topic-2.2.1.8.1-5"></a>

###### Quality of life during first-line intravenous chemotherapy: weekly vinblastine

> “Vinblastine was administered once per week at a dose of 6 mg/m2 intravenously over a period of 70 weeks. Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation/fusion status were also determined and correlated with outcome.”
> “Treatment was well tolerated, and quality of life was not affected during treatment.”

Source: [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/)

<a id="topic-2.2.1.8.1-6"></a>

###### LOGGIC/FIREFLY-2: planned patient-reported outcome comparison of tovorafenib versus chemotherapy

> “Patient-reported outcomes (PRO) assessments: comparison of changes in quality of life (QoL) and health utilities measures between study arms using the Pediatrics Quality of Life™-Core Module (PedsQL-Core), Pediatrics Quality of Life™-Cancer (PedsQL-Cancer), and Patient-Reported Outcomes Measurement Information System (PROMIS ® ) assessment”
> “PedsQL-Core, PedsQL-Cancer and PROMIS ® are being assessed at Screening, every 52 weeks from week 5 to end of treatment, and at year 5 as part of the LTFU.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.1.8.1-7"></a>

###### Patient and caregiver experience of current treatment and utility values: NICE appraisal of dabrafenib plus trametinib

> “The patient experts also explained that currently available treatments need regular travel to hospital, incur significant costs and need a substantial time commitment.”
> “They highlighted that the toxicity associated with conventional chemotherapy can lead to people with glioma and their caregivers choosing to stop treatment.”
> “The company's systematic review was unable to identify utility values for children and young people with glioma.”
> “The committee considered that the adult values likely underestimate the utility decrements that would be seen in children and young people.”
> “The committee noted the benefits associated with better school attendance and increased socialising that would result from fewer visits to the hospital which would not be captured in adult utility values”

Source: [NICE TA977 (2024)](https://www.nice.org.uk/guidance/ta977/resources/dabrafenib-with-trametinib-for-treating-braf-v600e-mutationpositive-glioma-in-children-and-young-people-aged-1-year-and-over-pdf-82615854973381)

<a id="topic-2.2.1.8.1-8"></a>

###### Caregiver distress at diagnosis of a pediatric brain tumor

> “Forty primary caregivers were enrolled (of 49 eligible), with the patient age ranging from newborn to 17 years (mean 7.7 years).”
> “Mean and median DT scores were 7.2 (SD 2.6) and 7, respectively. However, 12 (30%) rated their distress 10/10, and 85% rated distress 5 or greater.”
> “Families of children with newly diagnosed brain tumors experience high levels of distress and psychosocial risk.”

Source: [Rocque et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6944277/)

<a id="topic-2.2.1.8.1-9"></a>

###### Caregiver burden in survivorship: caregivers of pediatric brain tumor survivors versus matched comparison caregivers

> “As part of a five-site study, we utilized a matched-sample design to evaluate psychosocial functioning of 301 caregivers of 189 PBTS (ages 8-15) who were 1-5 years post-treatment, and 286 caregivers of 187 comparison youth matched for sex, race, and age.”
> “Caregivers of PBTS reported similar levels of psychological symptoms to caregivers of comparison youth. Mothers of PBTS mothers reported higher caregiver burden and lower perceptions of social support than mothers of comparison youth. Low SES exacerbated group differences in caregiver burden.”
> “Results demonstrated a significant main effect of group status on all subscales, such that mothers of PBTS reported higher levels of financial impact, disruption of planning, caretaker burden, familial burden, and significantly lower levels of coping than mothers of comparison youth.”

Source: [Bates et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8860870/)

<a id="topic-2.2.1.8.1-10"></a>

###### HRQoL in RAF-altered pLGG before the start of first-line therapy

No evidence found.

<a id="topic-2.2.1.8.1-11"></a>

###### Parent-proxy global health and fatigue during first-line dabrafenib plus trametinib versus chemotherapy

> “The difference in the overall least-squares means of scores between the trial groups for global health and fatigue favored dabrafenib plus trametinib over chemotherapy at all scheduled time points”
> “Outcomes on the pain subscale were similar in the two groups.”
> “The clinical benefit of dabrafenib plus trametinib as compared with chemotherapy is further supported by greater improvements in visual acuity and global health.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.1.8.1-12"></a>

###### Domains in which survivor self-report differed from the reference population

> “Thirty-three patients age 11-17 years old were included in the self-evaluated quality of life analysis compared with published norms for this age group (Fig. 1)”
> “They rated their total quality of life, physical well-being, and self-esteem significantly higher than their healthy peers (p<0.05).”

Source: [Musial-Bright et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21538130/)

<a id="topic-2.2.1.8.1-13"></a>

###### Psychological and social late effects and the state of quality of life evidence

> “Pediatric LGG patients have shown increased risk as late effects for social difficulties and psychological problems (e.g., anxiety 19%, depression 15%, fatigue, behavioral problems 13%), even without additional treatment with chemo- and radiotherapy”
> “Quality of life is gaining attention in LGG, but its evaluation still shows inconsistent results.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.8.1-14"></a>

###### Fatigue and adaptive behavior after treatment

> “For children, fatigue after a brain tumor still increases up to 8 years after diagnosis.”
> “Adaptive behavior after LGG, measured via the Vineland adaptive behavior scale, is decreased for communication (written skills) and the subdomain gross motor skills. These issues are worse in children with younger age at diagnosis and/or chemotherapy. Residual disease was associated with poorer total adaptive behavior”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.1.8.1-15"></a>

###### Divergent quality of life findings across instruments and the limits of the evidence base

> “Sixty-one percent of the patients had impairments (e.g., epilepsy, hormone deficiencies, and motor, visual, sensory, and auditory deficits). Unlike the findings in our study, the Aarsen group reported reduced quality of life for all domains of the TACQOL questionnaire, except in the emotions domain.”
> “All four LGG quality of life studies to date have limitations inherent to cross-sectional, single-institution studies. Small sample sizes, of which ours is the largest, decrease the generalizability of the results, reduce the power of the statistical analysis, and increase the chance that differences and correlations within the data may fail to reach a level of significance.”

Source: [Musial-Bright et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21538130/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Summary: healthcare resource use and costs

No study reporting total direct medical costs of pLGG care in the United States was identified. A Day One-sponsored U.S. study of linked claims and electronic health records (Optum Market Clarity) followed 154 patients aged 18 years or younger with pLGG for 36 months: most patients (95% to 98%) had office or outpatient visits in each 6-month interval, 18% to 28% visited an emergency room, and 9% to 27% had an inpatient stay; mean inpatient stay duration increased from 5.1 days at baseline to 8.1 days during follow-up. Over the study period, 74% of patients filled prescriptions for anti-infectives, 56% for antiemetics, and 65% received pLGG-directed treatment (most often brain surgery); chemotherapy was recorded in 14%. Tumor histology and molecular status could not be characterized.

For long-term survivorship, a Taiwanese national claims study of 33,105 five-year survivors of childhood cancer or benign brain tumor (median follow-up 7 years) reported median annual medical expenses of US $614.08 for brain cancer survivors (n = 2,241) and US $336.89 for benign brain tumor survivors (n = 7,825), versus US $203.90 for 64,754 matched individuals without cancer. No publication was identified that quantifies infusion visit, central venous access, or hospitalization costs of first-line carboplatin and vincristine or vinblastine in pLGG.

Source: [Zelt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11398936/); [Miser et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020904/)

<a id="topic-2.2.1.8.2-2"></a>

###### U.S. linked claims and EHR study: cohort and overall healthcare resource utilization

> “Optum ® Market Clarity Data were used to identify patients aged ≤18 years with an ICD-10 code for brain neoplasm, ≥1 physician notes, and with evidence of pLGG recorded between January 1, 2017 and June 30, 2018. Outcomes including health characteristics, HRU, medications, and procedures were assessed at 6-month intervals over 36 months.”
> “HRU, including speciality care visits, filled prescriptions, and administered medications, was common; 74% of patients had prescriptions for anti-infectives, 56% antiemetics, and 52% required pain or fever relief. Sixty-five percent of patients underwent treatment to control their pLGG, the most common being brain surgery. Little decline was observed in medication use during the study period.”
> “Eighty-six patients (56%) received commercial benefits and 68 patients (44%) received Medicaid benefits.”
> “Patients with pLGG have complex healthcare needs requiring high HRU, often over a long time.”

Source: [Zelt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11398936/)

<a id="topic-2.2.1.8.2-3"></a>

###### U.S. linked claims and EHR study: sites of care, inpatient stays, and emergency room use

> “Most patients (95–98% across the study period) visited an office or outpatient facility, 38–50% a diagnostic laboratory, 18–28% an ER, and 9–27% an inpatient facility in each of the 6-month intervals ( Figure 2D ).”
> “However, the mean inpatient stay duration increased by 59% from 5.1 days during the baseline period to 8.1 days during the follow-up period ( Figure 2E ).”
> “Time spent in ER visits and inpatient stays places a substantial burden on families and adds to time spent away from work, school, and normal activities, potentially adding to financial burden and overall stress.”

Source: [Zelt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11398936/)

<a id="topic-2.2.1.8.2-4"></a>

###### U.S. linked claims and EHR study: pLGG-directed treatments and limitations

> “In the overall study period, 65% of patients received pLGG-specific treatment, the most common being emergency brain surgery (55%) and planned brain surgery (27%) ( Figure 3D ).”
> “Chemotherapy was given to 14% of patients during the study, with the highest proportion of patients receiving it in the first 6-month observation interval (7%) and its use declining over the follow-up period.”
> “In particular, it was not possible to: characterize the tumors histologically or genomically, ascertain the patient’s history of disease, anatomical primary site, or determine their stage on the treatment journey.”

Source: [Zelt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11398936/)

<a id="topic-2.2.1.8.2-5"></a>

###### Long-term survivorship: annual medical expenses of brain tumor survivors (Taiwan national claims)

> “A total of 33,105 children had survived for at least 5 years after the first appearance of a diagnostic code of cancer or a benign brain tumor before the age of 18 years from 2000 to 2010 with follow-up to 2015.”
> “Survivors with female gender, diagnosis before the age of 3 years, and diagnosis of brain cancer or a benign brain tumor had significantly higher annual outpatient expenses (all P<.001). Moreover, the analysis of outpatient medication costs showed that hormonal and neurological medications comprised the 2 largest costs in brain cancer and benign brain tumor survivors.”

Source: [Miser et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020904/)

| Group | Median annual total expense, US $ per person (IQR) |
| --- | --- |
| Brain cancer survivors (n=2241) | “614.08 (267.05-1793.94)” |
| Benign brain tumor survivors (n=7825) | “336.89 (184.64-652.14)” |
| Hematologic cancer survivors (n=3934) | “268.48 (159.50-475.08)” |
| No cancer individuals (n=64,754) | “203.90 (118.98-347.55)” |

Source: [Miser et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020904/)

<a id="topic-2.2.1.8.2-6"></a>

###### Direct medical costs of first-line chemotherapy administration, central venous access, and survivorship care in U.S. pLGG

No evidence found.

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Summary: family financial burden and parental work loss

No study was identified that measures family financial burden specifically in pLGG. Evidence from pediatric brain tumors and pediatric cancer overall indicates the following. At a U.S. cancer center, 16% of 202 patients younger than 21 years who underwent neurosurgery for a cancer-related diagnosis had financial toxicity before surgery, and the 2-year cumulative incidence after surgery was 19%; among 86 patients who survived at least 2 years, 34% experienced financial toxicity, and most affected patients had commercial insurance. In a U.S. single-site survey of 254 caregivers of children with cancer, approximately one third reported that a parent quit or changed work because of the child's cancer, and this was associated with a 13.4-point higher financial burden score (0 to 100 scale) at 1 to 5 years after diagnosis. A systematic review of 35 studies reported frequent parental job loss or job quitting, particularly among mothers, with effects persisting into early survivorship. In a Canadian cohort of 28 families, median first-year indirect costs were $9,668 and median income loss was 55 days. In the Childhood Cancer Survivor Study (3,023 adult survivors; 16% with CNS tumors), survivors with 4 impaired neurocognitive domains had odds ratios of 3.12 for debt collection and 3.77 for bankruptcy compared with survivors with no impaired domains.

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/); [Warner et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4295420/); [Roser et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30970149/); [Forbrigger et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13569998/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12927753/)

<a id="topic-2.2.1.8.3-2"></a>

###### Financial toxicity in pediatric and adolescent neurosurgical oncology (United States)

> “A retrospective review of medical and financial services data was conducted at Memorial Sloan Kettering Cancer Center of patients under 21 years of age who underwent neurosurgery for a cancer-related diagnosis from 2016 to 2020.”
> “294 surgical procedures across 202 patients were analyzed. 16% (33/202) of patients experienced FT in the two years prior to the first neurosurgical procedure, and the most common toxicity identifier was utilization of the financial assistance program (45%). For all 202 patients, the 2-year cumulative incidence of FT following first neurosurgical procedure was 19% (CI:14%,24%). Among patients who survived for at least 2 years after surgery, 34% (29/86) experienced FT with the most common toxicity being having bills sent to collections (34%). Most patients who experienced FT had at least one commercial insurance policy.”

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)

<a id="topic-2.2.1.8.3-3"></a>

###### Parental employment disruption and perceived financial burden in pediatric cancer (United States)

> “Eligible patients were treated at a pediatric cancer hospital, diagnosed at age ≤ 21 years and were ≤ 5 years from diagnosis (N = 254). Financial burden was rated on a visual analog scale of 0 to 100.”
> “Approximately one third of caregivers in both groups reported a parent quitting or changing work as a result of their child's cancer diagnosis.”
> “When adjusted for sex, age at diagnosis, insurance status, and rural residence, caregivers whose child was 1 to 5 years from diagnosis with ≥ 5 unexpected hospitalizations experienced 24.9 (95% CI, 9.1 to 40.7; P < .01) points higher financial burden than those with no unexpected hospitalizations. In addition, when compared with families without employment disruptions, families of children 1 to 5 years from diagnosis in which a caregiver had quit or changed jobs reported 13.4 (95% CI, 3.2 to 23.6; P = .01) points higher financial burden.”

Source: [Warner et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4295420/)

<a id="topic-2.2.1.8.3-4"></a>

###### Systematic review: impact of childhood cancer on parents' socio-economic situation

> “Our systematic review included 35 eligible articles. Childhood cancer had a substantial impact on parents' socio-economic situation across all studies. This impact varied largely by geographical region. We observed a high prevalence of disruptions in parental employment such as job quitting or job loss, particularly among mothers. The associated income losses further contributed to families' perceived financial burden in addition to increased cancer-related expenses. Adverse socio-economic consequences were most pronounced shortly after diagnosis, however, persisted into early survivorship for certain groups of parents.”

Source: [Roser et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30970149/)

<a id="topic-2.2.1.8.3-5"></a>

###### Parents' employment after completion of childhood cancer treatment

> “We interviewed 56 parents of childhood cancer survivors (M = 2.13 years after treatment completion; 89% mothers) using the vocational and financial impact section of the Psychosocial Adjustment to Illness Scale-Carer Interview Form.”
> “Parents reported multiple sources of financial toxicity including travel to and from the hospital and needing to reduce their working hours during their child's cancer treatment. Workplace flexibility was an important factor to protect against unwanted vocational changes. After treatment completion, families living in low socioeconomic areas commonly reported ongoing financial difficulties.”

Source: [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)

<a id="topic-2.2.1.8.3-6"></a>

###### Indirect costs and income loss in the first year of childhood cancer treatment (Canada)

> “Thirty families participated in the study, with 28 providing financial information and 29 participating in interviews. Financial information was collected during the first year of treatment.”
> “Families spent a median of $9668 (IQR $7944-12958) on indirect costs and had a median of 55 (IQR 0-125) days of income lost. Most families (79%) in our study experienced a psychosocial burden using terms like stress, worry, or frustration directly as a result of the financial burdens from cancer treatment, in addition to the already significant anxiety around having a child with cancer.”

Source: [Forbrigger et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13569998/)

<a id="topic-2.2.1.8.3-7"></a>

###### Neurocognitive late effects and financial hardship in adult survivors of childhood cancer (Childhood Cancer Survivor Study)

> “The analytic cohort comprised 3023 adult (median age at financial hardship survey 40.5 [IQR 35.0-47.8] years) survivors of childhood cancer with the most common diagnoses being leukemia (31%), central nervous system tumor (16%), and Hodgkin lymphoma (13%).”
> “Individuals with 4 impaired neurocognitive domains had over 3-fold increased odds of debt collection (OR=3.12, 95% CI=1.91-5.09) and bankruptcy (OR=3.77, 95% CI=2.01-7.07) compared to individuals with no impaired neurocognitive domains.”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12927753/)

<a id="topic-2.2.1.8.3-8"></a>

###### Out-of-pocket costs and parental work loss specific to pLGG or to oral MAPK inhibitor versus intravenous chemotherapy

No evidence found.

<a id="topic-2.2.1.8.3-9"></a>

###### Definition of financial toxicity and insurance coverage in the neurosurgical oncology cohort

> “Financial toxicity was defined as meeting one or more of the following criteria: bankruptcy, bills sent to collections, settlement on medical bills, participation in a timed payment plan, copay assistance program use, financial assistance program use, social work philanthropy use and expression of financial concerns to social work.”
> “The median ZIP-code income, which is the median income living within a zip code, for these patients’ families was $88,636 (range $ 65,101, $116,191). 94% of patients had some type of insurance coverage with 60% of these insured patients being covered by private insurance and 33% by public insurance.”

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)

<a id="topic-2.2.1.8.3-10"></a>

###### Types of financial toxicity and predictors of post-operative financial toxicity

> “The most common toxicities were utilization of a financial assistance program (45%), use of social work philanthropy fund (30%), and having bills sent to collections (24%)”
> “The most common toxicities for patients surviving at least 2 years after last neurosurgical procedure were having bills sent to collections (34%), utilization of the financial assistance programs (31%), and use of the social work philanthropy fund (28%) (Table 2). Among these patients experiencing FT, 69% had at least one commercial insurance policy.”
> “In a univariate regression model, only living within the Tri-state area was significantly predictive of developing post-operative FT (p = 0.037) compared to living outside the Tri-state area (Table 3). Age at first procedure, sex, living in New York versus outside of NY, race, type of insurance, and diagnosis (neuroblastoma vs. diffuse midline glioma (DMG) vs. other) were not significantly associated with developing post-operative FT.”

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)

<a id="topic-2.2.1.8.3-11"></a>

###### Proportion of parents who reduced or left employment during their child’s treatment

> “Thirty-eight parents (67.9%) reported experiencing disruption to their employment while their child was on treatment, which is encapsulated in two subcategories.”
> “Twenty-nine parents (51.8%) reported that they and/or their partner reduced their hours or resigned from their employment after their child’s diagnosis. Participants and their partners reduced working hours by taking unpaid leave (n = 13, 23.2%), taking extended paid leave, including sick and long-service leave (n = 5, 8.9%), changing from full-time to part-time or casual employment (n = 6, 10.7%), changing their self-employed working hours (n = 3, 5.4%), resigning from their employment (n = 12, 21.4%), or a combination of these.”

Source: [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)

<a id="topic-2.2.1.8.3-12"></a>

###### Medical appointments as the leading cause of ongoing employment disruption after treatment

> “Two-thirds of parents (n = 38, 67.9%) reported that their child’s ongoing cancer-related needs caused disruptions to their employment, barriers to reentering the workforce, or barriers to increasing their working hours to full-time employment. The most frequent disruptions were medical appointments (n = 30, 53.6%) and their child’s ongoing health needs (n = 21, 37.5%; e.g., child being too unwell to attend day-care or school).”

Source: [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)

<a id="topic-2.2.1.8.3-13"></a>

###### Persistence of family financial toxicity after treatment completion

> “Only five parents (8.9%; of whom four had an SES decile greater than six and one was unknown) reported that at the time of the study, their financial toxicity related to their child’s cancer treatment had resolved.”

Source: [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)

<a id="topic-2.2.1.8.3-14"></a>

###### Family costs as a proportion of family income in a critical review of cost of illness studies

> “The major components of family’s direct costs were travel, food, and child care.”
> “Families’ costs, in relation to family income, ranged from 0.2% to 283.1% in the US”
> “During the first hospitalization of insured Mexican children diagnosed with leukemia, parents’ out-of-pocket costs and lost wages were US$ 679 (range US$ 127–1,882) exceeding the total household income for nearly half the families”

Source: [Tsimicalis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21370401/)

<a id="topic-2.2.1.8.3-15"></a>

###### Methodological limits of the family cost of illness evidence base

> “Existing research indicates that families incur significant variable costs throughout cancer treatment. However, problems with the published studies related to various PQAQ domains (e.g., time horizon, sensitivity analysis) rendered the magnitude of families’ childhood cancer costs somewhat uncertain.”
> “All data in the reviewed studies were collected within a 1-year time frame.”
> “None of the researchers examined how sensitive their results were in relation to the estimates used for particular variables or underlying assumptions”

Source: [Tsimicalis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21370401/)

<a id="topic-2.2.1.8.3-16"></a>

###### Scope of the systematic review and timing of employment and income disruption

> “Thirteen (37%) studies were conducted in Europe, 16 (46%) in North America/Australia, and 6 (17%) in Asia/Africa (Table 1). Eight (23%) studies included comparison parents. The majority of studies (85%) included different cancer types.”
> “Twenty-six (74%) studies reported on employment, 20 (57%) on income, 21 (60%) on financial situation, and 20 (57%) addressed financial assistance (Table 2).”
> “Most work disruptions occurred shortly after diagnosis and attenuated within one year”

Source: [Roser et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30970149/)

<a id="topic-2.2.1.8.3-17"></a>

###### Financial toxicity before surgery as a predictor of financial toxicity afterwards

> “Patients experiencing preoperative FT within 2 years of their first neurosurgical procedure had a statistically significantly higher cumulative incidence of post-operative FT (2-year estimate: 61% (95% CI: [41%,75%]) compared to their counterparts who did not experience pre-operative FT (2-year estimate: 11% (95% CI: [7%,16%]) (p < 0.001).”
> “This establishes the critical need for assessment and intervention for those at risk of FT prior to meeting criteria and longitudinally throughout treatment, to help decrease the initial and cumulative incidence of FT.”

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)

<a id="topic-2.2.1.8.3-18"></a>

###### Caregiver work loss and cost-related medication nonadherence in adolescents and young adults

> “In addition, working caregivers often need to take significant time away from work, utilizing unpaid leave, sick leave, a leave of absence, or quitting their job. This caregiver inability to work leads to reduced income and halted career progression”
> “As the patients age into adolescence and young adulthood, they become more likely to report cost-related nonadherence to medication, inability to afford medication, ask physicians for a lower cost medication, and use alternative therapies compared to a non-cancer control group of similar ages”

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)

<a id="topic-2.2.1.8.3-19"></a>

###### Why the measured financial toxicity rate is likely an underestimate

> “A notable limitation to this manuscript is that the data are derived from a quaternary cancer care center without a public emergency department. The rates of FT reported are likely lower than in the community due to the inherent barriers involved with navigating the health care system to receive care at a quaternary cancer care center.”
> “Indirect costs are often not captured by hospital financial service departments, and prospectively partnering with patient families is crucial to understanding the impact of indirect costs associated with pediatric neurosurgical oncology.”

Source: [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)

<a id="topic-2.2.1.8.3-20"></a>

###### Out-of-pocket cost categories and the supports families relied on

> “Thirteen parents (23.2%) discussed the factors that directly contributed to their financial toxicity after their child’s diagnosis. Major contributors during their child’s treatment included parking fees, petrol (fuel), and other expenses related to regularly traveling to and from the treating hospital (e.g., road tolls).”
> “Twenty-one parents (37.5%) discussed factors that helped protect their family from financial toxicity after their child’s diagnosis and throughout treatment. These included loans, donations, or gifts from friends and family, charitable support (e.g., free accommodation near their child’s treating hospital and petrol/fuel vouchers), government payments (i.e., welfare payments), and receiving paid leave from their employment.”

Source: [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)

<a id="topic-2.2.1.8.3-21"></a>

###### Employment effects persisting years after treatment completion

> “Nine mothers (16.1%) reported that their child’s ongoing cancer-related needs continued to affect their employment, an average 3.4 years after treatment completion (SD = 3.78). Mothers reported that they accepted lower-paid roles compared with roles prior to their child’s diagnosis, chose part-time or casual employment when they had previously been employed full-time, or chose to leave their employment altogether to become stay-at-home mothers despite expressing their desire to work.”

Source: [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)

<a id="topic-2.2.1.8.3-22"></a>

###### Thresholds for judging family cost burden

> “Lansky and coworkers indicated that the direct costs plus loss of pay were, on average, considerably more than 15%. For half of their sample, the figure was over 25%.”
> “According to the studies reviewed, families of children with cancer are experiencing an unfair burden regardless of whether the threshold is 5% or 15%.”

Source: [Tsimicalis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21370401/)

<a id="topic-2.2.1.8.3-23"></a>

###### Factors that drive family costs and resource use

> “Presently, socioeconomic status, distance from hospital, cancer type, and length of hospitalization have been reported to significantly influence families’ costs and resource use.”
> “Despite the high likelihood of cure, the costs families incur over the course of treatment may be unsustainable and lead to considerable stress and financial hardship”

Source: [Tsimicalis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21370401/)

<a id="topic-2.2.1.8.3-24"></a>

###### Caregiving time required and families at particular risk

> “A Swiss study estimated that parents need on average 240 working days for caretaking during the child´s treatment”
> “Also in the US, a study showed that 15% of families fell below the poverty level due to cancer-related financial strains”
> “We identified families with lower socioeconomic position, parents of children diagnosed with haematological cancers and diagnosed at younger age to be at particular risk for adverse socio-economic consequences.”

Source: [Roser et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30970149/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Summary: cost of molecular testing for BRAF alterations

Tovorafenib use in relapsed or refractory pLGG requires a BRAF fusion or rearrangement or BRAF V600 mutation, and FoundationOne CDx (a tissue-based next-generation sequencing test of 324 genes) was approved by the FDA as its companion diagnostic in January 2025. The Medicare advanced diagnostic laboratory test payment for FoundationOne CDx (code 0037U) was $3,500.00 during its initial period (July 1, 2018 to March 31, 2019); a current 2026 payment rate was not retrieved. No U.S. cost-effectiveness analysis of molecular testing for tovorafenib eligibility was identified.

Reported per-sample costs in other settings were US$1,000 for an outsourced RNA pan-cancer NGS panel (Jordan, 32 pediatric CNS tumors) and, for 82 pediatric LGGs, an average of $405 with a tiered approach (immunohistochemistry, targeted fusion panel or FISH, then targeted RNA sequencing) versus $745 with upfront targeted RNA sequencing. A Canadian microsimulation cost-utility analysis of BRAF fusion testing at diagnosis (100,000 simulated patients; 2018 Canadian dollars; targeted therapies not modeled) found testing dominant, with a gain of 0.38 quality-adjusted life-years (QALYs) and a $1,384 reduction in lifetime costs, driven by avoided radiation-related adverse events.

Source: [Foundation Medicine (2025)](https://www.foundationmedicine.com/press-release/fda-approval-foundationone-cdx-ojemda); [CMS advanced diagnostic laboratory tests list (2025)](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf); [Amayiri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10910540/); [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/); [Rios et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8722113/)

<a id="topic-2.2.1.8.4-2"></a>

###### Companion diagnostic: FoundationOne CDx for tovorafenib

> “FoundationOne®CDx is the first and only companion diagnostic for OJEMDA”
> “Using a tissue sample, the FDA-approved FoundationOne CDx test analyzes more than 300 cancer-related genes in a patient’s tumor.”

Source: [Foundation Medicine (2025)](https://www.foundationmedicine.com/press-release/fda-approval-foundationone-cdx-ojemda)

<a id="topic-2.2.1.8.4-3"></a>

###### Medicare payment for FoundationOne CDx under the Clinical Laboratory Fee Schedule

| Field | Quoted record |
| --- | --- |
| Test code | “0037U” |
| Test name | “FoundationOne CDx” |
| New ADLT initial period | “7/1/18 - 3/31/19” |
| Payment amount during new ADLT initial period | “$3,500.00” |

Source: [CMS advanced diagnostic laboratory tests list (2025)](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)

<a id="topic-2.2.1.8.4-4"></a>

###### Cost-utility of BRAF fusion testing at diagnosis in pLGG (Canadian microsimulation)

> “We performed a model-based cost-utility analysis comparing two strategies: molecular testing to determine BRAF fusion status at diagnosis against no molecular testing. We developed a microsimulation to model the lifetime health and cost outcomes (in quality-adjusted life years (QALYs) and 2018 CAD, respectively) for a simulated cohort of 100,000 patients newly diagnosed with PLGG after their initial surgery.”
> “Our findings indicate that patients who received molecular testing at diagnosis experienced a 0.38 (95% CI: 0.08;0.77) gain in QALYs and $1384 (95% CI: $-3486; $1204) reduction in costs over their lifetime. Cost and QALY benefits were driven primarily by the avoidance of long-term adverse events (stroke, secondary neoplasms) associated with unnecessary use of radiation.”
> “Molecular testing was defined as screening glioma tumor samples for BRAF fusion alterations using the NanoString assay (NanoString Technologies, Seattle, WA).”
> “We did not include targeted therapies as a possible treatment for PLGG.”

Source: [Rios et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8722113/)

<a id="topic-2.2.1.8.4-5"></a>

###### Per-sample cost of tiered molecular characterization versus upfront targeted RNA sequencing in pediatric glioma

> “We used a tiered testing pipeline of immunohistochemistry (IHC), customized fusion panels or fluorescence in situ hybridization (FISH), and targeted RNA sequencing in pediatric gliomas.”
> “The average cost per sample was more affordable when using the tiered approach as compared with up-front targeted RNA sequencing in LGG ($405 US dollars [USD] v $745 USD) and HGGs ($282 USD v $745 USD). The average TAT per sample was also shorter using the tiered approach (10 days for LGG, 5 days for HGG v 14 days for targeted RNA sequencing).”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="topic-2.2.1.8.4-6"></a>

###### Cost and turnaround of outsourced RNA NGS panel for pediatric CNS tumors (middle-income country)

> “We reviewed our experience with NGS testing (TruSight RNA Pan-Cancer-seq panel) for pediatric CNS tumors at KHCC/Jordan (March/2022–April/2023).”
> “The median turnaround time from samples’ shipment to receiving the results was 23.5 days (range, 15–49 days) with a median laboratory processing time of 16 days (range, 8–39 days) at a cost of US$1,000/sample.”

Source: [Amayiri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10910540/)

<a id="topic-2.2.1.8.4-7"></a>

###### U.S. commercial cost or cost-effectiveness of BRAF testing to select tovorafenib in first-line pLGG

No evidence found.

<a id="topic-2.2.1.8.4-8"></a>

###### Molecular testing treated as a routine cost already incurred in a pLGG cost-effectiveness model

> “No testing costs are included in this economic evaluation because patients diagnosed with glioma are routinely tested for common driver mutations, including BRAF V600 mutations, via next-generation sequencing panel testing.”

Source: [Rafia et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41825798/)

<a id="topic-2.2.1.8.4-9"></a>

###### Unit cost of each tier in the tiered molecular testing pipeline

> “To demonstrate the cost benefit of our tiered approach, the mean running cost (including labor cost and consumables) of testing per sample was calculated for the 86 LGG and 18 HGG samples in US dollars (USD), including failed and unsolved samples. The cost of Tier 1 testing is based on a minimum of 3 IHC stains per sample equaling $75 USD. The cost of running the Tier 2 tests is $100 USD per sample, and the cost of running Tier 3 (targeted RNA sequencing) is $745 USD per sample.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="topic-2.2.1.8.4-10"></a>

###### Infrastructure required before a tiered testing approach lowers per-sample cost

> “It should be noted, however, that a basic infrastructure is required for such an approach including the availability of a laboratory equipped with at least Tier 1 testing and a trained molecular pathologist. The initiation of such infrastructure requires additional up-front nonrecurring costs.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="topic-2.2.1.8.4-11"></a>

###### Distribution of samples across testing tiers, which is what produces the cost difference

> “Tier 1, Tier 2, and Tier 3 testing was performed on 98%, 41%, and 35% of samples, respectively. Collectively, 64% underwent either Tier 1 testing alone or Tier 1 and 2 testing, with 64% (52 of 82) not requiring Tier 3 testing (Fig 2A).”
> “Using our tiered approach, 95% (78 of 82) of LGGs were successfully molecularly characterized.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Surgical Resection and Observation

<a id="topic-2.2.2.1.1-1"></a>

###### Surgery as initial treatment and observation after incomplete resection

> “Around 40% of all LGG patients can be cured by complete neurosurgical resection and are followed by close observation. In case of relapse, second resection often is possible. Following incomplete resection observation is recommended, as long as there is no radiologic tumor growth and the patient does not suffer from significant, tumor-related symptoms.”
> “By contrast, clinical worsening and / or radiologic progression are an indication to treatment with either chemo- or radiotherapy.”

Source: [Gnekow et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31108561/)

> “The CCG9891/POG9130 study reported a 5-year PFS and OS of 94% and 99% respectively in children with confirmed gross total resection.2 However, many tumours are not amenable to complete resection because of anatomical location and /or metastatic disease.”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

> “Surgical resection is the mainstay of front-line therapy for symptomatic pLGG; however, more than 50% of pLGGs occur in locations that are either not amenable to surgery or only amenable to a biopsy or limited resection (e.g. tumors located in the diencephalon, brainstem, optic pathway, or spinal cord) (8).”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.2.2.1.1-2"></a>

###### Indications to start non-surgical treatment in unresectable pLGG

| Category | Indication |
| --- | --- |
| Radiologic criteria | “Increase  of tumour volume of > 25 %” |
| Neurologic symptoms | “Diencephalic syndrome” |
| Neurologic symptoms | “Focal neurologic deficits subsequent to tumour growth” |
| Infants | “Infants below 12 months of age with chiasmatic-hypothalamic tumours” |
| Ophthalmologic symptoms | “Visual deterioration on follow-up, a significant loss is defined as more than or equal to 0.2 LogMAR” |

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

<a id="topic-2.2.2.1.1-3"></a>

###### Brazilian consensus: surgery and molecular testing

> “Maximal safe surgical resection remains the cornerstone of treatment for low-grade gliomas (LGG).10 However, precision medicine strategies can inform prognosis and therapeutic decision-making, especially in cases of progressive or recurrent disease.”
> “LGG1 | For low-grade gliomas, regardless of histological subtype, BRAF gene fusions and BRAF V600E mutation testing should be performed as part of the molecular evaluation.”

Source: [Farias de Alvarenga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12969682/)

<a id="topic-2.2.2.1.1-4"></a>

###### Vision loss as the indication for starting chemotherapy in the SIOP-LGG 2004 UK optic pathway glioma cohort

> “VA loss was the most frequent indication to initiate therapy in both NF1 (n=34 eyes, 74%) and sporadic (n=39 eyes, 89%) groups.”
> “Early treatment was initiated in both NF1 and sporadic groups; median time from diagnosis to initiation of treatment was 35 and 21 days, respectively, with 77% and 93% of subjects, respectively, receiving treatment within 1 year of diagnosis.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.2.1.1-5"></a>

###### Published 2024 recommendations add criteria to start non-surgical treatment beyond the 2022 draft

> “Drug resistant seizures with or without tumour growth”
> “Symptomatic metastases”
> “Borderline vision (“Threat to vision”)”
> “Any visual loss in the second eye when the first eye is blind”

Source: [Roka et al. (2024)](https://doi.org/10.1016/j.ejcped.2024.100169)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Conventional Chemotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### European standard clinical practice: carboplatin and vincristine first line, vinblastine alternative

> “The carboplatin and vincristine regimen remains the standard first line systemic treatment for patients with pLGG, with the SIOP LGG 2004 Trial showing a 5-year overall survival and progression-free survival of 89% and 46.1% respectively.”
> “Vinblastine monotherapy as first line treatment for patients with pLGG needing chemotherapy is considered the standard of care for the Canadian Group (5-year PFS 42% in non-NF1 patients).”
> “Following Hypersensitivity reactions to carboplatin (HSR), first line treatment may continue with Vinblastine until total duration therapy of 70 weeks.”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### COG A9952: carboplatin and vincristine versus TPCV in children younger than 10 years

> “Of 274 randomly assigned patients who met eligibility requirements, 137 received CV and 137 received TPCV. The 5-year event-free survival (EFS) and overall survival (OS) rates for all eligible patients were 45% ± 3.2% and 86% ± 2.2%, respectively. The 5-year EFS rates were 39% ± 4% for CV and 52% ± 5% for TPCV (stratified log-rank test P = .10; cure model analysis P = .007).”
> “The difference in EFS between the regimens did not reach significance on the basis of the stratified log-rank test. The 5-year EFS was higher for TPCV on the basis of the cure model analysis. Differences in toxicity may influence physician choice of regimens.”

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

<a id="topic-2.2.2.1.2-3"></a>

###### SIOP-LGG 2004: vincristine and carboplatin with or without etoposide

> “Some 497 newly diagnosed patients (M/F 231/266; median age 4.26 years (interquartile range (IQR) 2.02-7.06)) were randomised to receive vincristine carboplatin (VC) (n = 249) or VC plus etoposide (VCE) during induction (n = 248), stratified by age and tumour site.”
> “Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively.”
> “The addition of etoposide to VC did not improve PFS or OS. High non-progression rates at 24 weeks justify retaining VC as standard first-line therapy.”

Source: [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

<a id="topic-2.2.2.1.2-4"></a>

###### Weekly vinblastine in chemotherapy-naive progressive pLGG

> “Fifty-four patients were enrolled onto the study, with a median age of 8 years (range, 0.7 to 17.2 years).”
> “Best response to chemotherapy was centrally reviewed with a response rate (complete, partial, or minor response) of 25.9%. Disease stabilization (complete, partial, or minor response or stable disease) was achieved in 47 patients (87.0%).”
> “Five-year overall survival and progression-free survival (PFS) rates were 94.4% (95% CI, 88.5% to 100%) and 53.2% (95% CI, 41.3% to 68.5%), respectively, for the entire cohort.”

Source: [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/)

<a id="topic-2.2.2.1.2-5"></a>

###### Chemotherapy outcomes and toxicities summarized by independent reviewers

> “While the 5-year overall survival (OS) with chemotherapy ranges from 86-94% on recent studies, 5-year progression-free survival (PFS) is less favorable at 42-45% in pLGG, with slightly better PFS reported in patients with NF1 (5-yr PFS 69-85%) (9, 10).”
> “Chemotherapy regimens including carboplatin and vincristine or single-agent vinblastine are commonplace today, and while the adverse effect profile of these agents is relatively well tolerated, they carry risks of myelosuppression, gastrointestinal toxicity, and peripheral sensory and motor neuropathy (9–11).”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

> “Standard systemic treatment for pediatric low-grade gliomas (PLGGs) has traditionally been chemotherapy with either carboplatin/vincristine or weekly vinblastine [3,4]. Unfortunately, many patients will progress despite this treatment approach (50%) and a second line of therapy will be needed [3,4].”

Source: [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/)

<a id="topic-2.2.2.1.2-6"></a>

###### Chemotherapy regimens used as the comparator in LOGGIC/FIREFLY-2

> “The SIOPe-BTG LGG WG reported a response rate of 29% (24 weeks after treatment start) and a five-year PFS rate of 45% [9], whereas the COG reported a response rate of 35% (end of treatment) and a five-year event-free survival rate of 39% [8]. A single-arm phase 2 study of single-agent vinblastine (VBL) resulted in a 19% response rate and a five-year PFS rate of 53% [10].”
> “The Arm 2 VBL regimen comprises VBL (BSA ≥ 0.6 m2: 6 mg/m2/day, without exceeding 10 mg; BSA < 0.6 m2: BSA dose × 1/30 × body weight [kg]/day) administered IV QW in four-week cycles until completion of treatment at 70 weeks.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.2.1.2-7"></a>

###### Schedule and duration of carboplatin and vincristine in the North American and European protocols

> “Consolidation lasted from week 13 to 53 and consisted of 4-week cycles of CV with a total duration of chemotherapy of 12 months.”
> “Patients who required systemic therapy were treated with CV for 18 months (10 cycles of consolidation compared to HIT-LGG 1996) and non-NF-1 patients were randomized to receive etoposide as an addition to CV during induction phase of therapy”
> “Later on, CV became the most used regimen for newly diagnosed or progressive PLGG around the globe with the reported 5-PFS ranging from 39 to 47%.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-8"></a>

###### Carboplatin monotherapy as a first-line alternative

> “An Australian retrospective study evaluated efficacy of carboplatin monotherapy (560 mg/m2 every 4 weeks) as a first line therapy in 104 patients treated between 1996 and 2013. Patients received a median of 12 doses and 86% of patients achieved disease stabilization or better (CR/PR/SD). A 5-year PFS was 51% with an excellent OS of 97%. Hypothalamic/chiasmatic location was identified as a main factor of poorer prognosis in regards to PFS.”
> “Hematological toxicity was predominant with grades 3 and 4 in 55/81 patients and allergic reaction occurred in 11% of patients”
> “Hence carboplatin monotherapy proved to be a possible alternative especially in very large regions with long-distance travels to the nearest oncology center. Moreover, there is no peripheral neuropathy risk compared to CV regimen.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-9"></a>

###### Scale of SIOP-LGG 2004 and the proportion of registered children who received chemotherapy

> “Total 3417 patients were enrolled between 2004 and 2012 in 118 institutions from 11 European countries. Out of 497 patients receiving chemotherapy, 249 were randomized to the CV arm.”
> “Presence of diencephalic syndrome was identified as the strongest predicting factor for poor PFS and OS.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-10"></a>

###### Response rate at end of therapy with carboplatin and vincristine in COG A9952

> “The overall response rate for CV arm was 50% at the end of therapy (MR 15%, PR 35%) with 5-year EFS 39%.”
> “Toxicity was moderately higher in the TPCV arm.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-11"></a>

###### Duration and tolerability of first-line vinblastine

> “The toxicity of vinblastine treatment was minimal, allowing most patients to complete the 70 weeks of treatment (one patient even extended treatment for two years without notable toxicities).”
> “Only 2 patients received red blood cell transfusions, and no patient received platelet transfusions.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-12"></a>

###### Chemotherapy assignment and duration in the SIOP-LGG 2004 UK optic pathway glioma cohort

> “Children received extended chemotherapy for 18 months. Children with NF1-OPGs received vincristine and carboplatin (VC). Children with sporadic OPGs were randomised to either VC alone or with etoposide.”
> “One hundred seventy-three children with OPGs were enrolled from 21 UK paediatric oncology centres between 2004 and 2012 (Cancer Research UK trial number CRUK/05/012).”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.2.1.2-13"></a>

###### Carboplatin and vincristine doses differ between the North American and European regimens

> “Interestingly, the administration schedule and carboplatin dosing differ between North America and Europe”
> “Northern American studies established the induction using carboplatin administered at a dose of 175 mg/m2 for 4 consecutive weeks, followed by a 2-week break, and then continued for 4 more weeks. Vincristine at a dose of 1.5 mg/m2 (maximum dose 2 mg) is administered for 10 weeks, concomitant with carboplatin.”
> “In contrast to North American CV, carboplatin was administered at a higher dose (550 mg/m2) every 3–4 weeks.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-14"></a>

###### Infusion schedules of the SIOP LGG 04 and monthly carboplatin protocols

> “The SIOP LGG 04 protocol utilizes carboplatin in a dose of 550 mg/m2 infused over 1 hr on weeks 1, 4, 7, 10, 13, 17, 21, 25, and 6-weekly thereafter, along with vincristine weekly for 10 weeks followed by weeks 10, 13, 17, 21, and 25, and then 3 weeks in every 6 thereafter”
> “The protocol used for monthly carboplatin was described by Gururangan et al. in a phase II study and involves carboplatin in a dose of 560 mg/m2 infused over 1 hr every 4 weeks for 12 doses.”
> “Infusion times for the two protocols were identical (1 hr) as was pre- and post-hydration (30 min each). There was no routine use of corticosteroids or antihistamine in either protocol.”

Source: [Dodgshun et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26207610/)

<a id="topic-2.2.2.1.2-15"></a>

###### Vinblastine starting dose was maintained in a minority of participants

> “The most frequent and important toxicity was hematological.”
> “The initial dose appeared to be high, as only 24% of patients maintained the initial dose of vinblastine (6 mg/m2).”
> “Therefore, the recommended initial dose in future clinical trials after this study has been 5 mg/m2.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.2-16"></a>

###### Choice of carboplatin over cisplatin and cisplatin dose reduction to limit hearing loss

> “Young age at exposure (aged < 5 years) and high cumulative dose (> 400 mg/m2 cisplatin) further increase the risk of developing cisplatin-induced serious hearing loss”
> “For this reason, carboplatin has been used most often in the treatment of pediatric LGG with lesser risk of hearing loss”
> “If indicated, lowered doses of cisplatin were applied from 90 mg/m2 to 75 mg/m2 per course”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.2.1.2-17"></a>

###### Monthly and weekly carboplatin doses and the planned duration of first-line treatment

> “Several different carboplatin-based regimens were used over the study period. Carboplatin was administered either monthly (median dose, 560 mg/m2 per infusion) or weekly (175 mg/m2 per infusion) with or without vincristine with a planned duration of treatment ranging from 12 months to 18 months.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 RAF and MEK Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### Dabrafenib plus trametinib versus carboplatin plus vincristine as first-line therapy in BRAF V600 pLGG

> “A total of 110 patients underwent randomization (73 to receive dabrafenib plus trametinib and 37 to receive standard chemotherapy). At a median follow-up of 18.9 months, an overall response occurred in 47% of the patients treated with dabrafenib plus trametinib and in 11% of those treated with chemotherapy (risk ratio, 4.31; 95% confidence interval [CI], 1.7 to 11.2; P<0.001).”
> “The median progression-free survival was significantly longer with dabrafenib plus trametinib than with chemotherapy (20.1 months vs. 7.4 months; hazard ratio, 0.31; 95% CI, 0.17 to 0.55; P<0.001). Grade 3 or higher adverse events occurred in 47% of the patients receiving dabrafenib plus trametinib and in 94% of those receiving chemotherapy.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.3-2"></a>

###### FDA approval of dabrafenib plus trametinib for BRAF V600E pLGG

> “On March 16, 2023, the U.S. Food and Drug Administration (FDA) approved dabrafenib in combination with trametinib (Tafinlar®, Mekinist®, Novartis Pharmaceuticals Corporation) for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.”
> “This represents the first FDA approval of a systemic therapy for the first-line treatment of pediatric patients with LGG with a BRAF V600E mutation.”

Source: [Barbato et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10841289/)

<a id="topic-2.2.2.1.3-3"></a>

###### Canadian consensus: upfront BRAF inhibitor with or without MEK inhibitor for BRAF V600E gliomas

> “We suggest that most patients with BRAF V600E gliomas should be treated with BRAFis ± MEKis upfront. Discontinuation of treatment can be considered in certain circumstances, and we suggest a slow wean.”
> “Our group felt that, given the fact that some questions remain regarding the duration of treatment with targeted therapy and outcome at discontinuation, chemotherapy should not be removed from the treatment options and that a thorough discussion with the family is crucial.”
> “Based on clinical experience and consensus, we currently suggest treating with BRAFi ± MEKi for a total of 36 months for PLGG and 60 months for HGG.”

Source: [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/)

<a id="topic-2.2.2.1.3-4"></a>

###### European standard clinical practice: targeted therapy in the first line

> “Currently, targeted therapy as first line therapy for paediatric low grade gliomas is only acceptable in the context of clinical trials. Taking into consideration recently published data, possible benefits of targeted therapy could however be discussed for BRAFV600E mutant LGG”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### Brazilian consensus: therapeutic recommendations for BRAF-altered LGG

> “LGG8 | For low-grade gliomas with BRAF V600 mutations, inoperable or with residual lesion, or refractory/relapsed, consider combination therapy with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).”
> “LGG9 | For low-grade gliomas with KIAA1549-BRAF fusion or wild-type BRAF, DO NOT use type 1 BRAF inhibitors (such as dabrafenib or vemurafenib).”
> “LGG10 | For patients with low-grade gliomas that present with the KIAA1549-BRAF fusion, consider using tovorafenib as a therapeutic option.”
> “Level of Agreement: 85%.”
> “Importantly, the panel recommended against the use of type I BRAF inhibitors (such as dabrafenib or vemurafenib) when a KIAA1549-BRAF fusion is detected, due to the risk of paradoxical MAPK pathway activation and subsequent tumor progression.25 For these patients, tovorafenib may represent an alternative.”

Source: [Farias de Alvarenga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12969682/)

<a id="topic-2.2.2.1.3-6"></a>

###### NCCN Guidelines for Pediatric Central Nervous System Cancers: scope

> “The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents.”

Source: [Gajjar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40073837/)

<a id="topic-2.2.2.1.3-7"></a>

###### Selumetinib in recurrent or progressive pLGG: PBTC-029 phase 2 trial

> “On stratum 1, 9/25 (36%) patients achieved a partial response (PR).”
> “On stratum 3, 10/25 (40%) patients achieved a PR with a median follow-up of 48.6 months (8.6–59.1; IQR=12.2) for the 17 subjects without progressions.”
> “These data not only provide an alternative to standard chemotherapy for these subgroups of patients, but this success has led to an interest in exploring efficacy in patients as a first-line therapy. In fact, these data have directly led to the development of two Children’s Oncology Group phase III studies in newly diagnosed pLGG patients both with and without NF1 comparing standard chemotherapy to selumetinib.”

Source: [Fangusaro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6628202/)

> “Twenty-five eligible and evaluable patients were enrolled with a median of 4 (1-11) previous therapies. Six of 25 (24%) had partial response, 14/25 (56%) had stable disease, and 5 (20%) had progressive disease while on treatment.”

Source: [Fangusaro et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8485450/)

> “The median follow-up for patients on strata 1, 3, and 4 without events are 60.4, 60.4, and 58.1 months, and 5-year PFS/OS were 30.8%/88.9%, 54.2%/100%, and 51.0%/100%, respectively.”

Source: [Fangusaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12526141/)

<a id="topic-2.2.2.1.3-8"></a>

###### Selumetinib versus carboplatin and vincristine as first-line therapy: COG ACNS1831 and ACNS1833

> “MEK inhibitors, including selumetinib, trametinib, mirdametinib, binimetinib, and cobimetinib, provide active inhibition of ERK signaling by targeting MEK, a kinase downstream from BRAF in the MAPK pathway. Several have been studied in pLGG, with demonstrated safety and efficacy data available in the recurrent pLGG and NF1-associated pLGG populations, and selumetinib is currently in clinical trials for newly diagnosed patients (NCT03871257, NCT04166409).”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

> “Selumetinib achieved objective response rates of 36–40% in recurrent or progressive pLGG [4]. This supported the initiation of a phase 3 trials (NCT04166409, NCT03871257) comparing selumetinib with standard chemotherapy in upfront settings that unfortunately closed early because of poor accrual [39].”

Source: [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)

| Field | Registry record |
| --- | --- |
| Brief title | “A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma” |
| Overall status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT03871257](https://clinicaltrials.gov/study/NCT03871257)

| Field | Registry record |
| --- | --- |
| Brief title | “A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma” |
| Overall status | “Recruiting” |

Source: [ClinicalTrials.gov NCT04166409](https://clinicaltrials.gov/study/NCT04166409)

<a id="topic-2.2.2.1.3-9"></a>

###### Trametinib with or without dabrafenib in relapsed or refractory BRAF V600-mutant LGG

> “In 49 patients with BRAF V600-mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36). Adverse event-related treatment discontinuations were more common with monotherapy (54% v 22%).”

Source: [Bouffet et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9870224/)

> “While large, prospective trials are still ongoing (NCT03363217), retrospective analyses show promising objective response rates in recurrent pLGG, supporting drug class efficacy in this population (34–36). Interim results of a phase 2 study of single-agent trametinib demonstrated an overall response rate of around 47% (complete, partial, or minor response) in pLGG and a 60% response rate using volumetric assessments in patients with NF1-associated plexiform neurofibroma (33, 44).”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.2.2.1.3-10"></a>

###### Type II RAF inhibitor tovorafenib: current approval limited to relapsed or refractory disease

> “On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

> “Tovorafenib is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric LGG harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies”

Source: [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)

<a id="topic-2.2.2.1.3-11"></a>

###### Treatment exposure, discontinuation, and crossover in the first-line randomized comparison

> “Twelve patients who were assigned to receive dabrafenib plus trametinib discontinued treatment, most commonly because of progressive disease (in 5 of 73 [7%]); in the chemotherapy group, 9 completed treatment and 16 discontinued, also most commonly because of progressive disease (in 9 of 37 [24%]). In the chemotherapy group, 9 patients had centrally confirmed progression and crossed over to receive dabrafenib plus trametinib.”
> “The median duration of exposure was 17.4 months with dabrafenib and 7.8 months with carboplatin; exposures to trametinib and vincristine were similar to those with dabrafenib and carboplatin, respectively”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.3-12"></a>

###### Dabrafenib plus trametinib in adults with recurrent BRAF V600E low-grade glioma in the ROAR basket trial

> “In the low-grade glioma cohort, median follow-up was 32·2 months (IQR 25·1–47·8). Nine (69%; 95% CI 39–91) of 13 patients had an objective response by investigator assessment, including one complete response, six partial responses, and two minor responses.”
> “Median duration of response by independent radiology review was 27·5 months (95% CI 3·8–39·5; six events [all progressions]).”
> “Adverse events led to dose reductions in 22 (38%) patients, interruptions in 24 (41%) patients, and permanent discontinuation in five (9%) patients”

Source: [Wen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34838156/)

<a id="topic-2.2.2.1.3-13"></a>

###### Design, dosing, and statistical assumptions of the first-line randomized comparison

> “Patients were randomly assigned in a 2:1 ratio to receive a combination of oral dabrafenib divided into two equal doses per day (<12 years of age, 5.25 mg per kilogram of body weight per day; ≥12 years of age, 4.5 mg per kilogram per day) plus trametinib once daily (<6 years of age, 0.032 mg per kilogram; ≥6 years, 0.025 mg per kilogram) or standard chemotherapy (carboplatin plus vincristine) according to the doses and schedule used in the Children’s Oncology Group A9952 trial.”
> “Liquid formulations of dabrafenib and trametinib were available.”
> “We estimated that the enrollment of 102 patients would provide at least 80% power to detect a relative increase of 30% in the overall response (which was estimated at 50% with dabrafenib plus trametinib and 20% with chemotherapy) in the primary analyses by independent assessment.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.3-14"></a>

###### Sites, baseline histology, and participants randomized but not treated in the first-line comparison

> “From September 2018 through December 2020, a total of 110 patients underwent randomization (73 to receive dabrafenib plus trametinib and 37 to receive chemotherapy) at 58 sites in 20 countries”
> “The most frequent investigator-determined histologic types of glioma were pilocytic astrocytoma (in 34 patients), ganglioglioma (in 30), low-grade glioma not otherwise specified (in 20), and pleomorphic xanthoastrocytoma (in 11).”
> “Four patients in the chemotherapy group withdrew before receiving treatment on the basis of a decision by the parent or guardian (in 3 patients) or by the investigator (in 1 patient).”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.3-15"></a>

###### Deaths during the first-line randomized comparison

> “No deaths were reported among the patients who received dabrafenib plus trametinib; 1 death was reported (from low-grade glioma) in the chemotherapy group. This death occurred more than 30 days after the last dose of randomized treatment.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.3-16"></a>

###### Population, prior therapy, and dosing in the ROAR low-grade glioma cohort

> “In the low-grade glioma cohort, 13 patients were included in the ITT population. Median age was 33 years (range 18–58) and median time since diagnosis was 6·9 years.”
> “All patients had previous surgery, eight (62%) had received previous radiotherapy, five (38%) had received previous chemotherapy, and two (15%) had received previous bevacizumab.”
> “Patients received oral dabrafenib (150 mg orally twice daily) and oral trametinib (2 mg orally once daily) until unacceptable toxicity, disease progression, or death.”

Source: [Wen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34838156/)

<a id="topic-2.2.2.1.3-17"></a>

###### Adverse events across the ROAR glioma cohorts

> “The most common adverse events across both cohorts combined were fatigue (29 [50%] of 58), headache (25 [43%]), nausea (20 [34%]), and pyrexia (19 [33%]); 31 (53%) patients experienced grade 3 or 4 events, most commonly fatigue (five [9%]), decreased neutrophil count (five [9%]), headache (three [5%]), and neutropenia (three [5%]).”

Source: [Wen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34838156/)

<a id="topic-2.2.2.1.3-18"></a>

###### Design of the TRAM-01 phase 2 basket trial of single-agent trametinib

> “The primary objective is to determine the objective response rate of trametinib as a single agent for treatment of progressing/refractory tumors with MAPK/ERK pathway activation. The TRAM-01 study is a phase II multicentric open-label basket trial including four groups.”
> “Eligible patients for a given study group will receive daily oral trametinib at full dose for a total of 18 cycles of 28 days. A total of 150 patients will be enrolled in seven Canadian centers.”

Source: [Perreault et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6935133/)

<a id="topic-2.2.2.1.3-19"></a>

###### Published 2024 update: first-line targeted therapy approvals and tovorafenib's regulatory designations, with unresolved duration and late-effect questions

> “Until recently, targeted therapy as first-line therapy for pLGG was only acceptable in the context of clinical trials.”
> “Taking into consideration recently published data regarding dabrafenib plus trametinib for patients with pLGG and BRAF V600 mutations, FDA and EMA have approved the use of this combination as first-line treatment for pediatric patients ≥1 year of age with low-grade glioma and a BRAF V600E mutation requiring systemic therapy”
> “Furthermore, tovorafenib-a type II RAF inhibitor- was recently granted rare pediatric disease designation for the treatment of pLGG harboring activating RAF alteration that disproportionately affects children and is now included in the LOGGIC Firefly 2 trial”
> “Tovorafenib was also granted FDA approval for LGG with RAF alteration relapsing after first-line therapy”
> “It should be highlighted that the main unknown issues of targeted treatments remain optimal duration as well as potentially unknown very late effects, thus, additional studies are required.”

Source: [Roka et al. (2024)](https://doi.org/10.1016/j.ejcped.2024.100169)

Additional sources: [NCCN Guidelines Pediatric Central Nervous System Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Radiotherapy

<a id="topic-2.2.2.1.4-1"></a>

###### European standard clinical practice: radiotherapy deferred, reserved for selected cases

> “Radiotherapy had previously been the mainstay of treatment for incompletely resected pLGG but nowadays remains a standard as salvage treatment or as primary treatment in selected cases in which surrounding normal tissue can be optimally preserved.”
> “Patients younger than 5 years of age seem to be more at risk of sequelae following conformal radiotherapy with higher risk of moya moya, increasing deficits over time and greatest decline in cognition.”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### NOPHO consensus guidelines on radiotherapy for pLGG

> “Radiotherapy remains the most effective treatment for unresectable pLGG, but its use must be carefully weighed against the risk of long-term side effects. The guidelines emphasise a personalised treatment approach, considering the evolving field of targeted therapies and the importance of multidisciplinary input in decision-making.”
> “Radiotherapy should generally be avoided when treating CNS tumours in NF1-patients as they have an increased risk of both developing secondary neoplasms [20] and vasculopathies [21].”

Source: [Embring et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12926702/)

<a id="topic-2.2.2.1.4-3"></a>

###### Conformal radiotherapy outcomes: COG ACNS0221

> “At a median follow-up of 5.15 years, 5-year PFS was 71%±6% and OS was 93%±4%.”

Source: [Cherlow et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6548322/)

<a id="topic-2.2.2.1.4-4"></a>

###### Late cognitive and endocrine effects of conformal radiotherapy

> “The effect of age exceeded that of radiation dose; patients younger than 5 years experienced the greatest decline in cognition.”
> “The 10-year cumulative incidence of GH replacement was 48.9%; of thyroid hormone replacement, 64.0%; of glucocorticoid replacement, 19.2%; and of gonadotropin-releasing hormone analog therapy, 34.2%.”

Source: [Merchant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2799064/)

<a id="topic-2.2.2.1.4-5"></a>

###### Optic pathway and hypothalamic LGG: vasculopathy and second neoplasms after radiotherapy

> “Possible RT-induced neoplasms developed in 8 patients, including 4 with NF-1. The 10-year cumulative incidence of clinically significant vasculopathy was 7.1% (95% CI, 2.9%-13.9%); vasculopathy did not develop in any child aged >10 years at the commencement of RT.”

Source: [Tsang et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29280458/)

<a id="topic-2.2.2.1.4-6"></a>

###### Long-term toxicity after photon radiotherapy

> “Of the 23 survivors analyzed for late toxicity, 15 (65%) developed grade 3+ toxicity. The most common Common Terminology Criteria for Adverse Events grade 3 toxicity (30% of survivors) was serious cognitive disability. Four patients (14%) died secondary to treatment complications, all occurring over a decade after completing RT.”

Source: [Williams et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/26808258/)

<a id="topic-2.2.2.1.4-7"></a>

###### Vision preservation with early radiotherapy in sporadic optic pathway glioma

> “BFS rates were 81% at 5 years and 60% at 8 years for CT and 100% at 5 and 8 years for early RT (P = .017).”

Source: [Hanania et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33739455/)

<a id="topic-2.2.2.1.4-8"></a>

###### Long-term survival without upfront radiotherapy and the trade-off against early tumor control

> “Despite multiple progressions, we observed >90% survival 20 to 25 years after the diagnosis in the absence of aggressive modalities such as radiotherapy and no late mortality due to tumor progression.”
> “Specifically, although radiotherapy may be associated with better tumor control in early years, it may lead to significant devastating sequelae affecting not only quality of life but also long-term survival during adult life.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-9"></a>

###### Visual acuity at last follow-up with early radiotherapy compared with chemotherapy

> “At time of last follow-up, 70% of early RT patients maintained normal to satisfactory VA (≤0.2 LogMAR) in a minimum of 1 eye and 60% maintained it in both eyes versus 36% and 18% in the CT group, respectively (P = 0.03, P = .02).”
> “Finally, in an analysis of all patients (N = 38) for clinical risk factors at diagnosis associated with poor long-term visual outcomes, the only statistically significant factors were blindness at presentation (P = .001) and <12 months of age at diagnosis (P = .04).”

Source: [Hanania et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33739455/)

<a id="topic-2.2.2.1.4-10"></a>

###### Endocrine supplementation and grade 3 toxicity after proton radiotherapy in sporadic optic pathway glioma

> “As of last follow-up, 11 patients (58%) required post-RT hormonal supplementation. Of the 16 patients with long-term follow-up, 3 grade 3 toxicities were appreciated.”
> “One patient developed orbital edema and pain requiring surgical intervention; another 2 patients developed treatment-related vasculopathy (moyamoya disease) confirmed by angiography at 15 and 36 months from RT completion at 8 and 10 years old, respectively.”

Source: [Hanania et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33739455/)

<a id="topic-2.2.2.1.4-11"></a>

###### Sources of bias in comparisons of upfront radiotherapy with nonradiation approaches

> “Studies comparing patients who were irradiated upfront and patients subjected to nonradiation approaches are subject to a selection bias at several levels.”
> “First, upfront radiation treatment is currently reserved for more aggressive PLGG; this is highlighted by the early deaths (1-3 years after the diagnosis) observed in these cohorts”
> “Second, these are usually deep-seated tumors for which only a small biopsy sample is available; this leads to a biopsy bias, and presumably a low-grade glioma may actually represent a heterogeneous tumor with high- and low-grade components.”
> “An analysis of patients who survived 5 or more years bypasses many of these limitations and enables a more accurate analysis of late deaths possibly related to radiotherapy.”
> “Because no plateau has been reached, the impact of vascular events and tumor-related deaths may be even higher with longer follow-up.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-12"></a>

###### Residual role for radiotherapy pending targeted therapy

> “While awaiting future studies performed to identify the patients who may benefit from more intensive treatment and anticipating the introduction of targeted therapies, we acknowledge that radiation therapy may have a role in the management of selected, non-NF1 patients with refractory PLGG after careful consideration of alternative lines of chemotherapy, surgery, and targeted therapies.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-13"></a>

###### Cerebrovascular events, moyamoya, and secondary meningioma after cranial irradiation

> “After cranial irradiation, the risk of cerebrovascular incidents is increased 16% at age 50 to 26% at age 65”
> “The risk of developing Moyamoya is higher in younger children, in patients with optic pathway glioma, and in those receiving higher radiation doses and occurs at a median of 40-62 months after RT with median dose of 52 Gy (range, 23-150)”
> “Latency periods for the development of secondary meningioma can be up to 20-40 years”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.2.1.4-14"></a>

###### Disease control by modality in sporadic optic pathway glioma

> “Patients undergoing initial treatment with RT experienced no progression at any time interval (100% progression-free survival [PFS]), and all patients had over 8 years of follow-up (Fig. 3A).”
> “Two patients received MAPK/ERK kinase (MEK) inhibitors as first-line salvage and remain free from progression at 81 and 84 months. Three patients received temozolomide as first-line salvage with a median PFS of 19 months, whereas 20 patients received other chemotherapy (mostly vinblastine) with a median PFS of 9 months.”
> “Most progression overall was local; however, 4 patients in the CT group developed leptomeningeal disease during their disease course following repeated local failure.”
> “Of the 19 patients eventually receiving RT, none progressed locally, and only the 1 above-mentioned patient progressed distantly, developing a new intracranial lesion months after treatment.”

Source: [Hanania et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33739455/)

<a id="topic-2.2.2.1.4-15"></a>

###### Definition of the upfront radiotherapy analysis set and the late deaths within it

> “To avoid bias, we excluded patients who had undergone gross total resection for PLGG because this is a curative intervention and abrogates the need for further radiation treatment.”
> “We also excluded patients who had died within the first 5 years after the diagnosis to avoid a potential biopsy bias of high-grade gliomas (which have an invariably aggressive course and, therefore, are more likely to require radiation therapy) misdiagnosed as PLGG.”
> “To further explore this observation, we constructed a cohort of clinically relevant Ontario PLGG patients for whom total resection was not performed and who survived the first 5 years (whole Ontario cohort, n = 607; SickKids, n = 385). There were 32 late deaths overall (>5 years after diagnosis) recorded for the Ontario cohort with an SMR of 8.9 (95% CI, 6.1-12.2).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-16"></a>

###### Replication of the late mortality association in an independent SEER cohort

> “The risk of late death for children undergoing radiation increased approximately 3-fold for all deaths (HR, 3.3; 95% CI, 2.3-4.7; P < .001) and tumor-related deaths (HR, 3.4; 95% CI, 2.1-5.5; P = .001).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-17"></a>

###### Outcome of the four children with neurofibromatosis type 1 who received upfront radiotherapy

> “A total of 4 NF1 patients received upfront radiation treatment: 2 died of tumor transformation (as discussed previously), and 2 patients were alive at 16 and 26 years.”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-18"></a>

###### Twenty-year overall survival stratified by upfront radiotherapy

> “Patients who received upfront radiation treatment showed significantly lower survival than those who did not (OS at 20 years, 76.9% ± 11.7% vs 96.9% ± 3.1%; P = .039; Supporting Fig. 4 [see online supporting information]).”
> “Furthermore, for the SickKids cohort, the tumor-related survival was significantly inferior for patients who received upfront radiation (20-year OS, 87.4% ± 4.9%; SMR, 23.0; 95% CI, 10.9-39.4) versus those who did not (20-year OS, 97% ± 1.1%; SMR, 7.5; 95% CI, 4.1-12; P = .007; Fig. 2C), and upfront radiation treatment increased the risk of tumor-related death approximately 4-fold (HR, 4.4; 95% CI, 1.3-14.6; P = .013).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-19"></a>

###### Twenty-year overall survival by radiotherapy in the SEER reference cohort

> “For children who received upfront radiation and children who did not, the 20-year OS rates were 84.4% ± 1.9% and 95.3% ± 0.8%, respectively (P < .001; Fig. 2B). Similarly, the tumor-related 20-year OS rates were 89% ± 1.72% and 94.3% ± 0.8%, respectively (P < 0.001; Fig. 2D).”

Source: [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)

<a id="topic-2.2.2.1.4-20"></a>

###### First-line radiotherapy PFS in the German SIOP LGG 2004 trial and management-strategy comparison in Fisher's series

> “The 5-year PFS reported for the subgroup with first-line radiotherapy in the German SIOP LGG 2004 trial is 80 % which has to be balanced against the risk of treatmentrelated toxicity”
> “Furthermore, Fisher’s series showed that the overall survival of the patients receiving radiotherapy immediately following incomplete resection and those with radiation following progression was the same after 5 and 10 years”
> “Moreover, PFS did not differ by management (P:0.32).”

Source: [Roka et al. (2024)](https://doi.org/10.1016/j.ejcped.2024.100169)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Limitations of Current Therapies

<a id="topic-2.2.2.1.5-1"></a>

###### Summary: limitations of chemotherapy, radiotherapy, and approved targeted therapy

First-line chemotherapy controls disease in fewer than half of treated participants over 5 years. In COG A9952 (274 participants), 5-year event-free survival (EFS) was 39% with carboplatin plus vincristine, and in SIOP-LGG 2004 (497 participants) 5-year PFS was 46% with vincristine plus carboplatin; in a Canadian cohort of 54 participants, 5-year PFS with weekly vinblastine was 53.2%. Carboplatin hypersensitivity occurred in 44 of 105 participants (41.9%) in a Canadian retrospective series and in 47% of 34 participants in a single-institution series, and 24 of 34 rechallenged participants (70.5%) had recurrent reactions. Chemotherapy requires weekly intravenous administration over 60 to 81 weeks, with central venous catheters recommended for infants and toddlers. Visual acuity worsened in 41% of participants with NF1-associated optic pathway glioma and 39% with sporadic optic pathway glioma after chemotherapy in the SIOP-LGG 2004 UK cohort. BRAF V600E tumors have a 10-year PFS of 27% after chemotherapy or radiation therapy.

Radiotherapy is associated with cognitive decline in children younger than 5 years, a 10-year cumulative incidence of growth hormone replacement of 48.9%, vasculopathy, and second neoplasms. Dabrafenib plus trametinib is approved for first-line use only in BRAF V600E tumors, and type I BRAF inhibitors are not indicated in BRAF fusion tumors, which comprise approximately 35% of pLGG. No targeted therapy is approved for first-line treatment of BRAF fusion-driven pLGG. After discontinuation of BRAF inhibition, 13 of 17 participants (76.5%) with BRAF V600E pLGG progressed at a median of 2.3 months, and the optimal duration of targeted therapy is not established.

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/); [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/); [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/); [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/); [Dodgshun et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26207610/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf); [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/); [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/); [Merchant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2799064/); [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/); [Nobre et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446502/); [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/)

<a id="topic-2.2.2.1.5-2"></a>

###### Carboplatin hypersensitivity reactions

> “Forty-four patients (41.9%) developed Cb HSR after a median of 10.5 infusions (range, 3-39 infusions).”
> “Thirty-four of 44 patients with Cb HSR were re-exposed to carboplatin, and 24 of 34 patients (70.5%) had recurrent Cb HSR.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

> “Those patients treated with 4-weekly single agent carboplatin had carboplatin allergy in 8% of cases whereas 68% of those treated with combined carboplatin and vincristine (every three weeks, according to the SIOP 2004 low grade glioma protocol) had carboplatin reactions (OR 23.6, P < 0.01). Desensitization was only successful in two out of 10 patients in whom it was attempted.”

Source: [Dodgshun et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26207610/)

<a id="topic-2.2.2.1.5-3"></a>

###### Treatment burden: intravenous administration, visits, and central venous access

> “Treatment with V/C or VBL may be accompanied by significant adverse effects, including bone marrow toxicity, neurotoxicity, hearing loss, renal dysfunction, and allergic reactions [3]. The burden of toxicity, frequent hospital visits as well as a significant number of patients progressing after first-line treatment, motivated the search for alternative strategies. In addition, these chemotherapy regimens appear even less effective in infants with pLGG [11]”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

> “Insertion of central venous catheter is recommended especially for infants and toddlers.”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

> “Selumetinib requires monthly, shorter clinic visits and is taken orally with no requirement for central line placement as compared to weekly CV, bi-monthly bevacizumab/irinotecan and weekly vinblastine visits which often require a central line.”

Source: [Fangusaro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6628202/)

<a id="topic-2.2.2.1.5-4"></a>

###### Visual outcomes after chemotherapy for optic pathway glioma

> “Per subject, VA improved in 24%, remained stable in 35% and worsened in 41% of children with NF1-OPG and improved in 18%, remained stable in 43% and worsened in 39% of children with sporadic OPG.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

> “After a median 11-year follow-up, 81.5% showed abnormal vision, 45.7% were visually impaired, and 26% were bilaterally blind. Only 36% showed BCVA improvement, while 32% worsened.”

Source: [Picariello et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13268981/)

<a id="topic-2.2.2.1.5-5"></a>

###### Poor chemotherapy outcomes in BRAF V600E pLGG

> “Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively (P < .001).”

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

<a id="topic-2.2.2.1.5-6"></a>

###### Limitations of approved targeted therapy: fusion tumors, rebound, and unknown duration

> “The use of type I BRAF inhibitors is limited to patients with tumors harboring a BRAF V600E mutation due to the risk of paradoxical activation of the MAPK pathway and accelerated tumor growth if used in patients with tumors harboring a RAF fusion, such as those involving BRAF or CRAF/RAF1 [23].”
> “However, data generated from ongoing studies of various MAPK pathway inhibitors have shown that responses in pLGGs driven by either BRAF V600E mutations (treated with type I RAF inhibitors and/or MEK inhibitors) or KIAA1549::BRAF fusions (treated with MEK inhibitors) are often only durable for as long as the drug can be administered [27, 28].”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

> “After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response.”

Source: [Nobre et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446502/)

> “While these treatments have heralded tremendous promise, challenges remain about how to best optimize their use, and the long-term toxicities associated with these inhibitors remain unknown.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “In the context of clinical paradigms favoring indefinite treatment, Dab-Tram is unlikely to prove cost-effective at the present price and would require a price reduction to facilitate sustained access.”

Source: [Gascon et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41740060/)

<a id="topic-2.2.2.1.5-7"></a>

###### Late effects of radiotherapy

> “Cranial irradiation is also very effective against pLGG and has demonstrated improved PFS compared to conventional chemotherapy (62% versus 42% 10-year PFS compared to carboplatin/vincristine on HIT-LGG-1996) (13); however, radiation therapy is largely avoided in most sporadic pLGG and almost all NF1-associated pLGG due to the risk of significant late effects, including secondary malignancy, neurocognitive impairment, hormonal dysfunction, growth delay, vasculopathy and cerebrovascular injury (14–17).”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.2.2.1.5-8"></a>

###### Toxicity burden of first-line carboplatin and vincristine in the randomized comparison

> “Carboplatin allergy was reported in 7 patients (21%) in the chemotherapy group.”
> “Permanent discontinuation because of adverse events was less common with dabrafenib plus trametinib than with chemotherapy (4% vs. 18%)”
> “The frequency of adverse events leading to a dose adjustment or interruption was similar in the two groups: 79% with dabrafenib plus trametinib and 79% with chemotherapy.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.5-9"></a>

###### Grade 3 and 4 toxicity and carboplatin allergy rates with carboplatin and vincristine

> “Allergic reaction to carboplatin was observed in 26 patients, and those with grade 3 or 4 discontinued carboplatin therapy. Peripheral neuropathy grade 3 and 4 occurred in 19% of patients. Hematological toxicity accounted for most of the grade 3 and 4 adverse events, in particular decrease absolute neutrophil count (94%), decreased platelets (21%), and anemia (35%)”
> “Toxicity profile was similar to the previous studies, most marked was carboplatin allergy affecting 53% of patients.”
> “Carboplatin hypersensitivity reaction occurred in up to 68% of treated patients and posed significant challenge to CV regimen application. Patients experiencing grade 3 and 4 reaction were required to discontinue the therapy.”
> “Desensitization might provide some benefit to 20–73% of patients”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.5-10"></a>

###### Progression-free survival falls with each subsequent line of chemotherapy

> “However, Kandels et al. studied 96 patients who required second line chemotherapy. In this study, 3-year PFS for second line chemotherapy (28.1 ± 4.8%) was significantly lower when compared to first line chemotherapy (65.7 ± 2.7%). Progression-free survival rates declined with subsequent treatment-lines yet remaining higher for patients with NF1.”
> “In non-NF1-associated tumors, vinblastine monotherapy vs platinum-based chemotherapy was noticeably less effective when used as second-line treatment”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.1.5-11"></a>

###### Duration of carboplatin-based treatment and the proportion needing further therapy

> “Carboplatin was administrated monthly in 46 patients (43.8%) patients for a median total duration of 11 months (range, 1–20 months) and weekly in 59 patients (56.2%) for a total duration of 12 months (range, 0.7–20.9 months)”
> “With a median follow-up of 5.1 years (range, 0.3–16.7 years) after diagnosis, 57 patients (54.3%) required further treatment for disease progression or relapse at a median of 21.3 months (range, 0.6–95.9 months).”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.1.5-12"></a>

###### Outcomes of carboplatin rechallenge with premedication or desensitization

> “By using premedication alone, 10 patients (55.5%) were able to complete their carboplatin treatment, including 7 patients who had no further allergic manifestations (38.8%).”
> “The median number of additional carboplatin infusions delivered with altering Cb HSR therapies was 4 (range, 0.5–34 additional infusions).”
> “Because of recurrent hypersensitivity symptoms despite altering Cb HSR therapies, carboplatin was discontinued in 20 patients.”
> “Such strategies are time consuming, costly, and add a significant burden and anxiety to the patient, family, and caregivers.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.1.5-13"></a>

###### Severity of carboplatin reactions and failure of a standard desensitization protocol

> “Sixteen carboplatin hypersensitivity reactions were noted in the 34 children with low grade glioma. They occurred after a median of seven doses of carboplatin (range 3–14 doses). Three reactions were grade I allergic reaction, 10 were grade II allergic reaction, and three were grade III anaphylaxis according to CTCAE 4.0 criteria.”
> “Only two of 10 patients had no reaction to this rechallenge and one has since experienced a reaction, four doses after the successful rechallenge.”
> “Of the eight patients with further reactions, two were grade III anaphylaxis requiring adrenaline, and the remainder were grade II requiring symptomatic management only.”

Source: [Dodgshun et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26207610/)

<a id="topic-2.2.2.1.5-14"></a>

###### Unknown long-term effects of targeted agents

> “The late effects of these systemic target agents are largely unknown due to its recent application and need further awareness.”
> “MAPK inhibition and PAN RAF inhibition lead to side effects mainly concerning the skin, nails, hair, gastrointestinal tract, blood counts, risen CPK increased weight, while for PAN-RAF inhibition, temporary decreased growth velocity has been described”
> “Until now, these side effects seem to be transient, but should be followed further.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.2.1.5-15"></a>

###### Dose interruptions with each drug in the first-line randomized comparison

> “Dose interruptions occurred in 56 of 73 patients (77%) receiving dabrafenib, 53 of 73 patients (73%) receiving trametinib, 23 of 33 patients (70%) receiving carboplatin, and 22 of 33 patients (67%) receiving vincristine”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.1.5-16"></a>

###### Severity of the first carboplatin reaction and worsening on re-exposure

> “Of the 44 children who developed Cb HSR, the severity of the first reaction was grade I or II in 36 patients (82%), grade III in 6 patients (13.6%), and grade IV in 2 patients (4.6%)”
> “Upon re-exposure, 4 of 18 patients (22.2%) who received premedication alone and 7 of 12 patients (58.3%) who received both desensitization and premedication had worsening of their hypersensitivity symptoms”
> “It is even more noteworthy that 32% of patients presented with a more severe reaction upon re-exposure.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.1.5-17"></a>

###### Limits of chemotherapy for preserving vision

> “These findings raise the question as to whether chemotherapy is effective in preserving vision; it may well be that treatment after a certain point of visual deterioration cannot prevent further decline.”
> “A systematic review found that chemotherapy did not improve visual outcomes in 86% of children.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.2.1.5-18"></a>

###### Timing of carboplatin hypersensitivity by schedule and its relation to cumulative exposure

> “Cb HSR occurred significantly earlier during the weekly schedule, at median of 4.4 months (range, 0.4–15.4 months), compared with a median of 9.1 months (range, 3.1–14.6 months) on the monthly schedule (P = .02).”
> “The occurrence of hypersensitivity reaction was not related to a specific cumulative dose of carboplatin. The cumulative incidence of Cb HSR increased with the number of infusions without any plateau effect (Fig. 1).”
> “Age, NF1 status, and tumor location were not associated with Cb HSR. The schedule of carboplatin administration (weekly or monthly) did not significantly influence the incidence of Cb HSR.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.1.5-19"></a>

###### Severity of the first hypersensitivity reaction and the failure of prophylactic premedication

> “Of the 44 children who developed Cb HSR, the severity of the first reaction was grade I or II in 36 patients (82%), grade III in 6 patients (13.6%), and grade IV in 2 patients (4.6%) (Table 4).”
> “Prophylactic premedication did not prevent Cb HSR significantly and did not influence the severity of the reaction (grade III and IV toxicity; 40% vs 15.3%; P = .22).”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.1.5-20"></a>

###### Desensitization outcomes and the regimens used after carboplatin was stopped

> “Among the 12 patients who underwent desensitization and premedication, only 1 patient (8.3%) was able to complete his carboplatin therapy (P = .018).”
> “Upon re-exposure, 4 of 18 patients (22.2%) who received premedication alone and 7 of 12 patients (58.3%) who received both desensitization and premedication had worsening of their hypersensitivity symptoms (P = .05).”
> “Four patients were observed without further chemotherapy, 2 patients underwent surgical resection, and 14 received another noncarboplatin-containing chemotherapy regimen, including 7 patients who received weekly vinblastine; 4 patients who received either combined thioguanine, procarbazine, and CCNU or combined thioguanine and PCV; and 3 patients who received another line of chemotherapy. The median duration of second-line chemotherapy was 7 months (range, 2–14 months). None of the patients received radiotherapy.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.1.5-21"></a>

###### Progression during carboplatin treatment and total time on chemotherapy

> “Fourteen (24.5%) progressions occured during administration of the carboplatin-based regimen.”
> “The median total duration of chemotherapy did not significantly differ for patients who did and did not experience Cb HSR (13.2 months and 11.3 months, respectively).”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated first-line position of tovorafenib

Current first-line systemic therapy for unresectable, progressive, or symptomatic pLGG is chemotherapy (carboplatin plus vincristine, or weekly vinblastine), except for BRAF V600E tumors, for which dabrafenib plus trametinib received FDA approval in March 2023 and is recommended upfront by Canadian consensus. European standard clinical practice recommendations (version dated December 2022) state that first-line targeted therapy is acceptable only within clinical trials. Tovorafenib is approved in the US (April 2024, accelerated approval) and the EU for relapsed or refractory pLGG with a BRAF fusion or rearrangement or BRAF V600 mutation; it is not approved for first-line use.

If LOGGIC/FIREFLY-2 is positive, tovorafenib would be positioned as first-line systemic therapy for participants aged 6 months to 25 years with RAF-altered pLGG that is unresectable and meets clinical or radiologic indications for treatment. The population with the largest unmet need is BRAF fusion-driven pLGG (KIAA1549::BRAF fusion in approximately 35% of pLGG), for which type I BRAF inhibitors are contraindicated and no targeted first-line therapy is approved; in BRAF V600E pLGG, tovorafenib would enter a setting with an approved targeted alternative. FIREFLY-2 excluded participants with NF1 and tumors with additional activating alterations (IDH1/2, histone H3, MYBL, FGFR), and FDA labeling carries a warning about potential growth of NF1-associated tumors, so NF1-associated pLGG is not an anticipated use. A Brazilian consensus published in 2026 already lists tovorafenib as a therapeutic option for KIAA1549-BRAF fusion LGG, with 85% agreement and without restriction to line of therapy.

Care is delivered in pediatric neuro-oncology centers with multidisciplinary tumor boards; FIREFLY-2 is conducted at academic centers (approximately 140 sites). Tovorafenib is an oral, once-weekly outpatient therapy that does not require central venous access, whereas chemotherapy comparators are given intravenously on a weekly schedule for 60 to 81 weeks. The primary FIREFLY-2 analysis is expected approximately 12 months after the last participant enrolled (May 2026), with preliminary results expected in 2027.

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf); [Barbato et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10841289/); [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/); [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/); [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [Farias de Alvarenga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12969682/); [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/); [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.2.2.2-2"></a>

###### Current first-line landscape by molecular subgroup

> “While chemotherapy remains front-line therapy for unresectable pLGG in most scenarios (with the notable exception of BRAF V600E-altered tumors), many patients recur following cytotoxic agents and require further treatment. Inhibitors of the MAPK pathway, primarily MEK and RAF kinase inhibitors, have emerged as effective and tolerable second-line or later therapy for pLGG.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

> “Dabrafenib in combination with trametinib (D + T) was approved by FDA in 2023 for the first-line treatment of pediatric patients 1 year of age and older with LGG with a BRAF V600E mutation who require systemic therapy.”
> “Prior to the approval of tovorafenib, there were no approved targeted therapies for patients with pLGG harboring BRAF fusions.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.2.2.2-3"></a>

###### Molecularly based treatment strategies: first-line options by alteration

| Molecular alteration | First-line treatment |
| --- | --- |
| BRAF V600E mutation | “Standard chemotherapy: Carboplatin/vincristine (CV)†Targeted therapy: DaBRAFenib (BRAF inhibitor)/trametinib (MEK inhibitor)‡Clinical trials: Tovorafenib vs. CV or vinblastine (NCT05566795)” |
| BRAF fusions | “Standard chemotherapy: Carboplatin/vincristine (CV)Clinical trials:• Selumetinib (MEK inhibitor) vs. CV (NCT04166409, COG ACNS1833)• Tovorafenib (RAF inhibitor) vs. CV/vinblastine (NCT05566795)• Mirdametinib (MEK inhibitor) (NCT04923126, SJ901)” |

Source: [Xu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12988086/)

<a id="topic-2.2.2.2-4"></a>

###### LOGGIC/FIREFLY-2: anticipated first-line population

> “LOGGIC/FIREFLY-2 is a two-arm, randomized, open-label, multicenter, global, phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy vs. current standard of care (SoC) chemotherapy in patients < 25 years of age with pLGG harboring an activating RAF alteration who require first-line systemic therapy.”
> “Additionally, an indication for first-line systemic therapy is required, meaning that the tumor is non-resectable (either completely unresectable or partially resected with residual tumor that can no longer be resected) at the time of enrollment”
> “Patients with NF1-driven tumors are excluded. Furthermore, patients with a tumor exhibiting activating molecular alterations in addition to activating RAF alterations are also ineligible for participation even if the tumors are histologically of a low-grade.”
> “Patients who experience progressive disease in Arm 2 can crossover to Arm 1 and receive tovorafenib.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.2.2-5"></a>

###### Regulatory pathway: FIREFLY-2 as the confirmatory trial

> “As a condition of accelerated approval, a confirmatory study to verify the clinical benefit of tovorafenib is required. FIREFLY-2 is an ongoing, international RCT that is being conducted in the front-line setting to compare tovorafenib to physician’s choice of chemotherapy in patients with pLGG with an activating RAF alteration who require systemic therapy.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

> “Reaching full enrollment in this trial is a critical step toward our goal of establishing OJEMDA as standard of care across all lines of therapy for individuals with BRAF-altered pLGG.”

Source: [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.2.2.2-6"></a>

###### Off-label first-line use of MAPK inhibitors before phase 3 results

> “Off-label use of MAPK pathway inhibitors, namely their use as first-line therapy in newly diagnosed patients with pLGG, is controversial.”
> “Prior to the results of these trials and maturation of the longer-term data on late effects, the use of MAPK inhibitors as front-line therapy raises important ethical considerations.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.2.2.2-7"></a>

###### Care setting: specialist multidisciplinary oversight

> “Decisions on treatment and/ or follow up in pLGG need multidisciplinary information, approach and interpretation. The multidisciplinary tumour board should consist of neurooncology, neurosurgical, neurology, neuroradiology, radiotherapy and neuropathology expertise and should meet at regular scheduled intervals in order to optimize diagnosis, follow up and treatment.”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

| Consensus statement | Topic |
| --- | --- |
| “MAPKi therapies should only be prescribed, and their management overseen, by an appropriate oncology team in a multidisciplinary setting” | General management |

Source: [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/)

> “The trial is being conducted at academic centers with patients being recruited from ~ 100 sites, including the SIOPe LOGGIC (Low Grade Glioma in Children) consortium in Europe, the Asia–Pacific region (Singapore, South Korea, Australia and New Zealand), and North America (Canada and the US).”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.2.2-8"></a>

###### Care setting: oral outpatient therapy compared with intravenous chemotherapy

> “Beyond convenience, oral MAPK inhibitors may also reduce financial toxicity for patients living in low resource or geographically limited areas, since on therapy monitoring necessitates fewer ambulatory office visits compared to a chemotherapy regimen administered weekly. Additionally, unlike chemotherapy, MAPK inhibitors are not associated with serious infectious complications since they do not cause significant myelosuppression or require central venous access, so unexpected hospital admissions are rare.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

> “Specific socio-economic situations, such as patients living far away from hospitals, can impact the decision since it is generally easier to administer oral drugs at home with BRAFis with or without MEKis than weekly intravenous (IV) chemotherapy infusions.”

Source: [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/)

<a id="topic-2.2.2.2-9"></a>

###### Proportion of children with a targetable alteration who actually received a targeted agent

> “Interestingly, only 23% (18 of 78) of those received a targeted agent at some point during therapy. Of the remaining 60 patients with a targetable alteration, 30 underwent a curative total resection and were subsequently monitored.”
> “However, only 23% received a targeted agent. This may be partly explained by the fact that most patients who underwent curative surgery did not require further intervention. Moreover, targeted agents such as MEK inhibitors are not yet considered a first-line therapy and are often reserved for rapidly progressing tumors or clinical trials.”
> “Importantly, for most patients, including ones who underwent a complete resection, a targeted agent has been identified for consideration at recurrence.”

Source: [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary: factors that modify treatment effect

Molecular subgroup modifies outcomes with both chemotherapy and targeted therapy. BRAF V600E pLGG had a 10-year PFS of 27% after chemotherapy or radiation therapy versus 60.2% for wild-type tumors, and CDKN2A deletion independently predicted poor outcome; in a 1,000-tumor cohort, BRAF V600E with CDKN2A deletion had a 10-year PFS of 0%, whereas fusion-driven and NF1 tumors had a 10-year PFS of 67%. CDKN2A deletion was not associated with lack of response to BRAF inhibition. In FIREFLY-1 (relapsed or refractory), RANO-HGG objective response rate (ORR) was 69% for BRAF fusion and 50% for BRAF V600E tumors (10 evaluable participants), with a shorter median time to response for V600E tumors (2.8 versus 5.5 months by RAPNO). NF1-associated tumors were excluded from FIREFLY-1 and FIREFLY-2, and nonclinical data showed increased tumor volume in approximately 17% of NF1 model mice treated with tovorafenib; in contrast, participants with NF1 had better 5-year PFS with vinblastine (85.1% versus 42.0%) and had selumetinib response rates of 40%.

Age and tumor location also modify outcomes: younger age and tumor size greater than 3 cm2 predicted worse EFS in COG A9952, age and diencephalic syndrome predicted worse PFS and overall survival in SIOP-LGG 2004, and chemotherapy appears less effective in infants. FIREFLY-2 stratifies randomization by supratentorial midline location, fusion versus mutation, CDKN2A status, and infant chiasmatic-hypothalamic glioma. Visual outcomes after chemotherapy were poorer for sporadic than NF1-associated optic pathway glioma.

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/); [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/); [Nobre et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446502/); [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/); [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/); [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/); [Fangusaro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6628202/); [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/); [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.2.3-2"></a>

###### BRAF alteration type: tovorafenib response by fusion versus V600E in relapsed or refractory pLGG

> “The ORR was 69% (95% CI: 56–81) in patients with tumors harboring BRAF fusions and 50% (95% CI: 19–81) in patients with tumors harboring BRAF V600E mutations. The ORR was 71% (95% CI: 54–84) in the 59% of evaluable patients who had received prior MAPK inhibitor (MAPKi) therapy and 61% (95% CI: 41–78) in those who had not.”
> “The median time to initial response (MR or PR) was 5.3 months (range, 1.6–11.2) overall; 2.8 months (range, 1.6–3.0) in patients with tumors harboring BRAF V600E mutations; and 5.5 months (range, 2.3–11.2) in patients with tumors harboring BRAF fusions.”

Source: [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/)

> “Exploratory subgroup analyses of ORR demonstrated similar response rates based on BRAF alteration (KIAA1549:BRAF fusion vs. BRAF V600E mutation), exposure to a prior MEK and/or BRAF inhibitor, and number of prior lines of therapy received.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.2.2.3-3"></a>

###### NF1-associated tumors: exclusion and potential for tumor growth with tovorafenib

> “In a neurofibromatosis type I (NF1) model without BRAF alteration, tovorafenib did not have antitumor activity, and while not statistically significant, an increase in tumor volume in ~17% of mice was observed with treatment (12).”
> “Although cases of patients with pLGG bearing both a BRAF alteration and loss of NF1 are rare, possible tumor growth in the context of NF-1 associated disease was considered relevant for clinician awareness (17).”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.2.2.3-4"></a>

###### NF1 status and outcomes with chemotherapy and MEK inhibition

> “Patients with NF1 had a significantly better PFS (85.1%; 95% CI, 68.0% to 100%) when compared with patients without NF1 (42.0%; 95% CI, 29.1% to 60.7%; P = .012). Age< 3 years or > 10 years was not associated with poor outcome.”
> “In this trial, there was no correlation between BRAF alterations and outcome.”

Source: [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/)

> “Stratum 2: among 14 evaluable patients, there was 1 partial response (PR), 7 stable disease (SD), and 6 progressive disease (PD); the overall response rate (ORR) was 7.1%.”

Source: [Fangusaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12526141/)

<a id="topic-2.2.2.3-5"></a>

###### BRAF V600E and CDKN2A deletion: prognosis with conventional therapy and response to BRAF inhibition

> “Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG.”

Source: [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)

> “Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition.”

Source: [Nobre et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446502/)

<a id="topic-2.2.2.3-6"></a>

###### Molecular risk stratification

> “pLGG harboring gene fusions or germline NF1 mutations comprise the low risk group. These tumors progress less frequently and often eventually stop growing with very few progressions seen after 10 years and almost no deaths at 20 years follow-up (10-year PFS of 67% and OS of 98%, 20-year PFS and OS of 58% and 96%, respectively) (Figure 7B–C).”
> “The intermediate risk group of pLGG includes tumors with BRAF p.V600E without CDKN2A deletion, FGFR1 SNV, IDH1 p.R132H or MET mutations. Intermediate risk tumors had a 10-year PFS and OS of 35% and 90%, respectively (Figure 7B–C).”
> “High risk pLGG include those with H3.3 p.K27M, or BRAF p.V600E with CDKN2A deletion. These tumors almost invariably progress (10-year PFS of 0%) and these patients often succumb to their disease (10-year OS of 41%) (Figure 7B,C).”

Source: [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)

<a id="topic-2.2.2.3-7"></a>

###### Age, tumor size, location, and diencephalic syndrome

> “On multivariate analysis, factors independently predictive of worse EFS and OS were younger age and tumor size greater than 3 cm2. Tumor location in the thalamus was also associated with poor OS.”

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)

> “Age and diencephalic syndrome are adverse clinical risk factors for PFS and OS.”

Source: [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)

<a id="topic-2.2.2.3-8"></a>

###### Stratification factors in LOGGIC/FIREFLY-2

> “Randomization between treatment arms will be stratified by primary location of the tumor (supratentorial midline vs. other), type of genomic RAF alteration (fusion vs. mutation), CDKN2A status (deletion vs. wild-type/unknown), and infant chiasmatic-hypothalamic glioma (CHG) diagnosis (yes vs. no).”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.2.3-9"></a>

###### Optic pathway glioma: NF1 status and visual outcome

> “Children with and without NF1 demonstrated the same rate of VA improvement, stabilisation or worsening; however, children with sporadic OPG had a poorer VA outcome. Better initial VA, older age, absence of postchiasm tumour and presence of NF1 were associated with improved or stable VA outcomes.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

> “The overall response rate in the OPG subgroup according to RANO-HGG, RAPNO, and RANO-LGG criteria were 64%, 50%, and 55%, with clinical benefit rates of 95%, 88%, and 90%, respectively.”

Source: [Nysom et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12187376/)

<a id="topic-2.2.2.3-10"></a>

###### Response by histologic subtype and CDKN2A status in first-line BRAF V600 pediatric low-grade glioma

> “In addition, responses were observed across the diverse histologic types of glioma in this trial, findings that support broad use of dabrafenib plus trametinib as first-line therapy in this population.”
> “In addition, among the patients for whom molecular data were available, responses were observed regardless of the presence or absence of CDKN2A homozygous deletion.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.3-11"></a>

###### Molecular subgroup and hemorrhage risk in pediatric low-grade glioma

> “Six of 37 patients (16.2%) with KIAA1549::BRAF experienced a hemorrhage vs. 6 of 199 (3.0%) without known fusion”
> “BRAF V600E mutation showed no association (0 hemorrhages among 28 patients, p = 0.996).”
> “No hemorrhages occurred among patients with underlying genetic syndromes, including neurofibromatosis type 1 and tuberous sclerosis.”
> “Adjustment for KIAA1549::BRAF fusion substantially attenuated the apparent MAPK inhibitor effect (univariate HR 4.70 to adjusted HR 2.22, p = 0.260)”

Source: [Grin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42414678/)

<a id="topic-2.2.2.3-12"></a>

###### Per-eye visual acuity outcomes after chemotherapy in NF1-associated versus sporadic optic pathway glioma

> “At initiation of chemotherapy, 26% and 49% of eyes in the NF1 and sporadic groups respectively had VA ≥0.7 logMAR”
> “At completion, in the NF1-OPG group, 49% of eyes had ≤0.2 logMAR, 23% of eyes had VA 0.30–0.60 logMAR and 28% of eyes had ≥0.70 logMAR. In the sporadic OPG group, 32% of eyes had ≤0.2 logMAR, 11% of eyes had 0.30–0.60 logMAR and 57% of eyes had ≥0.70 logMAR. Children with sporadic OPG, per eye, were significantly less likely to have a VA outcome of ≤0.60 logMAR compared with children with NF1-OPG (OR=0.30; 95% CI 0.16 to 0.56; P<0.0001).”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.2.3-13"></a>

###### Age and tumour location as predictors of visual outcome after chemotherapy

> “Age ≤5 years (OR 25.2; 95% CI 3.02 to 209; P=0.003) and Dodge stage 3 (OR 7.14; 95% CI 2.44 to 25.0; P<0.001) at presentation were associated with VA ≥0.70 logMAR on both univariate and multivariate analysis in the NF1 group.”
> “In our NF1 cohort, children with Dodge stage 3 tumours were seven times more likely to experience worsening VA and a poor final VA outcome despite treatment.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Summary: care management for children receiving systemic therapy for pLGG

European standard clinical practice recommendations call for a multidisciplinary tumor board (neuro-oncology, neurosurgery, neurology, neuroradiology, radiotherapy, neuropathology) with involvement of ophthalmology, audiology, and endocrinology, and state that maintaining visual, endocrine, and neurological function is a key aspect of management. A 2026 Delphi consensus of 82 experts from 29 countries (funded by an educational grant from Day One Biopharmaceuticals) reached agreement on 50 of 129 statements, including that MAPK inhibitors should be prescribed and overseen by an oncology team in a multidisciplinary setting, that patient and caregiver education is essential, and that early prophylactic skin care is recommended; consensus was not reached for most cardiac, ophthalmologic, and endocrine statements. Recommended monitoring for MAPK inhibitors includes sodium and glucose in children with hypothalamic-pituitary lesions, echocardiography and ophthalmologic examination for MEK inhibitors, and height and growth velocity for tovorafenib. After discontinuation, structured imaging is recommended, particularly in the first 6 months, and Canadian consensus suggests MRI at least every 3 months for 1 year off therapy and slow tapering. Long-term visual monitoring and survivorship follow-up are supported by data showing that 26% of children with optic pathway glioma diagnosed before age 3 were bilaterally blind after a median of 11 years, and that adult survivors with bilateral blindness were more likely to be unemployed and to live with a caregiver.

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf); [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/); [Jalal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11832571/); [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/); [Xu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12988086/); [Styczewska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13168116/); [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/); [Picariello et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13268981/); [de Blank et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4764436/)

<a id="topic-2.2.2.4-2"></a>

###### Multidisciplinary tumor board and functional preservation

> “Involvement of other specialties including ophthalmology, audiology and endocrinology is extremely important.”
> “There are therefore several strategies from different disciplines for tumour control for paediatric low grade glioma, and a key aspect of overall management is to maintain visual, endocrinological and neurological function. Management strategy should therefore always be planned in the multi-disciplinary team setting.”

Source: [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)

> “All patients need comprehensive neuro-oncological care, the principles and details of which are summarized in the current guidelines. These represent standard of care for diagnostic work-up (including neuroimaging and neuropathology), and for therapeutic decisions (including the indications to non-surgical treatment) as well as concepts for neurosurgical intervention, chemotherapy and radiotherapy as well as surveillance and rehabilitation.”

Source: [Gnekow et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31108561/)

<a id="topic-2.2.2.4-3"></a>

###### Delphi consensus on adverse event management with MAPK inhibitors

| Consensus statement | Domain |
| --- | --- |
| “Ensuring appropriate education of patients and caregivers on the potential AEs is essential to improve patient outcomes, manage patient/caregiver expectations, and aid treatment adherence” | General management |
| “Additionally, patients/caregivers should be educated on the need for proactive AE management in order to control some AEs, particularly cutaneous toxicities” | General management |
| “Proactive management of pre-existing skin conditions, including topical treatments and close dermatologic monitoring, is essential in preventing severe AEs in high-risk patients” | Cutaneous AEs |
| “Early signs of hyponatremia, such as headache, lethargy, nausea, and confusion, should prompt immediate evaluation, and serum electrolytes should be checked promptly” | Endocrine-related AEs |

Source: [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/)

> “Of the 129 statements drafted, consensus (≥75% agreement) among 82 global experts in pLGG was reached for 50 statements, mostly pertaining to the general management of AEs occurring with MAPKi and the management of cutaneous AEs.”
> “It is also important that for all patients with pLGG in the suprasellar region, treatment should be started in consultation with the pediatric endocrinologist for adequate monitoring and guidance of growth and serum sodium values.”

Source: [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/)

<a id="topic-2.2.2.4-4"></a>

###### Endocrine monitoring during BRAF and MEK inhibitor therapy

> “Clinicians using such treatments need to be aware of these potential effects, particularly the risk of hyponatraemia in patients with pre-existing central diabetes insipidus and monitor for these accordingly, including performing measurements of sodium and glucose prior to, during and after treatment.”

Source: [Jalal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11832571/)

<a id="topic-2.2.2.4-5"></a>

###### Growth monitoring during tovorafenib therapy

> “Reduced growth velocity has been reported with tovorafenib, and recovery of growth velocity may occur after treatment interruption; therefore, baseline and longitudinal monitoring of height/weight percentiles and growth velocity should be incorporated into routine care, with pubertal assessment and endocrine evaluation when clinically indicated [73].”

Source: [Xu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12988086/)

<a id="topic-2.2.2.4-6"></a>

###### Cardiac and ophthalmologic monitoring with MEK inhibitors

> “While the rates of cardiac toxicity are low in children receiving MAPK pathway inhibitors in published reports, most guidelines recommend routine echocardiograms (ECHO) to monitor for asymptomatic diminishing ejection fraction (EF) while on MEK inhibitor therapy.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

> “Regular cardiac and ophthalmological review is mandatory to monitor for rare yet significant events including reduced ejection fraction and retinal detachment.”

Source: [Alshammari et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13123665/)

<a id="topic-2.2.2.4-7"></a>

###### Imaging surveillance and discontinuation of targeted therapy

> “Since discontinuation of treatment can be associated with rapid clinical and radiological progression, we suggest tapering one drug at a time, starting with MEKis by approximately 25% every 3 months, and the BRAFis by 25% every 6 months.”
> “We suggest continuing with surveillance MRI at least every 3 months once off drugs for 1 year then as per institutional standard.”

Source: [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/)

> “Importantly, approximately one-third of RR events (34.8%) were reported to be clinically symptomatic, whereas most were detected radiologically during routine surveillance. This finding underscores the importance of structured imaging follow-up, particularly during the first 6 months after MAPKi cessation.”

Source: [Styczewska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13168116/)

> “Recommend scan sequences and slice thickness plus interpretation as per RAPNO pediatric low-grade glioma criteria (RAPNO pLGG)”

Source: [O'Hare et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11300023/)

<a id="topic-2.2.2.4-8"></a>

###### Visual acuity monitoring

> “In addition, screening for visual acuity is required for all patients; baseline assessments will be taken during screening.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

> “Our findings underscore the urgent need for earlier, vision-directed interventions and long-term visual monitoring.”

Source: [Picariello et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13268981/)

<a id="topic-2.2.2.4-9"></a>

###### Survivorship: vision loss and socioeconomic outcomes in adult survivors

> “Among 1,233 survivors of childhood astroglial tumor ≥ 5 years post-diagnosis, 277 (22.5%) had visual impairment. In multivariable analysis, survivors with bilateral blindness were more likely to be unmarried (adjusted odds ratio [95% confidence interval]: 4.7 [1.5, 15.0]), live with a caregiver (3.1 [1.3, 7.5]), and be unemployed (2.2 [1.1, 4.5]) compared to those without visual impairment.”

Source: [de Blank et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4764436/)

<a id="topic-2.2.2.4-10"></a>

###### Survivorship: occupation, income, and education after radiotherapy

> “On the long term, younger age at diagnosis and treatment with radiotherapy in LGG patients resulted in sevenfold lower occupation scores, more sheltered work, lower income, and less education in adulthood”
> “This lower occupation score was also related to vision, hearing, and motor impairments.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.2.4-11"></a>

###### Detection of hemorrhage and biology-informed surveillance in pediatric low-grade glioma

> “Five of the twelve hemorrhages were symptomatic at presentation (three with headache alone, one with nausea and vomiting, and one with headache and vision impairment); the remaining seven were detected incidentally on surveillance imaging.”
> “Patients with KIAA1549::BRAF fusion, particularly those receiving MAPK inhibitors or requiring CSF diversion in high-risk locations, warrant heightened surveillance and careful procedural planning. Patients with genetic syndromes, BRAF V600E mutations, or tumors in non-eloquent locations without fusion carry substantially lower risk and may follow standard imaging protocols.”
> “CSF diversion was independently associated with hemorrhage exclusively in high-risk anatomic locations (brainstem, optic pathway, hypothalamus), where it increased hemorrhage incidence sevenfold.”

Source: [Grin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42414678/)

<a id="topic-2.2.2.4-12"></a>

###### Management after carboplatin hypersensitivity: prophylaxis, discontinuation, and switching regimens

> “Five of 15 patients who received prophylactic premedication developed Cb HSR (2 patients developed grade I Cb HSR, 1 patient developed grade II Cb HSR, and 2 patients developed grade III Cb HSR).”
> “Four patients were observed without further chemotherapy, 2 patients underwent surgical resection, and 14 received another noncarboplatin-containing chemotherapy regimen, including 7 patients who received weekly vinblastine; 4 patients who received either combined thioguanine, procarbazine, and CCNU or combined thioguanine and PCV; and 3 patients who received another line of chemotherapy.”
> “In patients with carboplatin allergy, the current International Society of Pediatric Oncology LGG protocol discourages attempts to continue therapy by means of desensitization and suggests alternative combinations, such as vincristine plus cyclophosphamide or vincristine plus cisplatin.”
> “For patients with an early onset allergic reaction, alternative chemotherapy regimens that offer a good efficacy rate without evidence of long-term toxicity should be considered instead.”

Source: [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)

<a id="topic-2.2.2.4-13"></a>

###### Premedication and desensitization procedure used for carboplatin rechallenge

> “All patients received premedication with dexamethasone (between 0.05 and 0.15 mg/kg delivered intravenously 1 hr prior to carboplatin) and cetirizine (approximately 0.2 mg/kg delivered orally 1 hr prior to carboplatin) and nine patients received a desensitization protocol with successive infusions of increasing doses as described by Confino-Cohen et al.”
> “This protocol begins with premedication followed by infusion of 1/1000 of the total dose over 90 min followed by 1/100 of the total dose over 90 min followed by 1/10 of the total dose over 90 min followed by the remainder of the dose over 90 min.”
> “Two of the patients with grade I reactions required no treatment; the other patient with a grade I reaction and the patients with grade II reactions responded promptly to steroid and antihistamine; and the patients with grade III anaphylaxis required adrenaline and responded promptly.”

Source: [Dodgshun et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26207610/)

<a id="topic-2.2.2.4-14"></a>

###### Senescence-associated secretory phenotype score as a possible guide to follow-up intensity

> “These results could potentially have an impact on the therapeutic management and follow-up (FU) of these patient groups: (i) patients with a high or intermediate SASP sum score and GTR could potentially have longer FU intervals or even a shorter FU period overall; (ii) patients with initially subtotal resection and low or intermediate SASP sum score could benefit from a complete re-resection or possibly adjuvant therapy, to improve their PFS.”
> “The prognostic significance of the SASP sum score of course needs to be validated first in a prospective manner in upcoming clinical trials.”

Source: [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### Accelerated approval postmarketing requirement 4608-1: randomized confirmatory trial

> “Conduct a multiregional, randomized clinical trial comparing tovorafenib to physician’s choice of chemotherapy in pediatric patients with low grade glioma with RAF fusions or rearrangements, or V600 mutations, intended to verify and describe the clinical benefit of tovorafenib through assessment of overall response rate (ORR) as a primary endpoint and progression-free survival (PFS) and duration of response, as determined by blinded independent central review, as key secondary endpoints.”
> “Include the protocol-specified ORR and interim PFS analyses in the interim report.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-2"></a>

###### Accelerated approval postmarketing requirement 4608-1: timetable

| Milestone | Date |
| --- | --- |
| Interim report submission | “04/2028” |
| Trial completion | “10/2031” |
| Final report submission | “04/2032” |

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-3"></a>

###### FDA review: FIREFLY-2 as the trial to verify clinical benefit

> “Verification of benefit will be based on results from a randomized trial of tovorafenib compared to standard of care chemotherapy in patients with pediatric LGG with a primary endpoint of ORR and a key secondary endpoint of PFS.”
> “The Applicant intends to submit efficacy data from FIREFLY-2, an ongoing, international, open-label, randomized (1:1) controlled trial comparing tovorafenib to standard of care chemotherapy as first line treatment in 400 patients who require systemic therapy for pediatric LGG.”

Source: [FDA multi-discipline review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000MultidisciplineR.pdf)

> “The Company continues its commitment to the pLGG community with the Phase 3 FIREFLY-2/LOGGIC randomized clinical trial evaluating tovorafenib as a potential front-line therapy compared to chemotherapy in patients aged 6 months to 25 years with pLGG, which it believes will satisfy certain post-marketing requirements to the FDA.”

Source: [Day One Biopharmaceuticals accelerated approval announcement (2024)](https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated)

<a id="topic-2.2.2.5-4"></a>

###### FDA listing of the confirmatory requirement in September 2026

> “4608-1: Conduct a multiregional, randomized clinical trial comparing tovorafenib to physician’s choice of chemotherapy in pediatric patients with low grade glioma with RAF fusions or rearrangements, or V600 mutations, intended to verify and describe the clinical benefit of tovorafenib through assessment of overall response rate (ORR) as a primary endpoint and progression-free survival (PFS) and duration of response, as determined by blinded independent central review, as key secondary endpoints.”
> “4/30/2032”

Source: [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)

<a id="topic-2.2.2.5-5"></a>

###### Postmarketing requirements under 505(o): long-term growth, development, and gonadal toxicity

> “Conduct comprehensive safety analyses from clinical studies that further characterize the known serious risk of long-term adverse effects of tovorafenib on growth and development, including but not limited to growth plate abnormalities, in a sufficient number of pediatric patients.”
> “Monitor patients until discontinuation of study treatment or a minimum of 5 years from start of treatment, whichever occurs first.”
> “Conduct comprehensive safety analyses from clinical studies that further characterize the potential serious risk of gonadal toxicity in a sufficient number of adolescent and young adult patients treated with tovorafenib.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-6"></a>

###### Postmarketing requirements under 505(o): carcinogenicity and drug interaction studies

> “Conduct a carcinogenicity study in rats to evaluate the potential serious risk of carcinogenicity.”
> “Conduct a clinical pharmacokinetic trial of tovorafenib with a strong CYP2C8 inhibitor to evaluate the potential increased drug toxicity and provide dosage recommendations for tovorafenib when used concomitantly with strong and moderate CYP2C8 inhibitors.”
> “Conduct a clinical pharmacokinetic trial of multi-dose tovorafenib on substrates of BCRP to evaluate the potential for increased toxicity of BCRP substrates and provide appropriate drug interaction management strategies for tovorafenib when used concomitantly with BCRP substrates.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-7"></a>

###### Postmarketing commitments: FIREFLY-1 follow-up and CYP2C8 inducer study

> “Complete the FIREFLY-1 trial, including your planned additional follow-up for the 137 patients with relapsed or refractory low-grade glioma harboring a BRAF alteration enrolled to Arms 1 and 2 of FIREFLY-1 and treated with tovorafenib, to further characterize the overall response rate (ORR) and duration of response (DoR) as per Response Assessment in Pediatric Neuro-oncology (RAPNO) criteria including assessment by an independent review committee (IRC) for patients enrolled to Arm 1.”
> “Conduct a clinical pharmacokinetic trial with a strong or moderate CYP2C8 inducer with tovorafenib to evaluate the effect of a strong or moderate CYP2C8 inducer on decreasing the systemic exposure of tovorafenib and provide dosage recommendations for tovorafenib when used concomitantly with CYP2C8 inducers.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-8"></a>

###### Fulfilled requirements and open accelerated approval requirement in August 2025

> “We have reviewed your submissions and conclude that the above requirement/commitment were fulfilled.”
> “We remind you that accelerated approval PMR 4608-1 listed in the April 23, 2024, approval letter is still open.”

Source: [FDA supplement approval letter NDA 217700 (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217700Orig1s002,%20s003,%20s004ltr.pdf)

<a id="topic-2.2.2.5-9"></a>

###### European Union: specific obligations of the conditional marketing authorisation

> “shall conduct and submit the final report of the phase III randomised, parallel-group, two-arm study (FIREFLY-2) to evaluate the efficacy and safety of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with paediatric low-grade glioma harbouring an activating rapidly accelerated fibrosarcoma gene (RAF) alteration requiring first-line systemic therapy.”
> “The MAH shall generate additional PK data in paediatrics patients below 2 years of age and submit an updated population PK model incorporating these data, including an assessment of systemic exposure and, if necessary, revised dosing recommendations for this subgroup of patients.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

<a id="topic-2.2.2.5-10"></a>

###### European Union: CHMP view on FIREFLY-2 as the specific obligation

> “the interim study report (including the ORR primary analysis and the PFS interim analysis) can be projected to be available for submission in April 2028, with the final study report planned for April 2032.”
> “In addition, while the study is conducted in a first-line setting, which differs from the second-line setting to be authorised under the CMA, the mechanism of action of Ojemda is not expected to be line-dependent, the molecular-defined disease target is consistent across treatment lines, and as explained, the study is expected to reduce key uncertainties identified at the time of the CMA.”
> “However, there is some uncertainty in the fact that this study excludes patients previously treated with dabrafenib in combination with trametinib.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### United States: periodic reporting on the confirmatory trial

> “You must submit status reports of the progress of each clinical trial required under section 506(c) (listed above) to the NDA 180 days after the date of approval of this NDA and approximately every 180 days thereafter (see section 506B(a)(2) of the FDCA) (hereinafter “180-day reports”).”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-2"></a>

###### United States: enhanced pharmacovigilance for wrong-dose medication errors

> “We request that you submit all U.S. cases that describe a wrong dose error or potential for a wrong dose error involving Ojemda, as 15-day Alert reports (as described under 21 CFR 314.80(c)(1)), for a period of 3 years following the U.S. approval date.”

Source: [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-3"></a>

###### European Union: additional monitoring, periodic safety reports, and annual review

> “This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.”
> “the marketing authorisation holder (MAH) shall submit PSURs every 6 months.”

Source: [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)

> “Every year, the Agency will review any new information that becomes available.”

Source: [EMA Ojemda medicine overview (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda)

<a id="topic-2.2.2.6-4"></a>

###### European Union: risk management plan safety concerns

| Category | Safety concern |
| --- | --- |
| Important identified risks | “Growth retardation” |
| Important identified risks | “Intratumoral haemorrhage” |
| Important potential risks | “Decreased fertility risk” |
| Missing information | “Long-term safety” |

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="topic-2.2.2.6-5"></a>

###### European Union: long-term safety follow-up through FIREFLY-2

> “Further long-term safety data will be generated from the ongoing phase III study FIREFLY-2, agreed as an SOB under the conditional marketing authorisation. This study will follow patients for up to 5 years.”
> “No additional pharmacovigilance activities are required. This is agreed.”

Source: [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: benchmarks for first-line therapy outcomes

Overall survival in pLGG is high regardless of first-line therapy (5-year overall survival 86% in COG A9952, 89% in SIOP-LGG 2004, and 94.4% with vinblastine), so expected benefits of new first-line therapy are measured by response, durability of disease control, and functional outcomes. Chemotherapy benchmarks are 5-year EFS of 39% (carboplatin plus vincristine, COG), 5-year PFS of 46% (vincristine plus carboplatin, SIOP), and 5-year PFS of 53.2% (vinblastine). In the only completed randomized first-line comparison of a targeted therapy (110 participants with BRAF V600 pLGG), dabrafenib plus trametinib produced an ORR of 47% versus 11% and a median PFS of 20.1 versus 7.4 months with carboplatin plus vincristine.

FIREFLY-2 was powered (approximately 400 participants, 85% power) to detect a 15% absolute improvement in ORR over an assumed 30% control-arm ORR, and a PFS hazard ratio of 0.67 based on an assumed median PFS of 4.5 years with tovorafenib versus 3 years with chemotherapy. In the relapsed or refractory setting (FIREFLY-1, 76 participants), tovorafenib produced an ORR of 51% by RAPNO criteria with a median duration of response of 13.8 months; among 35 participants with optic pathway glioma and at least 2 visual acuity assessments, visual acuity was preserved in 80% and improved in 31%. Visual acuity improved in 20% of participants with optic pathway glioma treated with first-line vinblastine and in 4 of 19 participants (21%) with recurrent optic pathway and hypothalamic glioma treated with selumetinib. In May 2026 the sponsor described the FIREFLY-2 primary endpoint as ORR based on RAPNO-LGG criteria, whereas the 2024 design publication specified RANO-LGG.

Source: [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/); [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/); [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/); [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/); [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/); [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/); [Nysom et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12187376/); [Fangusaro et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8485450/); [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.2.2.7-2"></a>

###### LOGGIC/FIREFLY-2: assumed outcomes underlying the sample size

> “To assess the ORR per the primary endpoint, the planned sample size of approximately 400 patients will provide around 85% power to detect a 15% improvement for the tovorafenib arm at a two-tailed level of significance of 0.05, assuming a 30% ORR in the control arm and a dropout rate of up to 10%. To assess PFS as per the key secondary endpoint, the planned sample size of approximately 400 patients will provide around 85% power to detect a hazard ratio of 0.67 for PFS at a two-tailed level of significance of 0.05, assuming the median PFS for the tovorafenib arm is 4.5 years versus a median of three years for the control arm.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.2.7-3"></a>

###### LOGGIC/FIREFLY-2: endpoints as described at completion of enrollment

> “The primary endpoint of the trial is overall response rate (ORR), including duration of response (DOR), based upon Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO-LGG) criteria, with key secondary endpoints including progression-free survival (PFS) and event-free survival (EFS) per RAPNO-LGG, time to next treatment (TTNT), overall survival (OS) and other measures, including patient-reported outcomes.”

Source: [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)

<a id="topic-2.2.2.7-4"></a>

###### Functional outcomes assessed in LOGGIC/FIREFLY-2

> “Importantly, this study also includes endpoints to evaluate improvements in neurologic outcomes, visual function in patients with optic pathway glioma (OPG), and patient-reported outcomes to better describe the overall impact on patients’ lives and activities of daily living.”

Source: [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)

<a id="topic-2.2.2.7-5"></a>

###### Benchmark outcomes with first-line targeted therapy: dabrafenib plus trametinib

> “Clinical benefit was observed in 86% of the patients receiving dabrafenib plus trametinib and in 46% receiving chemotherapy (risk ratio, 1.88; 95% CI, 1.3 to 2.7).”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

> “Duration of response (DOR) was 23.7 months (95% CI: 14.5, NE) in the D+T arm and not estimable (95% CI: 6.6, NE) in the C+V arm.”

Source: [Barbato et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10841289/)

<a id="topic-2.2.2.7-6"></a>

###### Benchmark outcomes with tovorafenib in relapsed or refractory pLGG

> “In an efficacy population of 76 patients, the ORR was 51% (95% confidence interval (CI): 40, 63), and the median DoR was 13.8 months (95% CI: 11.3, not estimable).”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)

<a id="topic-2.2.2.7-7"></a>

###### Visual outcomes with systemic therapy for optic pathway glioma

> “VA per patient was preserved for 80% of patients; 31% demonstrated improved VA; VA per eye was preserved in 87%, with 27% improving.”

Source: [Nysom et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12187376/)

> “Visual improvement was observed in 20% of patients with optic pathway glioma.”

Source: [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/)

> “Nineteen of 25 patients were evaluable for visual acuity which improved in 4/19 patients (21%), was stable in 13/19 (68%), and worsened in 2/19 (11%).”

Source: [Fangusaro et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8485450/)

<a id="topic-2.2.2.7-8"></a>

###### Goals of therapy in a chronic disease

> “pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures.”

Source: [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)

> “The current focus of our efforts to improve outcomes in pLGG is to identify agents that lead to a durable response and reduce morbidity.”

Source: [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)

<a id="topic-2.2.2.7-9"></a>

###### Visual acuity change during first-line dabrafenib plus trametinib versus carboplatin and vincristine

> “The change from baseline in visual acuity was assessed in patients with tumors located near the optic chiasm (25 with dabrafenib plus trametinib and 11 with chemotherapy)”
> “Although visual acuity remained stable in most patients in the two groups, visual acuity per eye was improved in more patients who received dabrafenib plus trametinib than in those who received chemotherapy (14 of 41 eyes examined [34%] vs. 2 of 18 eyes examined [11%]).”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.7-10"></a>

###### Landmark progression-free survival at 6 and 12 months with first-line dabrafenib plus trametinib versus chemotherapy

> “At 6 months, the estimated progression-free survival was 87% (95% CI, 77 to 93) with dabrafenib plus trametinib and 58% (95% CI, 39 to 73) with chemotherapy; the percentages at 12 months were 67% (95% CI, 53 to 77) and 26% (95% CI, 10 to 46), respectively.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.7-11"></a>

###### Discordance between imaging response and visual outcome in optic pathway glioma

> “There was poor correlation between imaging and VA outcomes (n=66). Twenty-two per cent of patients with improved imaging outcomes had improved VA, whereas 30% of patients experienced worse VA despite improved or stable imaging outcomes”
> “There is however increasing evidence that serial changes in VA do not reliably detect tumour progression and, conversely, tumour progression does not reliably correlate with decreased VA.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

<a id="topic-2.2.2.7-12"></a>

###### Outcome measures prioritized by clinicians and survivors

> “The relevance of outcome measures after childhood cancer was recently investigated among 87 clinicians via two step Delphi questionnaire rounds and online focus groups of survivors”
> “For pediatric LGG, the fields of interest in late outcome were defined as motor function, vision, hypothalamic function, physical aspects, subsequent neoplasm, and psychosocial and neurocognitive aspects of quality of life besides overall survival and cause-specific mortality.”

Source: [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)

<a id="topic-2.2.2.7-13"></a>

###### Treatment continued to loss of clinical benefit versus a fixed number of chemotherapy cycles

> “Treatment was continued until loss of clinical benefit (as determined by the investigator), development of unacceptable toxic effects, initiation of a new anticancer therapy, completion of the protocol-defined number of cycles (in the chemotherapy group), loss to follow-up, or death.”
> “Continuation of dabrafenib plus trametinib after investigator-determined disease progression was allowed if there was an expectation of continued clinical benefit.”
> “Future studies are needed to evaluate functional outcomes (e.g., visual acuity), further molecular characterization, and most effective treatment duration.”

Source: [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)

<a id="topic-2.2.2.7-14"></a>

###### Vision during first-line vinblastine

> “It is noteworthy that in this study, only 4 out of all evaluable patients for visual response (24 patients) experienced worsening of vision during treatment.”

Source: [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)

<a id="topic-2.2.2.7-15"></a>

###### Visual acuity preserved or improved in most children after first-line chemotherapy for optic pathway glioma

> “With an average follow-up of 6.5 years, VA improved or remained stable in 59% and 61% of children with NF1 and sporadic OPGs, respectively.”
> “Although visual outcomes after chemotherapy are not optimal, timely treatment arrested the decline in VA in most children, and some children regained vision.”

Source: [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)

## Related pages
- [Tovorafenib (DAY101): RAF-altered pediatric low-grade glioma requiring first-line systemic therapy](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Terms and abbreviations](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/terms-and-abbreviations.md)
- [Tovorafenib (DAY101): RAF-altered pediatric low-grade glioma requiring first-line systemic therapy](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/executive-summary.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Clinical evidence](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/clinical-evidence.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Economic information and modeling report](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/economics) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/economics.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: References](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/references) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/references.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: prevalence by geography](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/prevalence) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/prevalence.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/cost-effectiveness-analyses.md)
